基因向善：因美纳企业社会责任报告 PDF Free Download

Name: 基因向善：因美纳企业社会责任报告 PDF
Author: _larry_garrett_

1 / 106

0 views•106 pages

基因向善：因美纳企业社会责任报告 PDF Free Download

基因向善：因美纳企业社会责任报告 PDF free Download. Think more deeply and widely.

基因向善

5~‘}5’æ&r"(’ªJª0˙ 

wJª0˙PR;  C RbP[  C  Rb Px

附录

’æ&r"(’ªJª0˙ 

首席执行官寄语企业社会责任战略与管理可及性社群简介可持续性员工尽责运营

高管寄语

3ﬁCJd>=>2

简介

6  C’æ&r"(’ª’mc? 

7}

8,"’55~‘}5 

9&.V" 

企业社会责任战略与管理

11ﬁC.>=1$ﬁC,,’2.>=¤|v7 

12 ’æ&r"(’ªIk;-/#g]fm‚Eg1 

14  CnaSß 

15 ’æ&r"(’ªvi 

16 -Dn$nq,"O/&x/œ,&¡~‡F

加速提高基因组学可及性

18 IkP0ƒˇ&xEg1 

19 ..-/P1$L¿–03KF 

22 =æ.˚6˙5}F=-2-/,0@ 

23 L.6˙5}F=[W&”.˚

24 )sHy2⁄’2&0?

26 6˙5}F=O¤L8·TKF

27 J8—6˙5}F=Eg1.

31 d.;J 

为社群助力

33 IkP0ƒˇ&xEg1

34 r"~Jˇ4 

35 0B¤/&x 

36 Cv&0  O«R…( 

38 d.;J 

融入可持续理念

40 IkP0ƒˇ&xEg1 

41 [^)«d. 

43 03Ko}oP6 

46 03Ko}o’a1w

48 03Ko}om‚’)Ø§F 

50 0Kƒ6˙5}F=m‚.¡ 

52 d.;J 

培养员工

54 IkP0ƒˇ&xEg1

55 I’m‚0B¤ 

57 (d8·+¸.˚n,CF1$.«>F

60 Jˇ40B¤ 

64 D,"FUO.˚ 

66 d.;J 

尽责运营

68 IkP0ƒˇ&xEg1

69 ’æ&vi 

70 0V 

72 (!i1$,Yß 

75 O¤L>,1$'gs 

77 03«m‚(C§F 

81 ,,O_v; 

附录

83 ,"’5R¥Jª0˙ 

86 ,"§v}kOjKwSß

100 KwSßw

n n n x 

105 )B8nP¨ 

106 JŒ““

在基因组学强大力量的驱动之

下，因美纳致力于为世界带来

积极影响，为全人类创造一个

更可持续、更公平的未来。

I’m‚u5’CC’æ&r"(’ªJª0˙{?

 C RbP[  Rb PR¤,0@m‚

h7ﬂnr"(1$\[iw x‹nas?G,s

d’+9P¨o 

YJª0˙¤£’+I’0E⁄m‚s?{C?R¢RßB¤

(r*-’+?Ro(r&„GVOnd&~(dn0B¤

&x5i>{5)m‚>JÆO{Ko}o(dI’?’5’

x«*4Dm‚J‹?C^?.˚o&gEg1o

详情请参阅“关于本报告”一节

基因组时代

已经到来

附录

’æ&r"(’ªJª0˙ 

首席执行官寄语企业社会责任战略与管理可及性社群简介可持续性员工尽责运营

首席执行官寄语

 CP5~‘}5Iu(  0Co’3/’8·CRß{I’&gnl

].’5’˜6˙5m‚.¡OV2⁄’x«*4Dod,\{E2&tm‚“=[

Zæ’˜E’ª(fP)«ŒR?.-{/pBDu(&g&¡R?*4Dn

R?03Ko}om‚&kr{)sr"(|V}0?o

6˙5}F=J8¿BOV2⁄P1$\[kºRßL¿/.,i/kº*4D

[Cn)s03Ko}o0?/œ,CF<L¿–6˙5}F=O¤Lm‚

’¿FnL¿/.&¡F.˚/kºm‚03/œF’˜/œ^?.˚’’?&kr

m‚iRo

6˙5}FP’¿B”}Q-LRß{5B/Æ,C¡}{>m‚0?}[I’

CRß’+BRo

基因组学推动全球迅速采取行动，减缓传染病传播。,

iﬁY·  lPm‚L-{c?eM’+6˙5}F-/P1$trpvm‚

bs+{o?J5lG0_OV2⁄’x«*4DoPl;/†(d(&vP

-h¡{(NI’J8¿/œP0h¡CL}-V,&(ND{J^PRR¡~‡ 

m‚o,iRcOjn/]5{0ZPQ\/œ*JﬁR'Csd.0V(r{

03’˜¤¨Yœ,i,DYe0Yx«lGo 

基因组学正在改变个性化医疗，并且挽救生命。na-x{

o‹JﬁR'B”Ck=’5mSl?\[kºm‚0P&¡h{03,‚‰~

(l;GVOm‚PqPGo8·s+-/Pkº\YßY5&CﬂunQ\

/œ{«?Pn$78·m‚l,l;x«6{o’H-/Pkº\?JCRß

ﬁR…o

基因组数据已经成为从诊断到精准治疗等一切工作的

“蓝图”。Z8{pGtU’0Œ5^?,pGtU(0D{o

?Rc.’5’+R&kr&sS’,(:›˙m‚l,l;1$,,/ak0KIo

d,\{6˙5}FO¤L=‚5P¨Qm‚&vC{/p?,i’0!m‚

8·TKF’¿&v¨oI’&x0V(r((6MJ[{’˜RL¿–6˙

5}FO¤Lm‚8·TKF{C.Z&g(YGVOE⁄-LtrpvFkº\m‚

\[kºo

基因组学技术正被用来应对气候危机。6˙5}F=JﬁR'B”

}Qk=’5’+R1›’Hs+='’a¡RR–IRRJJßECP1$l,l;o

na-x{  6˙5}JﬁR'&B”k=’5L¿–Uˆf1$5|

8]E˛k0fK&1$*=‚8—[^q+m‚Hd,J.o6˙5}F=?I

&„R,y›y>,¤|‹m‚¡~‡P0\{C.,iO¤m&p’M

·ﬁ˘ﬁo

Francis deSouza

首席执行官

基因组时代已经到来，在过去几年里，它

的发展给我们带来了希望。然而，当下的需求

比以往任何时候都更加迫切，即通过建立一

个更健康、更可持续的世界，促进社会繁荣

发展。

&t‹}o



附录

’æ&r"(’ªJª0˙ 

首席执行官寄语企业社会责任战略与管理可及性社群简介可持续性员工尽责运营

首席执行官寄语

5,0@(“1m‚D‚‹&t{I’sdS’¨~-2A&Ik{¡w0Rc

.m‚nRcH&—m‚&¿L{.L¿–6˙5}F=03/œF{&„r"

~..{,h7ﬂ03Ko}oFm‚iFA{6˘«’J^{C

’ª5Xo 

加速提高基因组学可及性

I’BL-trpvF-/P’a1w{¡~P>A&—6˙5}F=m‚03

JF{.,i/kº*4D‹60E⁄RcEg1.m‚s?o5

I’m‚&vIn..&t{P&g’¿]5C‚w xJﬁR'm‚IR¥¤

([’+  ’˜&s{L.]5C‚JﬁR'[W&”.˚{CC.GVOn

r"~/œJ>Rc’’¢6˙5}F=&¥&n$oI’L-’+8·Y·-/P

’a1w{.«KM TM4oPI’na-xRRE8—nRR

03Ko}om‚]5C‚y„}aoI’K*?’+  Hy2⁄‹na{&x

&¥5B-k0}ˆ'4C‹ºOy.6˙¡(w 

xDu(’+0V(roI’n5

}i}o&„l;/†(d6˙5}F=‹naw xL¿(Hy2⁄OEKo{C

C.«]1$&/B’G5/6˘,.,"§vm‚,,/ak0J.o0%8“{

I’n?‘~(d6˙5}F=‹naw.«KM P.5y5,¥ *4DpGtUx

D?0V(r{0.’+  ‹na{naSßP?P.5  &p

’sd  ]5C‚1$-S@o 

为社群助力

6˙5}F=m‚R¢Rß0,’5E2’  =k0m‚[oYn-/

#.1$cGo’C{5~‘}5.,’+  R…(ºnE

w { x{?&xmﬂ>as0

JﬁO_v;.,>Tw 

x0V(r{,0ZL.~‘5Bs0=nJﬁR'n

B¤snO¤=1$/=w xk0FVy„}a0« {]'y„

}aF'{p{L¿–  ,CFoIR¥’v~-’+&g?,

D)L{‡[BO_C˛1$O«‹?’?vR…s0=}5, 

Csm‚6˙po¨-o 

融入可持续理念

I’^?o{OV2⁄’x«*4D&x-/#R?*4Dm‚&krGGnq,"{

I’?BHgX’˜/œ0V(r((6RcEg1.m‚B¤(rRß>$

Io&gnaSßo5~‘}5 -L  C>Jh¡^>T[^(d,“*LWO^

m‚naSß&E⁄’+s0=q+naSß)‚}F}Iw xm‚Øo

I’&,¥I&„,iﬁJ s0=,“*LWO^ naSßm‚’æ&&&g{

&Pﬁ>{}QØm‚6˙5}F=,0@oI’?h7ﬂ/9i6

Oﬁ0V-LRRP]5C‚C05 TM&¥{(“.«3v.˚

{7UOæk=¡,‚?1 {C&(“&?[^)«0.˚m‚Eg1

¤([ o0%8“{I’?,0@CC‡,Z&6˙5}F4.‹

na6˙¡·LG}[’+B…ﬂ k0f0VI-/PpGtUJ>w 

x{4.’›’pG

tU6˙5}F=5R,q+?=‚nh)B1$y›y>,¤|‹P0«m‚

‘¶.o

培养员工

‡>Jh¡(8—(“1{,0@0P&¡?{})Œ“=‡Rc(sm‚0B¤1$

‹?Oo5~‘}50B¤P-/PD‚N~{&PL.6˙50b2⁄m‚

,"§vo&„’+D.«>FO.˚Rß)s-/P1$-/#.{I’

5J>RcB¤(r&¥Œ(d8·+¸.˚1$,CFoI’B”v}o5C

>Jh¡’+“*,„Bo0%8“{I’v}ou&rCL¿/.’+9NF

–vZæ({5~‘5B0B¤&¥{?1O¤P[R0B¤/Q o5

C{I’kM<’+ ‹P&-D{O¤¡-/&t/07},E6{

C&9NF0P¨’O¤¡’d,P~‘5B,5B[Cm‚&)oI’

Iu(’+Pm‚0B¤4_B?-}F{&&„GVRcENIP}ENZNl,1$r_

}Q8·TKFl,l;m‚0B¤L¿(OEKooIB”v~- 

,"’5 ZNl,.«>m‚ﬁCJd>=)L- {O)0Zd)sCv1$

.«>o

基因组学的未来已经来临

 CRß{I’&gnl50b&kr?r6˙5}F=m‚{9i0?-x

Q^’˜/œ0V(rm‚.¡o5&x,i0P5m‚>PJ*n0V(r((61$

6˙5}F=)‚?O0V(rm‚Bs&¥{I’^?oo’H0V(r?C

Rß1›’H03JFoh¡5PP)«trpvkr¤{,’x«,’g6˙

5}F=CRßm‚(.7ooH1nÆ“=‡p`)B6˙5}F=O¤LJ

8¿/P,i’0!m‚8·TKF{oH1nÆI’“=‡?6˙5}F

=D‚,&Cﬂ>J(&¥{CJ8—,&Ck=·55o 

?RR¢Rß{I’?}i}o..{].’5I&„RR9im‚'˛&”n

RR9im‚h7ﬂviO1$RR(’æ&,[Wo 

«C"H-gI’,i0P5m‚>PJ*n0V(r((61$0B¤{8—>{

,0Z..5~‘}5LsK˝Oyk01m‚B¤(r{5ﬁØI’m‚r"~{

’=nqOEKo{(dI’m‚(“1o 

Francis deSouza

ﬁCJd>=

在公司使命的引领下，我们积极部署商业战

略，采取有力的、有意义的举措，加速提高基

因组学可及性，为社群助力，融入环境可持续

性的理念，培育人才，并负责任地运营。

尽责运营

(r&„6˙5}F=‹6,;m‚+nO{I’nÆ’˜JﬁR'L.

-/P{&„’x«#r•m‚’ª{p`)BI’-/#m‚JﬁR':$}JP

’˜>,{0V&(!i1$’ªm‚P0D›(“k=oI’J8—’+

L¿0\ ,0@vi:<0(m‚R·55{’›’/8.’2(

n/o,0@m‚¡~‡  ’2‹{&¤v:<Jo}[,&’›’2(:<0

(m‚G,'8“o5~‘}5,Y·’;un)LG=sC‚B”&E⁄ 

 5B¤'gsØo

&x nqZæ{6˙’5~‘5BSß’{)œZ’6˙5}FTKR¥k0I  m‚O¤Lo

5~‘}5’50P5B\E+¨m‚Rı’&tsdnq,"B¤(ro



2022 年企业社会责任亮点荣誉关于我们业务概览

’æ&r"(’ªJª0˙

附录

首席执行官寄语企业社会责任战略与管理可及性社群

简介可持续性员工尽责运营

简介



荣誉关于我们业务概览

’æ&r"(’ªJª0˙

附录

首席执行官寄语企业社会责任战略与管理可及性社群

简介可持续性员工尽责运营

2022 年企业社会责任亮点

Gˆ/œ12 亿’0!

L¿(’)Ø 1,100 万美元m‚>JfKØP{

&„l;/†(d6˙5}F=‹naL¿(OEKo 

Gˆ/œ30,000 多名/=O«=&O 

HIu(’˜Rß4.’+ 74 家6˙5}F=-2

-/,0@

BL- TM? 全基因组

测序成本降至 200 美元

启动了~&x+ ,n$‹nawJ)PQF 5. 

x

pG0Jˇ,* 10 亿美元w/Q,COP

m‚22%x

加速提高基因组学可及性

F“KØP›* 1,770 万美元

50% m‚0B¤/&xKØP1$FHfRj.

‹na 

H  C’˜Rß{  =&O’

O¤B 1,200 万

L¿(’+B 20,662 小时m‚FHf

Rj.

,Rc 1,747 个,n$’2&&E⁄OEKo 

r"~Jˇ4»n7 46 个5B>{5/

为社群助力

)BKo净薪酬差距为零

?1O¤P[R5~‘5B0B¤&¥m‚/QZæ&„ 52%

,i9NF0B¤m‚/QZæ&„ 45%

5B/Æ&rC&¥{9NF5–v?{&¥m‚/QZæ

提高了 5%

员工敬业度指数达 86%

启动了OEKoZNl,’8fm‚P  ‹na

Z(Y0B¤m‚C5†6˘P¤* 62 小时

培养员工

ﬁ>{KFRc}Q Øm‚ 净零目标m‚

6˙5}F=,0@

100% m‚,iXk=kO¡_BH03,Dk0

J_B 

100% m‚Ik(C2A].’5RR8—s

C,‚?1,&h7ﬂ¨” 

&xTM nqZæ{(“k=

TM?[^)«0.˚m‚Eg1¤

([’+ 61%

融入可持续理念

5~‘}5m‚TMEæP6100% /&xu&r

P0>N‹na 

5Ls(C2A8·+¸.˚P0«m‚OE-/QZæ

*-L’+ 18%

&E⁄’+'gs)LGvi ISO 27701 Ø

J8—提名 /公司管理委员会的职权范

围，’˜/8.’2(n/o  ’2.

尽责运营



2022 年企业社会责任亮点关于我们业务概览

’æ&r"(’ªJª0˙

附录

首席执行官寄语企业社会责任战略与管理可及性社群

简介可持续性员工尽责运营

荣誉 

2022 年所获荣誉

工作场所荣誉

 RR(B¤(r5J>9

 RR(B¤(r5J>9

 KwO¤,imE

 m8—OEKo*4D>{C1$r"~m‚~‘5B,0@

 0B¤,CF1$](.F9



w/6?7sPJªx  E

地区荣誉



5I  }.w9



~‘5B2A(’æ&&xr"(d.P.5/>I?‘9 



w•niB¤s0Jﬁx&¥5B‡  >{P¨,0@·



P.5Dv0k=[Ojhgw xØ



wP.5]s@PJªxRR('˛&”9



P.5B¤(r5J>>,9

管理层荣誉



RRﬁCJd>= 



RR(ﬁC’.4_B>= 

 RR,(Eg1.•–’–v 



r•BP  (Y ?Ł’˜&sS-9NF 

1 | 1 | 3



2022 年企业社会责任亮点荣誉业务概览

’æ&r"(’ªJª0˙

附录

首席执行官寄语企业社会责任战略与管理可及性社群

简介可持续性员工尽责运营

关于我们

我们的目标我们的使命

以基因的力量改善

人类健康。

推动基因组学的积极进展，

造福全人类。

我们的价值观

关于因美纳

5~‘}5P&g>{].’5pGtU6˙5}F={)s’x«*4Dm‚,i.˚,0@{&„&¡F.˚/kº/œ,&’›‹6m‚R¢

Rß0?L¿(..o

I’u@5JﬁR'nk0f=1$*4Dm‚’\/łc?&s&vP-/P{¡~PS,G,"’5’x«*4D1$5i*4Dm‚R?8·03

JFo

I’L¿(-/P]5C‚’a1w{(“pGtU’01$&Cﬂ/k0J8¿0h¡nU,]5nP1$\[kº0Ps+l,l;4’¢mS

l?-L {’¢)BJÆHd,4’a-Lp`)B03Ko}om‚y›y(C{,«]n7o

Rc\5Rc一种技术{

03’˜&g-Œ0E⁄ 更好=

P’&˛?]mS}Htr0= 

9u(f-F*ł  oTKm‚

P6l;ZºCpG-VlP= 

[^)«0.˚?k0f8·TKF

Rc(fEg1= 

9u(fP~(l;= 

I’9u(f)B'{,im‚y›y

(C= 

5,0@(“1m‚n.&t{I’].’5L¿–5~‘}5JﬁR'm‚03KFn03/œF1$03Ko

}oF{&„,iO¤/’’,(>Jh¡*4D,Co 

我们态度开放创新刻在我们的

DNA 里

我们不断创造

伟大的产品

我们深入合作我们快速行动，

拥抱变化

肿瘤学生殖健康遗传病科研 /应用基因组学传染性疾病药物发现多组学

基因组学&v’J}[-o’H¤|‹m‚v7Ti{\&nJ&„I/*&s&pm‚,(Rv7?

’›’Rß9RR&„zm‚&g’H¤|‹o

(r&„6˙5}F=-/Pm‚D‚N~{I’Yß5&vPn.R¢Rßm‚s0=0h¡

应用

基因组学?‘P

oTKm‚JﬁR' o



2022 年企业社会责任亮点荣誉关于我们

’æ&r"(’ªJª0˙

附录

首席执行官寄语企业社会责任战略与管理可及性社群

简介可持续性员工尽责运营

业务概览

因美纳概览

全球布局

业务概述

美洲地区

~‘5Bi¡},BB…?7m‚M 4

~‘5B.-Dr•?r’GBr•Pf6y 3, 4, 6

~‘5B.-Dr•?r’GB]s\E 2, 4

~‘5B:›PDB•L 2, 4, 6

~‘5B.-Dr•?r’GB5I 1, 2, 3, 4, 5, 6

B…ﬂ5)B~ 4

大中华区

&¥5B.’i 4

&¥5B&s]s2, 4

&¥5B05. 4

欧洲、中东和非洲地区

E5BS£SL 4

5B-T 2,4, 5, 6

,6i5“Z^ 4, 5

\5B6i8¡} 4

5|›,&’ßP5B?7 4

Zæ-DPT˘_(! 4

)~PPs0 4

\5B“-Fł 4

,P595O 4, 5

’˜-)fK}v8 4

¤º}K: 4

亚太地区

aL8—-D’G7?7R¥4

PR¥8—¤…

4

«œ5Bﬁ?7 4

P.5 2, 4, 5, 6

PR¥&’i 

1F“¨{ 2k0’a{ 3&Cﬂ{

42A&X{ 5-§H&¥Eæ{ 6pG0

10,200 名

0B¤ 

10 亿美元

pG0Jˇ4 

45.5 亿美元

 COP, 9,500+ 名

>PJ*

>PJ*,L[)Ø

23,000+ 台

z!]5C‚’4<

3R…¡

9,178 项

,i&-DO¤¡

155 个

5B>{5/OP-L

I’m‚’a1w

1998 年

Iu(C’

财务状况

测序仪

2016

$2.4B

2017

$2.8B

2018

$3.3B

2019

$3.5B

2020

$3.2B

2021

$4.5B

2022

$4.55B

11% 5 年CAGR

71% 耗材

OC‰-V81$&Rc]5C‚-kn1w9u

](.Wu1$-kx{k=’5I’m‚]5

C‚1$fY’4<

12% 服务及其他

,0@>J>TJ‹Lym‚y„}a1$Rj.m‚)B)]&x}vJÆ

0V0Zno’aR)n(d8“P03n¤ZﬂF

ISS1$k0)L-S@Rj.OP,

17% 仪器

I’m‚]5C‚y„}a&v’,P0(Y»n7J>

RcCk={\&nOEKok=’56˙5-6

m‚fY’4<

45.5 亿美元

收入

收入总览

22%

pG0Jˇ45,C 

F“OP,&¥m‚/QZæ

NovaSeqTM 6000MiSeqTM MiniSeqTM iSeqTM 100 NovaSeqTM X 系列

低通量中通量高通量

用于临床诊断

NextSeqTM

500

NextSeqTM

550

NextSeqTM

1000/2000

R¥Jª0˙/P5~‘}5TMEæ&.o 

NovaSeqTM 6000DxNextSeqTM 550DxMiSeqTM Dx



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

ﬁC.>=1$ﬁC,,’2.>=¤|v7 ’æ&r"(’ªIk;-/#g]fm‚Eg1 2030 CnaSß ’æ&r"(’ªvi -Dn$nq,"O/&x/œ,&¡~‡F

’æ&r"(’ªJª0˙

企业社会责任

战略与管理



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªIk;-/#g]fm‚Eg1 2030 CnaSß ’æ&r"(’ªvi -Dn$nq,"O/&x/œ,&¡~‡F

’æ&r"(’ªJª0˙ ﬁC.>=1$ﬁC,,’2.>=¤|v7

问：因美纳在设立新的公共事务部门时，将 ESG

职能从首席财务官办公室转移到了首席公共事务官

办公室。两位能否谈谈这项举措？

答：

（John）5~‘}55u(Pm‚,,’2.¨¤vP{?O_C˛’2.n

’æ&r"(’ªn'gsn(!i1$GVO)‚?v,;¨5¤›Oﬁ0V5&gp

P&g’EHd,m‚’2G{oTK{o’H5¤›03’˜R?z>50V(rCJ

0Kƒ/80ZOjCoI&-x5E˛–B¤(r{‹?º0V5B’2.5¤›{

E˛–?O_C˛’2.nº0V5B03Ko}o0?naSß1$,0@  B¤(rz>

}U0V-L’+&gp{I’Ø&„5~‘}5&03’˜o&˛*o

答：（Joydeep）I0ZH  m‚c?{?  5¤›’¢.

¨¤vﬁst-L,,’2.¨¤v0_{&&¡¨¤vJ8¿Zæ’˜ER?&\⁄’5Jˇ

4O1$›e'vio0P&¡¨¤vJ8¿>-0V(r{C&'enÆ0Ps+E-V

Fn/vJª0˙‡[P&TT{o’H0V(r&(Rßz>o5.F/

]5C‚JﬁR'5h¡RcB5m‚Q\/œC{C&„6˙5}F=-/#RR,(Eg1

.m‚PR…(P{I’?   (r&„&1$-Dn$nq,"O-/#’)Ø

m‚,"§vIkn..o

Joydeep，您最近被任命为首席财务官，相比您

担任首席业务战略和企业发展官时，职权范围扩

大了。您计划如何将因美纳的环境、社会和治理

（ESG）方法融入公司的整体财务和业务战略？

答：（Joydeep）^?.˚  Ik?L.I’2A&v;kCE.˚

I’m‚(“1{’˜6˙5m‚.¡OV2⁄’x«*4DoI’m‚0Jo’’ª

vi(Ø¡~’5vi›e'{L¿–&}k1$p`)B2A&)LoI’? 

P0\&xh¡Rc.vinq}U0V{,&&¥.«KM¤|-VCn›e'-S@n

,;¨n/L}nJª0˙P¨C1$O¤L)Bo

(r&„ﬁC.>={IYß5?[J8¿)BJÆ,0@m‚§¸R2A&’)Øm‚

P0\{,&&¥.«KM&x›e'1$R…nq,"m‚.1$«.Jˇ,o 

P(.os+›e'1$R…m‚&g&¡KwSß{>?J>Rc-Dn$nq,"Om‚H

Œ}5,’+L¡·55o

Jˇ4’5 {?J8¿n.&.7§¸{ah0-/P{..’æ&0E⁄

§¸RI.o

因美纳对 ESG/CSR 治理方法做了哪些修正？

答：（John）8—>{&g]Ø&„{&sB,0@’2(’2C*5n/

o  ‹na1$)LGJŒ““P0«0KƒR?8—m‚(rk=<d,\{5’2(

KJ9u(fsdn/oP0«’d,=‚5nÆBDoY-x{,0@J’2(

,"’55~‘}5  ‹na/œ,&&t«0P&¡&”‹m‚n/oB¤(rE1,h¡Rc:<

0(B¤(r·55o/ÆC{I’J8—’+L¿0\ ,0@vi:<0(m‚

R·55{’›’/8.’2(n/o,0@m‚  ’2‹{&¤v:<Jo

}[,&’›’2(:<0(m‚G,'8“o„:<0(}i}on/o8·

+¸.˚1$.«>F’2.C0bvi?{L¿(nq,"H{\>N:<0(--

}i}on/o}ł}^>,’2.ooTK>LWJ(“I’R?^aQ‘nR?RcOj5

n/o,0@9u(fvi¡~8—  ¤|‹m‚R…(&x›e'{0ZPnJEeQ

 ?,0@&.I.m‚¡~‡Fo 

首席财务官和首席公共

事务官问答

鉴于气候风险对投资界和关键利益相关者的重要

性，因美纳将如何向这些利益相关者告知贵公司的

气候行动计划？

答：（Joydeep）(r&„&g>{’˜s0Jﬁ&„R¥m‚,0@{I’BR¡w

k=s0=TeSy-V>Ah7ﬂnaSßoI’-V>A’+&g‹RcP¤m‚[^)«ﬁ6

-"{CTOLh¡RcRR([^)«s0=D1$s0=q+naSß)‚w x

>A’+,((dnaSßoI’m‚[^)«ﬁ6-"w.«KM,‚LWnaSß1$,“*

J‹?x&E⁄’+  ØokKY0b-Dn$nq,"OP¨{I’?]

.’5¤([’a1w?[^)«m‚Eg1{C&I’>A’+&gy„-)03)Lm‚

’ªnaSß{..>Jh¡,i  ^L}naSßo 

Y8“{I’5/ÆC Rb’L-m‚  &(dh¡’+I’m‚

[^)«d.J‹?o J8¿Q|,‚?1CDf’˜/œ?h7ﬂ

m‚Eg1{oP¨5~‘}5].’5-Dk=JﬁR'OV2⁄’x«*4DC)BJÆ5

ih7ﬂo&x  nqZæ{  m‚.«3CD

f1$¡~¡,‚?1’+ {7UOæk=¡,‚?1’+ oI’OEKo5h7ﬂ

^C&tX-k{oTKZC?Jn[  0C,z{0ZPnJ

C.>PJ*Q|,‚?1XBs&¥’ak0m‚CDfo

您对因美纳 ESG/CSR 的未来有何看法？

答：（John）I’.’0J>Rcm‚-Dn$nq,"Ow.«KM>PJ*n&

.0V(r((6n0B¤1$r"~xŒ/&x,&&¥C10L8—>{,0Z..{

kKY{I’?Ko}oL.S,DR?,(«łFm‚0?W•D›{-/#§¸R2A

&’)Ø{L.s0JﬁsY’˜..,(*4D&x5i*4Do

Joydeep Goswami

首席财务官、首席战略和

企业发展官

John Frank

首席公共事务官



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

ﬁC.>=1$ﬁC,,’2.>=¤|v7 2030 CnaSß ’æ&r"(’ªvi -Dn$nq,"O/&x/œ,&¡~‡F

’æ&r"(’ªJª0˙ ’æ&r"(’ªIk;-/#g]fm‚Eg1

我们的使命是以基因的

力量改善人类健康，在

这一使命的驱动下，我

们致力于提高因美纳产

品的可负担性、可及性

和可持续性，为全球数

十亿公众实现健康公平。

作为一家目标驱动型公司，我们通过将

企业社会责任战略融入业务中，来实现

可持续的长期商业价值和影响力。

我们的企业社会责任战略一直受重要性

评估和持续的利益相关者参与影响。它

通过管理 ESG 风险、把握机遇、提高

业绩和确保商业诚信，促进业务可持续

管理。

企

业

社

会

责

任

愿

景

通

过

为

患

者

、

社

群

、

人

类

以

及

地

球

服

务

，

深

化

我

们

对

人

类

健

康

事

业

的

影

响

。

目

标

推

动

基

因

组

学

的

积

极

进

展

，

造

福

全

人

类

。

使命

以基因的力量改善人类健康。

加

速

提

高

为

社

群

融

入

可

培

养

尽

责

基

因

组

学

可

及

性

助

力

持

续

理

念

员

工

运

营

将企业社会责任

战略与我们的

业务相关联



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

ﬁC.>=1$ﬁC,,’2.>=¤|v7 2030 CnaSß ’æ&r"(’ªvi -Dn$nq,"O/&x/œ,&¡~‡F

’æ&r"(’ªJª0˙ ’æ&r"(’ªIk;-/#g]fm‚Eg1

5R¥Jª0˙&¥{I’(“k=R'2‡¡~‡·1$‡¡~‡F·r5~‘}55h7ﬂnr"(1$\[iP0«RcH&—m‚Eg1o?‘k=m‚-Z\I~‘5B’ª(f,&’›\E\{o’HR'2m‚(“k=&vC &„J‹ØR¥Jª0˙&¥’ª(f)LGm‚¡~‡F{I’&&v(5.Jª1$.Jª0˙&¥(“k=o’HR'2o

 5~‘}5’50P5B\E+¨m‚Rı’&tsdnq,"B¤(ro

I’].’5.L¿–6˙5}F=03/œ

F{&„,iO¤/’’’>Jh¡*4D,Co

I’5ˇ)L{6˙5}F=&vC’&„?1O¤

’Rj.{\PCE2Gˆ/œ,’x«o

加速提高基因组学可及性

I’].’55ﬁØr"({BI’m‚

&.-/#,0Z’)Ø{C?J“R…(&„

S,D&g&¡R?.Cvn03Ko}on?'’5

J>Rc’m‚R¢Rß*-g˜o 

为社群助力

I’].’50¤D‚S-’J^{C.’›’

&vPI§¸o,"\⁄8·+¸.˚n,CF1$.«

>F{Jˇ40B¤{Jg#,"FUO.˚{7

.0V(r1$Dr"~m‚’)ØoI’MJ[

Cs{J8—I’m‚sdS’Eg1{ah0I

’m‚P}¤‘¶.o

培养员工

I’].’5?h7ﬂvi,I’m‚

XP0D›o’x«*4D1$h7ﬂ*4DG

Gnq,"{oOT,"&„,’x«-/#*4Dn

03Ko}om‚R¢Rßo

融入可持续理念

I’].’5’˜>Jn,Yßn?#¡~m‚

P0D›E’d’2o(r&„6˙5}F=‹6

,;m‚+nO{I’’˜JﬁR'L.-/P{

&„’x«#r•{p`)BI’-/#m‚JﬁR'

:$}JP’˜>,{0V&(!i1$’ª

m‚P0D›(“k=o

尽责运营

我们优先处理最重要的

环境、社会和治理w ESGx

问题，同时确保强有力

的治理机制、透明度和

问责制。

创造独特的影响

5R¥Jª0˙&¥{I’’}O’+viP0\n

naSßn&xº0V5B03Ko}o0?naSßm‚

,"y„{’˜/œI’R,Z&¡¡~8— 

¤|‹m‚&¿Lo

Bvi&xZ&¡¡~8—  ¤|‹nq,"

m‚›e'1$R…{I’>Jh¡’+naSß{

C&„’æ&Hgn-Dn$nq,"O1$5i

CRß’+S’&„sdS’m‚Eg1o 

-/P 

>A’&x03KF 

L.6˙5}F=[W&”.˚  

重要主题

联合国可持续发展目标

r"~Jˇ4 

 O« 

重要主题

联合国可持续发展目标

[^)«d. 

03Ko}oP6 

03Ko}o’a1w 

03Ko}om‚(C§F 

重要主题

联合国可持续发展目标

8·+¸.˚n,CF1$.«>F 

’.4R¥vi 

0B¤*4Dn>,1$Cr•H- 

重要主题

联合国可持续发展目标

O¤L'gs1$>,F 

’æ&vi 

(!i=1$P¨C 

’a1w>,1$¡ 

重要主题

联合国可持续发展目标



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

ﬁC.>=1$ﬁC,,’2.>=¤|v7 ’æ&r"(’ªIk;-/#g]fm‚Eg1 ’æ&r"(’ªvi -Dn$nq,"O/&x/œ,&¡~‡F

’æ&r"(’ªJª0˙ 2030 CnaSß

我们的 2030 年目标

加速提高基因组

学可及性

目标 17.6：>Jh¡o,’g&x0V(r{’˜

&E⁄s0=onJﬁR'1$-/P

目标 3.d：OVsPR‹ºiy„}a{C?

,i*4D/mR…

目标 17.7：0b0?&¥5B>{LC03Ko}oJﬁR'

目标 17.16：.E,i03Ko}o0?0V(r

尽责运营

目标 9.2：Ls.«>1$03Ko}om‚’a&0?

目标 10.3：p`)BR…(CvC]'Z

目标 17.16：.E,i03Ko}o0?0V(r

为社群助力

目标 5.b：’˜s0Jﬁ;J9NF目标 10.3：p`)BR…(CvC]'Z

融入可持续理念

目标 12.2：>Jh¡Hd,4_Bm‚03Ko}o

vi1$(“k= 

目标 12.5：8—C4,‚?1CDf’ak0¡

目标 13.2：?[^)«0.˚LP6}5,,0@ 

O_v;1$-"

培养员工

目标 10.3：p`)BR…(CvC]'Z

我们关注的领域

(“ 100 美元基因组测序I&„03J

B J)PQF 5. 慈善项目助力  0\GVO

-L  C 让20 亿人0n$ 

Jˇ4 超200 家基因组初创公司

.l;/†(d6˙5}F=)‚KØ.{ 践行 6,000 万美元捐赠承诺

ZC[?1Gˆ/œ 25,000 名/=O«=&O

确保 100% 战略供应商J‹?RR8—¤C5,‚?1,&h7ﬂ¨”

(C2A8·+¸.˚P0«m‚OE-/QZæ*-L 20%w~‘5Bx

&E⁄ ESG 行业最高评级

Gˆ/œ500 万名 STEM 学习者

g˜ 100,000 多小时的志愿服务时间

50% 的员工参与KØP1$FHfRj.‹na

-L  C 实现净零排放

w n n x 

将排放量减少 46%

w n x

将排放量减少 46%

w x

可再生电力比例达到 100%

TMEæB¤/实现 90% 的76u65⁄

ﬁL 

TMEæ.,5J> 的用水强度下降



? 包装减少 75%

Jˇ4 2,000 万美元k=’5Hy2⁄03

Ko}o0?‹na 

100% 的战略供应商J‹?RR8—¤

C5,‚?1h7ﬂ¨”

L¿– 全球领导层中的F-F5†Zæ( 

)BKo净薪酬差距为零

7. 美国高管层中的?1O¤P[R/QZæ

L¿– 黑人、原住民、太平洋岛民、西班牙裔 /拉丁裔、2个或以上种

族的人士5~‘5B0B¤1$‹??{&¥m‚Zæ(

¤([ 可记录伤病率

2030 年目标

..-/P1$L¿–03KF

2. =æ.˚6˙5}F=-2-/,0@{J?6˙5}Fk0FVy„}a

3. 7.6˙5}F=O¤L8·TKF

4. L.6˙5}F=[W&”.˚

5. )sHy2⁄’2&0?

6. B/kºOE’P0»n7nD?6˙5}Fos0Q\1$&„GVOL¿(OEKoRß^?.˚

6˙5}F=m‚Eg1.

>JdERc.m‚’æ&vi

2. )BKo0VO.˚

3. J>*m‚&g-Œ’˜)L&„6˙p

Du(03«m‚(C§F

5. E˜RR–O¤L>,1$'gsSß,¥

6. /&xsdS’m‚,,O_v;

L¿(RcH&—m‚IkFr"~Jˇ4

2. ‚=. 0B¤5ﬁØr"({&„r"~CRßsdS’Eg1

3. L.>Jh¡  O«,C

L.[^)«d.

2. X03Ko}oP6

3. 6˘,.03Ko}o’)Ø§F

4. D003Ko}o’a1w

5. 0Kƒ6˙5}F=m‚.¡5i0E⁄R?*4D

(d8·+¸.˚n,CF1$.«>F

Jˇ40B¤

3. D,"FUO.˚

目标与联合国可持续发展目标一致

已实现正在进行



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

ﬁC.>=1$ﬁC,,’2.>=¤|v7 ’æ&r"(’ªIk;-/#g]fm‚Eg1 2030 CnaSß -Dn$nq,"O/&x/œ,&¡~‡F

’æ&r"(’ªJª0˙ ’æ&r"(’ªvi

企业社会责任管理

企业社会责任是公司经营中不可或缺的一部分。我们的

管理架构可推动问责制，提升透明度，促进持续改进。

董事会

I’m‚RR–vi?{vi’æ&r"(’ª{CLy0’2(,(dI0m‚n/o{kKL¿0\ ,0@vi:<

0(L¿(OEKoo 



os+E8—m‚‹?.J8¿.E?¡~8—h7ﬂnr"

(1$\[i¤|‹m‚vi{,&&¥.«KM[^)«d.n

8·+¸.˚n,C1$.«>n’Rn}ł}^>,’˜/œ

0V&(!in’ªm‚2A&d&„ 



,(d’2(n/o{ZC[?1OP-L&gYRc

,"E2-xh¡1$R¢RßIk-"m‚R?PJª0˙w9u

SS0k0¡~8—0.˚{--R?Pm‚‹łhg(R?–x 



„:<0(}i}on/o8·+¸.˚1$.«>F’2.C

0bvi?{L¿(nq,"H{\>N:<0(--}i

}on/o}ł}^>,’2.



>Am‚  naSß(}5,CC,0@naSß{C

Bvi}kOjı-/SEg1–v?{m‚„o

„:<0(}i}on/oJ>Rc„’2.o

'’+,(d’2(sdn/o8“{I’n 扩大了提名 /公司管理委员会的职权范围{

’›’/8.’2(n/o,0@m‚¡~‡h7ﬂnr"(1$\[iw x’2‹{&¤v:<Jo}[

,&’›’2(:<0(m‚G,'8“o

9uY+}H’+RI’m‚’2(vinI0’ªRng]u(F1$8·+¸.˚{<¤@ 

尽责运营章节 

CSR/ESG 执行指导委员会

 JdKw?:<0(kK,0@–?{viO}FI{kKﬁC,,’2.>=K’ª&”

C{?‘  Ik-"1$>J(L¿(Kw?{>NJ&”‡  ‹na{Cn/

L}naSßs?G,o 



I0.«KMﬁC/=>=nF“\E‹¤|n,iXF“n/nﬁC’.>=nﬁC

JﬁR'>=nﬁC§H>=1$,i  ’o 

捐赠管理

•

5~‘}5’æ&,[WKw?:<0(?5~‘}5m‚Hy2⁄KØPsdn/oo:<0(

I0.«KMﬁCJd>=nﬁC.>=nF“\E‹¤|nﬁC/=>=nﬁC’

.>=1$.-F“*o 

•

5~‘}56˙¡(P&g>{s’6˙¡({P&g>{g]u(m‚>J(d{5~‘}56˙¡(

’2(vi&x*6˙¡(Rc,"m‚Hy2⁄].o6˙¡(’2(m‚I05†&„5

~‘}5m‚–?{viO{.«KMﬁCJd>=nﬁC.>=nF“\E‹¤|nﬁC

/=>=nﬁC’.>=1$.-F“*o 

I’B0P‹6˙?{B¤(r0B¤J8¿nlLy/&x,0@m‚  ‹naoo’H5¤›

&„0P50.  ‹naL¿(’+&“>¢m‚F|1$ERc.m‚OEKo{P5?I’m‚

 B¤(r&x,0@m‚(“1ºy„pRßo 

8“¨(!i1P’:<0( (?‘&gy„-)Ik¤|‹L¿(Kw?{,&&¥.«KMƒˇ?&x6˙5

}F=d&nq,"m‚nP-h¡m‚(!i¤|‹nO_v;1$\L¿-Do 详情请阅读

尽责运营章节 

 J¨¤v-V>AIk{ >JP6‹na’˜/œ},W  Jª0˙o 

JB¤(r}F50PHm‚‹na&&¥>JP6COﬁ0V’æ&r"(’ªo

首席执行官和高管层

CSR/ESG 执行指导委员会

慈善管理委员会

内部支持小组

–v?{8·+¸.˚:<0(  Kw?:<0( 

¡:<0( ,,O_v;:<0( 03Ko}o’a1wTMEæ5¤›



(C§F03Ko}oF&x’ªB¤(r}F 

(C2A8·+¸.˚vi:<0( 'gsKw?:<0(

员工参与小组

03Ko}o0?}5¤› 5~‘}5,"FUFHfO5¤› 0B¤4_B?-}F

CSR 职能小组

外部伦理咨询委员会

董事会

提名 /管理董事会

委员会



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

ﬁC.>=1$ﬁC,,’2.>=¤|v7 ’æ&r"(’ªIk;-/#g]fm‚Eg1 2030 CnaSß ’æ&r"(’ªvi

’æ&r"(’ªJª0˙ -Dn$nq,"O/&x/œ,&¡~‡F

利益相关者参与及其重要性

通过让利益相关者参与到我们至关重要的 ESG 问题中来，加深其对我们企业社会责任战略的认知。

投资方

• ESG 投资者活动˚I’&¿.’+u’3?CC  Jˇ4O].{-’g’+sCI

SSCRv7’+nq,"¤|‹ 

•

投资者日˚I’&¿.’+‡Jˇ4OP·].{].&s{5~‘}5–v5¤›I0

*’+‘5C5}ARv7’+8—>{L¿-m‚¤|‹ 

客户

•

I’m‚>PJ*(d5¤›(>AR?>PJ*sd_HCHS¯{’+RI’“=‡OVsm‚

5P0oI’Z/1Csd&gYHS¯{-Dk=R…4<=&B¤,({CL¿(DO^^⁄{

’¢h¡50B¤8&E⁄>PJ*/ﬁØHoos+/ﬁØHk([J8¿C.I’OV2⁄’a

1wm‚03Ko}oFo 详情请阅读“可持续性”章节

患者

•

I’}i}o..&„,iGVOL¿(RR(&Cﬂ/kº{sdS’&x/kºR…S,1$O_C˛0V

(r{p`)B(l;r"~&v’J8¿BPJ“-L\[kºm‚BR{nJ8¿0-HB„

m‚8n‹o

员工

•

0B¤_HCHS¯[?1&gCD?&Yo 详情请阅读“员工”章节

社群合作伙伴

•

r"~Jˇ44¡&E⁄O“=‡5>$I‹na0_7,WEg1Jª0˙{C.I’sd

R¢RßJˇ4{0ZPL¿(/ﬁØHo 详情请阅读“社群”章节

政府和监管机构

•

5~‘}5&x,i0P5m‚O_C˛1$}F}IDu(’+ºy„{&xO_v;-V>AO1$,"§v-D

n$nq,"O?‘Eg1I’(“11$&.m‚¤|‹sd’\](o

重要性评估

•

I’B¡~‡F(.p`>A?I’m‚&.1$-D

n$nq,"ORR¡~‡m‚¡~8— ¤|‹{’˜/œI’J>

,(Rcm‚g]f(.7Rß-/#RR8—m‚sdS’Eg1{d,

0_LY-V>A’æ&r"(’ªIk 

•  C{I’R?P’+6˙’5  C6˙,¥}A

m‚¡~‡F(.oR?P0_m‚¡~‡F(.s&gY

>$2⁄Cp`Ø’+I’m‚(+’2‹1$¡~c?‹6o

我们有

各种利益

相关者

政府与监管机构

医护人员

社群合作伙伴

行业领导者

渠道合作伙伴

企业社会责任同行

分销商

非营利组织

投资方

供应商客户

员工

报告框架与外部基准

让利益相关者参与进来

I’].’5P¨.˚’æ&X{CBDO^m‚\2P0D›{.[&xJ>Rc-Dn$nq,"ODu(’=nq)L’ªm‚,"y„oI’>AROP'¸-Dn$nq,"O?‘h7ﬂnr"(1$\[iw x

‹L¿-m‚/ﬁØH{CsdDB,m‚?"o5Ko}oL¿–-Dn$nq,"O/&xCm‚Bs&¥{I’B8·s+P0D›RßOP'¸/ﬁØHCLYLs‹na{.«KM>PJ* 

HS¯n0B¤HS¯nd&(P5(d/&xnRßHnq,"TeSym‚Kw?{’˜/œ8“¨6˙,¥o

我们最重要的 ESG 问题

环境社会管理

气候行动推动基因组学民主化创新

可持续设施社群投资与慈善定价与可负担性

可持续产品 STEM 教育数据隐私和安全性

可持续的供应链多元化、公平性和包容性企业管理

人力资本管理伦理学和透明度

员工健康、安全和幸福感产品安全与质量

深入了解我们的企业社会责任战略→



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙

󱶩󸷀󳱠󺂿

󲙨󲒵󶳧󲵷󱿔󱾛󳘮



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

-/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1

󳦗󵬽󳿑󹙰󱘙󳔈󲄨

我们致力于加速提高基因组学可及性，为全球数十亿人实现健康公平。

我们坚信，基因组学不应仅为少数人服务，而应当惠及全人类。

要释放基因组学的潜力，大幅改善人类的处境，需要不断创新并推动基因组学民

主化。

󶾌󱿷󲓣󱿔󳬐󶴐󱾥󲼾󵸂󴎜

1 󱶵󱶣󱳐󳾾󲃅󳱠󺂿󱿔󸢰󳪱󳘮

2 󲶒󱹫󲙨󲒵󶳧󲵷󱳓󱳐󱮷󱿡󽘜󳨩󲼾󲙨󲒵󶳧󵫑󳗷󶥚󶴂

3 󳰡󱶴󲙨󲒵󶳧󲵷󴫸󱙛󱹫

4 󲝿󱶩󲙨󲒵󶳧󲵷󳽉󳮹󲡕󴏬󳘮

5 󱢼󸴔󳠚󲉅󱛓󱘭󱾥󲼾

󸶲󸳣󱺶󵮌󳻦󱝑󳿑󸉜󵷘󳐴󲼾󲙨󲒵󶳧󵾝󸚬󶋑󴃽󲃅󱙚󳛷󶻰󳱠󱡹󳻦󳬐󴊜󴷠󱹫󲙨󲒵󶳧󲵷

󵵙󳔈󲄨󱶣

关键目标

为了达成改善人类健康的使命，我们必须努力扩大

基因组技术在医疗服务中的可及性，改善医疗结果，

让社会地位不同、收入不同、生活在不同地区的人们

都有机会受益。我们必须继续弥合差距，确保个体的

基因组分析数据能够体现全球多样性。

Phil Febbo 医学博士

首席医学官

L. 󲙨󲒵󶳧󴳖󳍙󴈋󱶪󳦎󴉆

󱘕󳰓󷋼 100 󶸁󱭬

B  Hy2⁄‹na..

50,000 󱿽󳛷󶻰

ZC[?1Gˆ/œ 25,000 󱿽/=

O«=&O

0.l;/†(d6˙5}F=)‚KØ.{

‹º-L  C? 󸧉󸀅 6,000 󱘑

󶸁󱭬󳮊󸣱󳩍󸛠

-L  C 20 󱜪󱜤0n$

..B 200 󲸜󲙨󲒵󶳧󲵷󱳓󱳐

󱮷󱿡

 CL¿’\’+ 193 󹲁󳾾󱘢󱳥

kM<

pG0Jˇ,/Q,COPm‚

22%

󲔩󱮭󵢶󳙋󱯀󳫧󴈄 9,178 󹲁

&-D

󶐓󶀗󳘮 NovaSeq™ X y„-)

’a1wYßD›0B

2030 年目标 2022 年进展

2022 年亮点

1,704

>30,000 名

1,100 万美元

12 亿

200 美元 1

}(  ~‘+¸{6˙’5~‘5BSß’{)œZ’6˙5}FTKR¥k0I  m‚O¤L

w&x  nqZæxo



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ -/P&x03KF

󱶵󱶣󱳐󳾾󲃅

󳱠󺂿󱿔󸢰󳪱󳘮

I’B&\⁄1$Ko}om‚-/PP¨’+Rp&6˙5}Fm‚.¡J8¿8—C4OV2⁄’

x«m‚87ﬂo(r&„6˙5}F=-/PD‚N~{I’P¨mﬂ{I’m‚0V(r((6}ł}^

8—{Gˆ/œm‚GVO?‘8·o

I’‡-s2E’0{5&„I’o⁄{’8m‚Z&g‹0h¡Œ03JC.-LP¨8m‚GVO{CJR,&kr&s&g’HS’,&z

m‚¤|‹oZ&g‹J8¿¤([IR¥nL¿–¡n}«p0ﬁP¤IL¿–Pk=Fm‚JﬁR'trpvŒJC.I’0Kƒ‘¶J{

OV2⁄R?8·’m‚k0]{)BJÆI’m‚5io

¤([Z&¡6˙5}Fm‚]5C‚IR¥{

L¿–Z&¡6˙5}FIR¥’˜8“m‚’)Ø

Jˇ4’5IkOP{

D?0V(r 

L¿(trpvFJﬁR'1$

B¤(r](s

=æ.˚6˙5}F=

-2-/,0@ 

󸉔󱶵󱶣󱳐󳾾󲃅󳱠󺂿󱿔󸢰󳪱󳘮󽘜

󳦏󱝭󹧞󸉔󱶷󱶣 󾗜

H  C’˜Rß{/@(Y’x«6˙5}F]5C‚IR¥B”}Q

¤([’+[?1/’&p){/†Rß“=‡ ’~‘+¸{\9u’

(“k= ]5C‚’0+“=‡8—}( ~‘+¸{

‹º&v&?‘(>Jh¡?]5C‚IR¥¤[  ~‘+¸m‚

UGoJﬁR'-/PYßPn$L¿/.Z&¡6˙5}FIR¥’˜

8“m‚’)Ø{0ZPL¿(RR,«m‚6˙5}F)LGo

2001 年1亿美元

2014 年1,000 美元



2010 年10,000 美元



2020 年600 美元

 -kn1

2022 年200 美元



2030 年100 美元基因组测序成本

/@(Y6˙5}F]5C‚IR¥}(  ~‘+¸{6˙’5~‘5BSß’{)œZ’

6˙5}FTKR¥k0I  m‚O¤Lw&x  nqZæxo 

降低每个基因组的测序成本，

提高每个基因组成本以外的价值

200 美元

L-  0_m‚

6˙5}F]5C‚IR¥

100 美元

/@&¡6˙5}F]5C‚

IR¥

2022 年进展

2030 年目标



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ -/P&x03KF

通量、准确性、高效率经济性用户体验可持续性

通量󳱠󺂿󱛌 2.5 󱤵 󴪇 Gb 󴳖󳍙󳦎󴉆 *󹢎󱟼󱛌 60% 󱜤󱠅󳉉󶌱󲵷󱳐󳾾 󱹌󸃔󹄟󹄡󲃅󳍲󳐺󵙀󱱙󲻒

󱛌90%

󲝿󸷀 2倍󲙨󲒵󶳧󴳖󳍙󳦎󴉆约200 美元

󽘘󲙨󱛖󶸁󲓣󴎜󱞀󽘜󱦛󸚤󴪇󱞈󲙨󲒵󶳧

󴏬󴉆󵫑󳦎 120 Gb 󵵙󳽉󳮹󽘙

󳻦󳬐󵛾󶓉󱘔󴏬󵵙󴳉󱶴󴜖󸶲󸹅󽘜󲔩󴉝󸱠󶥚

󶴂󱘔󷋩󱶴󲷅󳦎󱘔󴏬󽘜󸴏󱯉󴈄󷋩󱶴󴀞󳮡󳽉

󳮹󱼴󶵌󱶧󷃫

󲛶󳾒󵫞󹄡󱱙󲻒󱛌 50%

󸶲󸳣 XLEAP-SBS 󱹫󲵷󳩏󴉊󲺽

󱱆󶁢󳘮󳱠󺂿󱛌 3倍

󱡋󵫞󴇠󲡕󱿔󲒱󳻱󲛶󳾒󽘜󴀞󹧞󳌢󱰛

󳦕󱰛󸁮󽘜󱙚󲷱󳧋󷐽󵸢󲠦󵢻󳦎󴉆

󹄘󵫞󶦳󱱞󳑎󱻴󵷒󲃅󱹌󸃔󽘜󶵌󵾫󱛌󳪳󱹌󴀿

󹠣󳌨󱭯󱲵󱳥󵫞󱛌󲵙󱩑󶐀󹠣

󲺽󲺧󴫿󱥌󱾮󱹫󵵙󳔈󲄨󹢎

󱟼󱛌 61%

󸴐󴂞󹺘󴥕󳉛󲷅󳦎  󴱅󱯤󳌨󸶲󸳣  󸚊

󸚧󵵙󱠅󲡋󸚰󳾸󽘘󽘙󺂿󸶲󹄡󴳖󳍙󱝪󽘜󶕸

󱿷󴇳󺂿󱿷󸊿󴎜󱱆󽘜󳌨󱘣󷃫󲡠󲼁󳛷󶻰󱺶󵮌

󳱠󱡹󱿔󸀅󳿑󴐊󸛋󳩏󴉊󲔩󹄘󵫞 󱜂󲄘

󵵙󲓣󲸜 󲔲󱺴󳨩󲼾󱛌󳍟󵫞󲃅󱙑󳍐󸚻󺀪󵵙

󷕕󲓖󽘜󱝥󱿔󳨩󲼾󸶲󹄡󳱠󺂿󱛌󱙑󳍐󲙨󲒵󶳧

󲵷󵵙󱿔󱾛󳘮󽘜󱿻󴀿󸴏󴂲󷠝󹢎󱟼󱛌󴪇 

󴳖󳍙󳦎󴉆󲃅󳙋󱠅󶥚󶴂󳦎󴉆 

󴂞󱘈󶋌󳐴󳻿󳌣󱿖󽘜󱯉󴈄󱜲󱡹󵿨

󶏶󱡋󵫞󽘘 󽘙󲃅 󱘺󶋌󴝘󳑎󽘜󸴏󹀢

󲠫󱛌󱘢󵫞󵵙  2󴈋󱶪󲏝󽘜󷃫󲡠󷋩

󱶴󵉔󴲿󲔲󸴔󸀅󺂿󸢹󹄡󳽉󳮹󲠦󵢻󽘜󴇳󲡱

󶌱󳍿󷐽󵸢󲷅󳦎󹲁󵸂󳧟󹧞󵵙󴀿󹠣󲃅󱜤󱶣

 CC{I’L-’+ y„-) {oPI’RR

E8—nRR03Ko}om‚P&g’¿–¡]5C‚’oo‹trpvF-/P

’a1w¡wk=’+Pm‚  .˚=JﬁR'{5¡nW•n

03Ko}oFn,¥p`F1$}Q]8Ojn$P0«ŒRctrpvFL¿/.o

阅读“可持续性”章节，详细了解可持续性 

NovaSeqTM 6000 Dx

}(  ~‘+¸{6˙’5~‘5BSß’{)œZ’6˙5}FTKR¥k0I  m‚O¤Lw&x  nqZæxo

因美纳 2022 年产品创新



NovaSeqTM X 󶥚󱳊

准确度评分为 99.87%{kK 

 ]5E⁄

&xna-xm‚§¸@§¸JﬁR'nqZæ{

DNA 起

始量减少了 90%

工作流程简单{03H.sdOC‰-V8{

0+“=&g8/p03>$I

突破性技术和工作流程

5~‘}55JﬁR'nk0f=1$*4Dm‚’\/ł‹6&vP-/P{¡~PS,GJ&„&Cﬂ/k0-/#1›’H03JF{« P

U,]5nP1$\[kºmSl?’˜/œ,&’›~l;n(S'l;1$(l;m‚P0D›oI’m‚naSßPah. >PJ*8——/Æ*o

NOVASEQTM X 󶥚󱳊󱜎󵋠

kK’56˙5}F=‚5–C¡~8I–C0Z_B/

6{6˙5}Fm‚&g?-¨-&gnl’˜RßE'…}Z

-V{&„’+R,o&¡¤|‹{I’D0-&g

s+P6m‚ –FJ §¸@§¸-S@P0\ {*Jﬁ

R'03’˜.-S@-¥(n}(  m‚6˙5/6{

k0II’:’&„YœRR,«m‚6˙5}F 5Co

Illumina Complete Long Read

Technology

首款已完成 FDA 注册

并通过 CE 认证m‚(d8“

Pw x–¡]5

C‚’



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ -/P&x03KF

55~‘}5{I’g8’5,i6˙5}F=X.m‚RR-x\‘{n8’5,i*4Dﬁ

6m‚&¥EæoB/Æ,CRß{6˙5}F=?““-{9i0?-xQ^’˜/œ0V(rm‚.¡o

I’MJ[0V(r{03’˜0E⁄R?8—m‚I.o‡G..-/P{L¿–03KF{’

L¿(]5C‚’1$O¤Lntt&v8¿oI’n“=‡L¿(Rc’)Øm‚\>¸{.W•D›

ﬁ0{L.6˙5}F=I&„/kºJÆim‚Sß,¥&&g{’˜YRßOV2⁄GVOm‚\[kºOj

SS{¤([Oﬁ(d/kºIR¥o 

因美纳推出与默沙东共同开发的一种科研检测产品，用于深入了解肿瘤基

因组

*s0pGU,]5’a1wu(¨’55~‘}5].’5C\sd,Q^0D-S@{C.E?>Jh¡

¯ly5,¥/kº[,"¡~‡m‚pGtUm‚J‹?o ’+RR?8·

因美纳与阿斯利康达成战略研究合作，加速药物靶点的发现

YYpGtU0V(rP5+˛-}U0V/P056˙’5’B¤QpJw xm‚6˙5}FR@1$6˙5

}F-S@JﬁR'(.7/œd&&§¸o ’+RR?8·

因美纳与 GenoScreen 合作提高耐多药结核病基因组检测的可及性

*0V(r?Rc.’5Ls&kr/ak0}F}I-L  C}JYœ,i}UTMl;](dm‚naSßo0%

8“{YY0V(r}U0V’+5~‘}5]5C‚’a1w1$  U,]5{

o&g6˙’5P&g’¿]5C‚w xJﬁR'm‚«60bU,]5P0\?J?,&,i03/œF{.

.F/nC\5U,]5J}UTMfcF{/œP&„\[kº,v;L¿((Lo ’+RR?8·

因美纳收购之前从因美纳剥离出去的公司 GRAIL，以改进癌症早期检测技术

（2021）

 &\⁄’5pG0J8¿K˝Oyk01m‚8·mSs+PRU,]5 —— GVO’“=5/k0

>Tsd&g‹v/@m‚N]˚U,]5/p03o  L-m‚  N]˚U,]5J8¿5GV

Ol?gQh¡&-xU,]5-  8·s+&v0Zm‚mSl?oI’>$I?  m‚OP?.

o‹K˝Oyk01m‚U,]55,i·55,;m‚Q\/œ1$(“k= o

因美纳收购 IDByDNA

 Yß5D0&gs+03k=’5(S'Fl,l;U,]51$l;/†(dn/]5m‚>*6˙5}F]5

C‚JﬁR'o5&x  Du(0V(r((6,"y„*&C0_{(r&„R¥YOP0V(r

m‚&g¨-{  &xI’,0ZD0CL-’+&gs+10¤⁄l;Zº  ’a

1w{03¢„>A

 8·s+l;/†(d{.«KM  1$  8·s+JRzc

Fv(Y6˙5o*’a1w55~‘}5  ]5C‚y„}a&sXd{¡wk=’+

 m‚ -S@–’o

oTOLYnE:<0(0Bm‚&PLP6{  m‚J>RcR1$}QRE‹g]u(’55~‘}5{YnE:<0(’5  C RbPTOLwYnECRı(xrYœ’+  ’\Po



5~‘}5&x  Du(,0ZD

00V(r ((6,"y„ 



5~‘}5&x.=SLTTZ†TT&*I(6'e

P0V(r,"y„



5~‘}5 &x D?0V(r{J

8—6˙5}FU,]55’QmS\[kº&¥m‚

C k=



5~‘}51$

>RB&x>s*I]5C‚0V(r

投资于战略收购，开展合作

I’B  CIu(m‚g]u(,0@  &„

6˙5}F=-2-/,0@L¿(s&gYOEKoo*,0@&\⁄’5C.

Lrz6˙5}F=Ck=n..y5,¥/=0?m‚-2-/,0@oI

’&„o’H-2-/,0@L¿(4¡nIk1P’{C.’›’&E⁄

&kr‹+m‚6˙5}F=R,P0TiL¿(2Am‚&“>¢}Q1$&&

oo’+RRc,"  m‚R?8·)LGo

因美纳参与了对 Time Boost Capital I LP 的投资{

0_O’¢6˙pJˇ4O n,&’›~‘5B1$Y]Jˇ4On

5~‘}51$ ,v'¸-L  &p§

w  &p~‘+¸x6˙5}F=›eJˇ6˙¡oou·Y·‹?&„’¢5

~‘}5-T.4<Z&m‚-2-/’æ&L¿(/4¡{naSßP

L.’x«*4D‹6m‚trpvo 

Illumina Ventures



5~‘}5&xPR¥5Bu(mSl?pGtU&¥Eæ

Du(0V(r



5~‘}5&x\5B0P5m‚ &¥Eæ0V(r{L

.Q;RmSl?GVOm‚y5,¥/kºP0\



5~‘}51$ 

0V(r. fD0

2022 年其他收购、合作与协作

'’+n.,;¨-/P’˜8“{I’n-Dk=IkOP1$D?

0V(rRß..*I(“1{L¿–03KF{R?F/56˙5}F=

Gˆ/œJ>Rc’{’¢\&¡F.˚/kºm‚‘¶.E⁄’˜0Kƒo

Joydeep Goswami

首席财务官、首席战略和企业发展官



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ 6˙5}Fk0FVy„}a

6˙5}F=-2-/,0@5,i6˙5}F=k0FVy„}aJ?&¥0KƒnÆRß¡~‡m‚(r

k=o5~‘}5-"BOEKo 5~‘}5,i-2-/’æ&C05w x

1$  Rß)s-2-/,0@m‚0?oo’H-2-/,0@>Jh¡m‚¡~‡-/

PRc.’5¤([IR¥{R§IPk0f=‹61$B5Ck=o 

󲒵󶸁󶳖󱳓󱳐󳑙󳸟



P/jC&g>{0VIk0f=,0@{

&\⁄’5 利用微藻D003Ko}o

m‚›y1wR,P0Ti{#r•’x«

1$5io

D?RcOj 诊断{

U,]51$‹º¤¨l,l;

发现新药物{

\[kºGVO

项目发展赛道

󲶒󱹫󲙨󲒵󶳧󲵷󱳓󱳐

󱮷󱿡

H‹na0.’˜RßJUˆm‚-2-/

,0@O¤¡ 

200+ 󲸜

6˙5}F=-2-/,0@E⁄-L

OEKo

2022 󳌤󸴔󲼾

2030 󳌤󵸂󴎜

󱳓󱳐󱮷󱿡󶾙󵎬

55~‘}5.4<m‚J>

J>H->$,OV0’+I’

?6˙5}F=-2-/,0@R¢

Rß0?m‚n\o

Felix Dobbs 博士

Broken String Biosciences

联合创始人兼首席执行官



¡~‡m‚ 农业和食物创新{

’˜R??1m‚5|5,.]R?8·’

5~‘}5.4<

~‘5BP¡?¸

5~‘}5.4<

5B-T

5~‘}5,i-2-/’æ&C05

P.5 5~‘}5,i-2-/’æ&C05

aL8—-D’G7?7R¥

}$R&¥5BQpJ/kº6˙5}F==æ.˚4< 

w5~‘}5JﬁR'n.x

&¥5B&s]s

5~‘}5,i-2-/’æ&C05&\⁄’5B&x‹+m‚›e'Jˇ4O1$’æ&>{0V(r{-/

Dn0.1$6˘«6˙5}F=-2-/,0@{&„6˙5}F=d&D0-/Pk0FVy„}ao

5~‘}5,i-2-/’æ&C05m‚&¿L.«KM-/u(’5  Cm‚5~‘}5.4<1$’5

 CIu(m‚}$R&¥5BQpJ/kº6˙5}F==æ.˚4<w5~‘}5JﬁR'n.xo

因美纳全球初创企业平台

11 亿美元

›eJˇ6˙¡ 47%

9NF-/:$’

/QZæ

5家

,i.’28 93%

-2-/,0@v'¸-L

R?8·4¡ pG0P 合成生物学方法{

Jg#R?03Ko}om‚R¢Rß

¡wk=软件和工具{

s&gY0h¡P\>¸

消费者驱动的应用{

C.I’R?9i5’+RHg



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ L.6˙5}F=[W&”.˚

󳰠󱶴󲙨󲒴󶳧󲵶

󴫷󱙛󱹪

我们坚信，基因组学不应仅为少数人服务，

而是应当惠及全人类。

要释放基因组学的潜力，需要教育、宣传、普及

以及能体现全球人口多样性的基因组学数据。

推动基因组学和基因组测序民主化可以让家庭、

社群及所有人从新一代测序（NGS）技术中受益。

)sHy2⁄ 

’2&0?

B/kºOE’P0»n7nD?6˙5}Fos0Q\1$

&„GVOL¿(OEKoRß^?.˚6˙5}F=m‚Eg1.

7.6˙5}F=

O¤L8·TKF

󳦏󱝭󳔯󷋩󸝾󷃫󲡠󱙚󱝥󱘕󹲁󵸂󳱠󱡹󳻦󳬐 󾗜



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ )sHy2⁄’2&0?

 C{I’>RBJ? ™‹na{5«-D

}F}I6˙5ºnEm‚OEKo&t0.’+ ™(*4D

‹naoJ?0_{*‹na?].’5&„,iO¤’˜&p

m‚D.7>{CL¿( {,&&¥~‘5B’˜8“5/0n$

m‚GVO[?1/Q&g/1{«]GVO[?1/Q&r-&&go

 C{I’D9i’+,"§v6˙pP6{C&Du(

’+,"§v0V(r((6,"y„o+}H’+R (*4

D‹nao

iHope™ 󸹑󱞼󱧕󳎡󹲁󵸂

6˙’5 J)PQF ™‹nam‚0?W•D›{ C{5&¥5B-k0}ˆ

'4C‹ºOy.6˙¡(m‚0p&t{ ~&x+ ,n$‹naw 

&¥5B‹nax YßD›0.{&„Rc“=‡m‚GVOL¿(,6˙5}F]5 

C‚o~&x+ ,n$‹na-"5R¢Rß&rC&„,5B  8·

&¡~l;GVO>{CL¿(+)(l;U,]5oY8“{*‹na

n?&„  >{/'m‚  8·0\&g}A&Cﬂ/k0L¿((l;

&&/=O«6˘{L.OV2⁄&¥5B~l;kºh¡go

R¢p`(l,l;GV+˜m‚>{CC"RcnÆ&vp`>An&v

03‹º]5m‚R¢Rßo50*5B>{ 5/{’›’m‚p`P

¤03J§¸*&kC&&{\5&¥([OP,w x5/{

8·>{C[t&vo⁄=='-LCE⁄’+’&˛l;o 

 ™P&g‹Hy2⁄‹na{P5&„&kr0P5m‚D

.7>{CL¿(&Cﬂ,6˙5}F]5C‚w xo*‹na

’5  C0.{B”0¤D‚’+(8·}F}I.,{P5}«

pPqPG{}[GVOC/ÆBRo5  COP\[m‚

l;(&¥{[  RßH&¥([OP,5B>{ 5/w.}5n

-.SS[W&”,1$5Bns=·1$7ﬂ1¥xm‚&k&¡ ™

‹na>JP65{oP¨*‹na50P&¡5/Œ’ak0’+

Eg1oRßH&¥([OP,5B>{ 5/ ™‹na>JP6

5Ly0-='Pm‚GVO5\[kºP0D›OV0hg&s&xRß

H–OP,5B>{ 5/m‚GVOB&v8·oI’?’5*‹

nam‚7§¸1$J?H--LE,#9{oP¨R¢Rß ™

?JGˆ/œR?8·>{Co+}H’+R o

󸶲󸳣󳠚󲉅󴉝󴋍󱙆󲓣󱲡󵫑󶵤󹣕󳌢󹲌󳼚󱶵󲙨󹄥󱞵

󲀸󱶴󶶢󱘙󱭶 ™󱮷󵷅󹲁󵸂

󸚏iHope™ 󳝤󱾛󴇠󲡕󲸜󳎎

_BH’O¤B  m‚¤›-) o

iHope 󵵙󳔈󲄨󱶣

1,704 名

GVO0n$’5*‹na

wHIu(’˜Rßx

70%

m‚GVO5Ly0

 0_OV0’+

\[kºP0D› 

40%

m‚GVO5Ly0

 0_p` 

,im‚ ™

&Cﬂu@c?

3个

P&Cﬂu@c?{--F(Y

’5\łB…B«n.i,&

‹1$P.5

󱢼󸴔󳠚󲉅󱛓󱘭󱾥󲼾

因美纳 iHope™ 项目将改变全球基因组医学的发展轨迹，帮助那些可能被忽视的患者能够得到诊断和进

行预防性治疗。

1,704 名

GVO&E⁄OEKo

50,000+ 名

GVOB ™‹na

&E⁄OEKo

2022 年进展

2030 年目标

’ª(fGVRc(l;m‚+˜uYŒ&v

C*J‹0&vE‡m‚l;leo ™

Kw0b’+Z&¡GVOŒJE⁄-LP

1$y5,¥\[kºm‚R¢Rßo

Ryan Taft

科研副总裁兼

iHope™ 负责人



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ O¤L8·TKF 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ )sHy2⁄’2&0?

kK’5&g&¡5P0-h¡,,/ak0:›˙’2’(=\/œ&kr0P

5{5Y5,i·55,;L¿–l;/†(d6˙5}Fn/]5J.03’˜

)BJÆZ&¡’m‚*4Doº0V5B03Ko}o0?naSßw x 

.«KM&xOVsPR‹ºiy„}a’˜C?,i*4D/mR…Rc,"m‚na

SßoY8“{  P¨“=‡)so,’g&x0V(r{’˜

&E⁄s0=onJﬁR'1$-/Po 

I’E–,#J8¿/&xl;/†(d6˙5}F=‹naw x{ o

P&g&¡8·¨¤v0V(r‹na{/&xO.«KM,i4.R…S,nd&n

«O_C˛}F}I1$,,/ak0R…S,o  C  Rb{ «]l;/†

(d6˙5}F=-" YßD›0.{nam‚PB8B¤,(n’.

4_B1$O¤L6˙pP6m‚]}~0V>J>T}ł}^{+˛--Dk=

,"§v6˙5}F]5C‚JﬁR'{.El,l;n/]5{L¿/.,,/ak0[

Co*-"m‚HfQ^P?l;/†(d6˙5}F=1$k0f)LG=

,C",,/ak0n/]5y„}a{’˜/œlGHS¯n/œPC?(

S'l;:›˙n’ªm‚O¤L,’g1$OVs0_m‚l,l;L}-V1$‹º

¤¨B¤(ro

YY0V(rm‚nam‚PJ8—P&g’¿]5C‚w xB¤,(1$&

&om‚03/œF{.E&¥([OP,5B>{ 5/m‚,,/ak0

n/]51$>J>T}ł}^{C.’›’C?P,_‰blG’˜/œ,&

’›](dl;:›˙1$5P0l;{9u_–l;n}UTMl;nkl,1$“Z’o

l;/†(d]5C‚n03’˜C.I’ƒˇ?E2-x1$P-h¡m‚(S'l;

pG0PlPnPPP0\1$Pkº\o

  C{«]0+Rc &¡5B>{5/m‚,,/ak0>J>T

KFRcP&g’¿]5C‚JﬁR'o-L C{o&gO¤=¶B”7[ &¡{

,&&¥ &¡5B>{

5/E⁄-L’+5~‘}5m‚KØPOEKooPm‚

6˙pP6B”’5  Cu(/pJˇ,(“k={k=’5¤¨L}6i/GK

l;Zº1$g˛l_lGvo

󱶩󳒣󱙆󱟼󳻱󱮧󲓣󲸜 /󲔲󱺴󵵙󵯜󱽓󱠅󲙨󲒵󶳧󵷐󴳖

5~‘}5B”J‹?5’@C,;L¿(’)Ø  &p~‘+¸m‚>Jf

KØP{.«KM&„*-"L¿(  C05n-k1$6˘OEKoo

*-"?L.I’?tPDI‹ºiy„}a{C.I’0h¡P

0lG{6˙5}F=#r•,’x«o

0+sdP,_‰bl;/†(dn/]5n&v8¿oº0V5Bh7ﬂ-"

~-i0˙sf{kK’56yB.˚.F/’˜/œB¤&.˚,Z&0?{’k

,GVl;w/p5’k&¤(NDm‚H-S'l,l;x›e'Rß8—o

S,D&gs+OEKo

 P0\nk=&CFEm‚

,il;/†(dn/]5y„}a{5vio’H›e'P0««C"¡~‡{

\o&P  HfQ^m‚TMEæ¨-o

l;/†(d6˙5}F=‹naw xPkK«]l,L}&¥Eæl;/†

(d6˙5}F=pGtUJ>n~‘5Bl,l;L}-V1$‹º¤¨&¥EænZæ?7/œ

T˘ig* n76˙¡(nE˛–,0@n5~‘}5’˜/œ,&’›d&

0V(r((6,0Z0pm‚0V(r‹nao‹naRR-2.«KM  &p

~‘+¸KØP{RR}J>Jh¡,iW•D›m‚K*?o5~‘}5J‹?5’@

C,;›8“KØP’)Ø  &p~‘+¸m‚’a1w{k=’5OEKo,i

J?1$OEKo,&’›&¥([OP,5B>{  5/m‚l;/†(d6˙5}Fn/

]5{/B’G5/?hg+0n$o

  ?].’55,i·55,;Du(&g&¡,«m‚l;/†(d6˙

5}F}ł}^{C.Rc“=‡m‚5/0?,"§vm‚,,/ak0’2&o

该项目将推动我们尽早建成预警系统，帮助我们改善

全球健康危机，让基因组学造福全人类。

非洲 PGI 影响力亚洲 PGI 影响力

KØP

900 万美元

KØP

200 万美元

20 个

5B>{5/0n$

4个

5B>{5/0n$

践行 6,000 万美元捐赠承诺

5’@C,;>$I

󵸂󴎜

1,100 万美元

H‹na0.’˜RßL¿(m‚

>JfKØP’)Ø

2022 󳌤󸴔󲼾

非洲联盟大厅里的一句非洲谚语充分体现了全球伙伴精神与合

作精神：如果你想走得快，就独自行动。如果你想走得远，就

结伴而行。



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? 6˙5}F=Eg1. d.;J

’æ&r"(’ªJª0˙ O¤L8·TKF

卡塔尔基因组项目

/S7\?76˙5}F‹na w xYß5(“k=5~‘}5JﬁR'?/S7\?7

Q\’~&¥m‚&¡(dsd]5C‚{C5¤K(-1$&¥&’~&¥Ls

(pGtUo

埃及基因组计划（EGP）

’C{ s0=pG tU&xJﬁR''w 

x1$5B¤¨¨ C§r]’+&x5~‘}50V(r0.

6˙5}F‹na&0C<*‹naP5«0b6i/œ’>JP6/L6˙5}Fo

新加坡 SG100K 项目

 C{>JP6P.55B>{y5,¥/kºIkm‚f›8/@(Y4 P

.5y5,¥*4DpGtU w x

&x5~‘}50V(r0.’+  ‹na o*‹na&„R&rC{na

SßP?  &pP.5’w/6RniRßRn/jCRxsd 

]5C‚1$-S@o'’+?/07&s’¿F&v¨m‚~(dsd6˙’5~(d

m‚pGtU8“{ n?-Dk=OP'¸m‚)LGRßp`>AP.58·

P[~’0!&¥&xyj?vl;n–N/nmSl?1$,&’›¡~8—l,l;nq,"m‚

r"(nh7ﬂnk0]P0D›1$(5zo 

非洲人类遗传与健康

5~‘}5&„«]’x«(&x*4D w xL¿(OEKoo

 -S@(“k=RßH«]’~&¡(dm‚Pm‚,6˙5}F,;>{

’˜  fY§Sy&„6˙poo’HpGtU(“k=(n&Cﬂ1$](

dl;=P0\Rßp`>A(1$h7ﬂ5z?*4D1$l,l;m‚Eg1{’¢

\R?9i5R,«]6˙5}F8·TKF¤|‹{OV2⁄«]’[W1$,&’›

5/’[Wm‚*4Do

将遗传研究扩展到癌症起源

}?}(6˙5}F&¥Eæw x  ‹na 

w x&\⁄’5R,D.7~(d&¥m‚mSl?/kºJÆi&vC

vg,{P5L.mSl?\[kºm‚[W&”.˚CK*>,&03/œFo

5~‘}5L¿(’+’)Ø  &p~‘+¸m‚>Jf’a1wKØPRßOEKo

o‹‹na{C.’›’¢„>A&v0Zs+P[¤m‚BD{o’HBD

03JP&v0Zx«6m‚mSl?50k0hgn\[kº/C1$k0=‚hgP0

«=‚5BDm‚/†5o*‹na¡wk=,6˙5}F]5C‚w x{

?’ak0m‚O¤L'¸«0bOﬁ&¡pGtUkr,D{’˜-/DRR8—nRR

8·TK.˚m‚¯l,6˙5}F?'¸0Vo

美洲原住民基因组研究

w xP~‘5Bu&g>{

kK/†(^[Ws0=>{1$¨Er"~I0}FDn‹?m‚«-DF

s0pGR…S,oH  CIu(’˜Rß{*ºnEm‚naSß:$}JP

p`)B/†(^[WJ8¿0n$’5(=1$*4DpGtUm‚0?o 

 C{&„’+7E/†(^[Wr"~C?P,_‰blG1$

R¢Rß›e'm‚J.{I’0b8D\N<P[¨EKØP’+&g05

/FYU4FR5.   ’˜/œ9rRCL¿(6˘o  &v’

J8¿n/]5  lG{\&nJpGtU,&’›I8·I

?1?’’#IEg1m‚l,l;{9uyj?vl;nEæNvl,l;1$}U

mSo

澳大利亚 OurDNA 项目

aL8—-D’G~(d6˙5 }F=&¥Eæw {kK  /=pG

tUJ>1$•8·++˜uYpGtUJ>0V(rDu(x0p’+&g‹P-"{

P5&v0Zr"//&x-L6˙5}FpGtU&¥o5aL8—-D’GO_C˛

L¿(m‚  &paL+¸w &p~‘+¸x4.’˜/œ5~‘}51$

,&’›}F}Im‚4.&t{aL8—-D’G(8·TKFO¤LC‰‹nawsf

&„x?OP'¸O¤L{’˜OV2⁄/kºRı’&v¨r"/m‚

l,l;‹º]5nP1$\[kºo

基因组发现联盟（AGD）

5~‘}51$  >RB&x>s*I]5C‚

0V(r{? ?  ’  TKR¥sd,6˙5}F]5C‚{o

’HTKR¥&”‡kK«R~‘5B’  TKR¥S,I{*~(dna-x

56˙5}F=&CﬂCk=pGtU&¥’¿F&v¨o

󱝠󸀮󱮭󵢶󱮷󱞮󵵙󲙨󲒵󶳧󳽉󳮹

6˙5}FO¤L?‘*ł&gD˛5C{»n7’¢Pl,l;¢„>A-Ly5,¥

fD0v/kºhooH1nÆO¤L'¸E‹,(Rc’¿F{

p`)B6˙5}F=J8¿}[J>Rc’CRßsdS’Eg1o

?tv6˙5}F=’˜/=07&s-xJ>R¢Rcm‚C,’+&Cﬂ

>J({(NP&v,Ch¡(d,=‚5o8—8·P0*5B>{J^Rc

J.0Kƒ6˙5}F=m‚.¡o5,"’5l,l;›e'm‚6˙5}FpG

tU&¥{  m‚/&xO,(RcY]N}ao

&„p`)B5,i8·TK.˚Q^&tiR6˙5}F{I’-"L¿

–6˙5}FO¤L’¿m‚CvFooTK{I’?‘Jƒˇ?R?8·

6˙5}FD0kº\1$R,P0Ti{’¢\¤([R¢Rß/=&¥m‚*

)›Fo

我们很自豪能够为商业和慈善事业提供支持，为提高人

类遗传多样性以及确保将基因组代表性融入未来公平医

疗做出贡献。

󲝿󱶩󲙨󲒵󶳧󲵷󳽉󳮹󲡕󴏬󳘮

让基因组学惠及

所有人

增加6˙5}F=O¤L 多样性

1$’¿CvF

确保每个人可&E⁄TOL,&&¡’*4D

“=[>A-Vm‚KQOyk01m‚\[kº

填补4_B&v¨r"~m‚

缺口

确保基因组可5E2m‚,i8·TKF

Q^&t 解读



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF d.;J

’æ&r"(’ªJª0˙ 6˙5}F=Eg1.

󱮭󵢶󸉜󵷘󳜵󱰤󴘬󸋃 1

󸶲󸳣󱺶󵮌󳻦󱝑󳿑󸉜󵷘󳐴󲼾󲙨󲒵󶳧󵾝󸚬󶋑󴃽󲃅

󱙚󳛷󶻰󳱠󱡹󳻦󳬐󴊜󴷠󱹫󲙨󲒵󶳧󲵷󵵙󳔈󲄨󱶣

L¿–Jª§HZæ(1$

OE’P0/&xC 

k0I&Cﬂ>Jk=F

L

«0b/JÆ’01$

O_C˛’¿D?O« 

L¿–¡wk=hg

‡G..-/P{L¿–03KF{’L¿(]5C‚’1$O¤Lntt&v

8¿oI’n“=‡L¿(Rc’)Øm‚\>¸{.W•D›ﬁ0{?6˙5}F

]5C‚(r&„&g‹/kºJÆiSß,¥{’˜YRßOV2⁄GVOm‚\[kºOjSS{¤

([Oﬁ(d/kºIR¥oBLk0InO«1$r"~LC].{5~‘

}5].’5J8—/kº»n7·55{.6˙5}F=m‚Xk={(“,&I&„

&gs+RcOjm‚PB¤,(o

󶸁󲓣󸉜󵷘󵠈󳽉󳮹󽘘2022 󳌤󳌤󳍡󽘙

󳨩󲡱󳛷󶻰󸉜󵷘󷕕󲓖󽘜󳱠󺂿󳪄󹛩󴪒󱡟

无创产前检测（NIPT）

F“)B'’O¤ 2.597 亿

»n7J>Rc=†9

2.248 亿

87%

’»n7–›e'’~

3,430 万

13%

R¢»n7

50 万

<1%

体细胞突变组合（肿瘤学）

»n7«60b1$J?}F0V

2.733 亿

86%

’»n7«60b}F0V 

3,100 万

10%

R¢»n7

1,290 万

F“)B'’O¤ 3.173 亿

全外显子组和全基因组（遗传病）

’»n7 

1.67 亿

64%

R¢»n7

3,040 万

12%

»n7  1$ 

6,230 万

24%

F“)B'’O¤ 2.597 亿

12 亿人

20 亿人

0n${,i·55,;

w-L  Cx

2022 年进展

2030 年目标

↑1.49 亿0ZZæ7§¸

9.86 亿5.36 亿

↑5,200 万0ZZæ7§¸

7.14 亿

↑6,200 万0ZZæ7§¸

2022 年进展 2022 年进展 2022 年进展

6˙’5

NIPT

nQ;RmSl?,Q^0D-S@I(l;

WES/WGS

m‚»n7hg1$Jª§HZæ(

,i»n7hgO¤Lrm‚PI’?,i  &¡5B>{5/w~‘5Bn.Km8—nZæ-DPnL&+,1$5Bn&‚•Ln\5BnE5Bnf6?7,nH8—-Dn,nﬂhfni,)n

5Bn’˜-)nPR¥n«œ5BnaL8—-D’Gn&¥5Bxm‚vG,o



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF d.;J

’æ&r"(’ªJª0˙ 6˙5}F=Eg1.

󳦗󵬽󳘮󸚧󳮹󹲁󵸂󽘜󴀬󲔩󸚏󱮭󵢶󱼂󵫑󶥚󶴂󱾍󱘙󸴔󴊜󳌨󸚧󴁩󲙨󲒵󶳧󲵷󱙑󳍐󲷫󵫞󳘮

普罗维登斯（美国）*,0@Yß5sd,«(

5Cv-S@w x{’˜P¨,&5}~0V/kºy„}a

&¥m‚>Jk=FoYY0V(r’ak0’+  8·wM‡{

C&nRc8·w0Zd>NOuN?5 C-f\o

Ballett（比利时）*pGtU?}5,RßHZæ-DP

 &¡mSl?&¥Eæ1$

&¡ >J>Tm‚  0\

GVO{B5BRc/@&gOE’y„}a>J  m‚>J

k=Fo

小狮子宝宝计划（德国）[“?:›/='?(.

 m‚(“k=G,{Rß9P¨5Pk0+˜¡~l?n/JÆ

>Twx?k(C(l;;+˜GVOsdPR

P1$\[kºm‚sdS’H&—o

复旦大学附属儿科医院（中国）&s]s8P8—=¤Æ

?'+˜s0/'Yß«0b  ;+˜GVOL¿(  ?-P

F/  PR,P0Ti{(“&¥5B?‘  F/

 Ck=ﬁY*I&>{,{C0’+u&gwnq

,"pGtUOuNo

Optum/ 联合健康集团（美国）*,0@5~l;n

¯l1$EæNvl,l;‹60.’+8·&¡Lk0I‹

na{nam‚P.k0IR§Iy5,¥/kº-xQ^J>“=m‚

Lo

小羚羊宝宝计划（以色列）5~‘}5&„’˜-)/ak0

¨m‚&g&¡c?‹naL¿(’+OEKo{*‹nakKfK}v

8  /kº&¥Eæ(=pGtUJ>f›8{P5

(“k=,6˙5}F]5C‚w x?5  ,;Ly0

\[kºm‚/m¡~l?Pk0+˜sdF/Poh¡B”e5&

Cﬂ}USSJª0˙{p`hgLy[ oTOL?-~u~Y>H

>H-"0E⁄m‚sdS’ISS{/ak0¨RcR5  C

*-&g‹,"’5?  &¥m‚F/,6˙5}F]5C‚

w x>JdJª§Hm‚,v;{CDu(,"’5’˜-)0P

5/'(“k=  (r&„PB¤,(m‚5B>{Jª§H-VCo

800 多篇 263

Ik&Cﬂ0Zd>NOuN

5~‘}5OuN5 w6˙5}F/=CC5‹xw 

x ,"’5  CJª0˙m‚Xk=6˙5}F)LGD?&Cﬂ\[kºm‚/’8—s?&¥

sd’+¡~c?’}O

HpG1$pGtU0V(rYß5,isd



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF d.;J

’æ&r"(’ªJª0˙ 6˙5}F=Eg1.

The Adolescent and Young Adults

,mSl?pGtUJ>w { x

1$,  6˙¡(m‚pGtU’0Yß5D?&g‹5B>{8—W•

6˙5}F=HpGo5o‹HpG&¥{pGtU?-}F?LrtU  GV

O?,6˙5}F]5C‚w xm‚¡~ sC’˜/œ’›’m‚8

iP0D›oHpG}USSk=’5&„R¢Rß¯l>J(L¿(Kw?w5&„

 5&Cﬂ&sRßC".˚x{COV2⁄o’HGVOm‚\[kºo 

了解你的生物标志物

*].kK ,i}UmSl?/8(w 

x 0p{P5L¿–’’?k0fSßFfU,]51$

\[kº,v;m‚Øo0%8“{*].’˜GVOOf’2&„&”{¡~c?

EHk0fSßFfU,]5?}UnlmSGVO‹º0_m‚Eg1o 

Rare Barometer ：罕见病患者诊断之旅

 P  m‚SßFFHS¯‹na{P

5&„  ’˜GVO&„&¥Eæm‚>R(L¿(Kw?o*HS¯

‹nana-xHpG’+,i  &¡5B>{5/m‚  8·0\GV

Ow]n7  8·s+~l;xoHS¯}USS?0P&¡GVOm‚}Q

/1$H[¤F“IRc'¸(d’¿H&—m‚O¤L{k=’5Kw?,v;{

)s)LG’\](1$L¿–Øooo‹HS¯’5  C\

I{P5LrtUEg1~l;p`Bsm‚&¡’1$8“¨5zo 

津巴布韦“我们‘关注’罕见病”（We LOVE Rare）

’+R-L0P&¡5B>{ 5/5&E⁄PR…(P0«=‚5BD0_{

\łB…B«s’FHf}F}Iw { x

0.’+&g&¡‹na{nam‚PL¿–’’m‚Øo{C‚=. ’’

’uH-/Æ “?J“ ”~l;+˜uY1$“?1CGVO{0ZPD:$

-/DLO¤LC‰{},W,"’5\łB…B«~l;](d1$Eg1

m‚’)ØTi(o 

年度罕见病宣传活动 #照亮罕见病

I’m‚0B¤?~l;r"~JıRcS’8—cGo’›’P¨mﬂ{6˙5}F=Rc.’5}URGVOm‚

PqPG{OEKo’›’m‚/kºvio’¢  Cp{,&kr5’3RbRR0_&g8&¿d~l;

P].{L¿–~l;m‚,,Øo{EH,&?GVOk0]m‚Eg1oZC{I’m‚0B¤Œ

(/.*].{5~‘}5’æ&6˙¡(--(0bE2CKJm‚Hy2⁄R…S,sdKØPo

OV2⁄GVO‹º0_PI’(“1m‚TMEæ‡zoI’&xGVOn>{

C1$’¿r"~m‚}F}Isd0V(r{C.,(Du(?l,l;m‚

Øo{C.GVOTu()LEæ{>Jh¡OV0o  C{I’

BOEKo&v0Zm‚‹na{O^8—GVOm‚8n‹{?0P&¡Of’20VC

I,"’56˙5}F=5¯l1$~l;\[kº&¥’)Øm‚L'¸0Vo

支持患者

罕见病青年患者实习项目（Rare Youth Intern

Program）

*‹naP5C.&kr0P5m‚~l;“CGVOL¿–JﬁJ1$

)LEæ{..’›’J“-LRcH&—m‚B¤(r{0ZPL¿/.&t&g’¿)‚

?Om‚J.ooP5~‘}5u’3C&„o&¡RcEg1.m‚‹na

L¿(OEKoo

因美纳患者大使

5~‘}5GVO8—(“ºnEP&g&¡kKGVO/œ,&>{CI0}FIm‚

ºnE{].’5L¿–’’?6˙5U,]5¡~‡Fm‚Øo?R?

C\m‚r"~&¥,(Rcnq(C}Q/m‚>{Cºy„pRß{C.’›’

5?J“P&¥L¿(OEKo1$.¡{0ZPOV2⁄GVO/kºJÆi

1$vio*ºnEB-’gGVO/œ,&>{CI0m‚&¡’}Q/

RßO«1$n.Oﬁ&¡k0FVy„}am‚OEKoo



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF d.;J

’æ&r"(’ªJª0˙ 6˙5}F=Eg1.

扩展基因组学教育

.L¿–6˙5}F=03/œF{I’“=‡L¿–,(?>m‚Øo5~‘}5].

’5L¿–/kº‹6?6˙5}F=m‚Øo{L.y5,¥/=0?oI’m‚naSßP

.E6˙5}F=O«{,((dP0\.«KM&„/kº&&’8f1$O_C˛’¿L¿(OEKo{

Du(6˙5}F=&&’8f&¤m‚ºy„{’˜/œah. &t&g’¿s0=>{n-/PO1$

s0pG’0.DN–@‰o

I’].’5B&xr"//ak0y„}aDu(ºy„{L¿–’’?6˙5}FU,]5m‚

Ø{J8—6˙5}FU,]5J^03/œFo 

 C{I’&¿.’+ﬁ? 5~‘}56˙5}F=

5—w x{<’+RßHs0pGﬁL1$&CﬂpGtU}F

}InO_C˛R…S,/œ=R'krm‚  8·0\Rctm‚

’8fn>PJ*1$‹?O{’˜/œ/'‹?n&Cﬂ/k0n

OE’P01$GVORn$)‚?Oo0%8“{nRc 

’/.’+}A&s5—o(r&„6˙5}F=-/PD‚N~{

I’Yß5¡~PS,GR?8·03JF{Cah. >PJ*8—

—/Æ*o

’+R R?8·5~‘}5].o

5~‘}5E}CJ8¿&¿.o5g]fn?

({0Px«(s’J^‚¯ł&g6{,"’5

C?E2’&g’H&@KIm‚R,P0Ti{¡~P

>A&—I’J&gp-/#m‚03JFo

Francis deSouza

5~‘}5ﬁCJd>=

󲒵󶸁󶳖󲙨󲒵󶳧󲵷󸚠󲕱󽘘IGF󽘙

J?&x&&/8(1$/=kr&¤m‚g]u(

/=O«w x0V(r,"y„{&„J>Rc

&Cﬂ¨¤vL¿(O«R…(

2030 年目标

>30,000 名

=&OB  &n$

2022 年进展

98%

/&xOo1$J.

7§¸hg

>95%

m‚/=O«OEKo‹na03L¿/./&xOm‚

o1$J.

25,000+ 名

/kº&&=&OZC0n$

30,000+ 名

/kº&&=&O0n$

Francis deSouza

5~‘}5ﬁCJd>=

 C{I’&x ~‘5B‹º¤¨Eænl;=( w 

{ x0V(r{,0Z-/D’+&gy„-)ND>P{J

[CC{B”Rc  8·0\=&O’¢&¥0n$oI’}i}oOEKo ~‘5B’x«

(=( w x&„(=&&’0L¿(5}AO«{C/.’+ 

u/’?CC‹?5PTq({’+9u(fBD/',;m‚6˙5}F=J

.C./JÆ’0>Jh¡,"§v/kºnaSßo ’+RR?8·



󱞒󱘭󶇃󱞵󸢴󱞄󳦗󵬽󱘙󶙸󵢻 可及性 󶇃󶸩 󲁸󳉉 󲼕󸢴󸳹󷞳

󶘮󱜾 附录󱿔󳬐󶴐󳘮

󹺘󳊰󳨥󸀅󲷞󲸶󸛓

IkP0ƒˇ&xEg1 -/P&x03KF 6˙5}Fk0FVy„}a L.6˙5}F=[W&”.˚ )sHy2⁄’2&0? O¤L8·TKF 6˙5}F=Eg1.

’æ&r"(’ªJª0˙ d.;J

C-x{  P&„Q;R‰mSoo(Y/B.B?[WP&r&¡=='m‚f?’u{’›m‚

&&¡‰ŒRc¯lo  -Lm‚&g(Y/k0D’›*k0fSßFfU,]5{os+U,]5P0\-D

k=P&g’¿]5C‚JﬁR'Rßp`>A&¡(d]mS6˙51$,&’›SßFfoBU,]5p`>A6˙5tr0/†

50_{GVO03’˜KJLy0R?&¡F.˚m‚\[kºI/.Rcn$m‚&Cﬂo?’5  Rß9{

k0fSßFfU,]5}[’›CRß’+«60b\[kº-"{CJ&x8—>{-’g’›&xmSl?*O’0m‚Of

’2o ’+RR?8·

󱮭󲙨󲒵󶳧󴳖󳍙󸚰󳾸󽘜󳭮󳼚󲭑󱭥 Fitz 󵵙󵫑󲂱

󸀅󱶴󸣜󷃫 󳨈󸢶 IV 󴈮󷁞󵳴 󾗜

󵫑󵙀󴎜󳖬󵙀󴓍󴳖󳻷󱾮󱛌󱘈󱲸

 C{I’&E⁄  Øm‚(d8“PU,]5’a1w ™

w x w xP7’+&g‹(6'eP

w xR,P0Tioo&gU,]5-kn103(.8·&¡¯l6˙51$k0f

SßFf{LrGVOmSl?m‚f>A-='5CvoI’?}i}o&\⁄’5R§I

Pk0fSßFfm‚‘¶.{p`>ARRRc03J’¢y5,¥/kº&¥0n$m‚k0fSß

Ffo&xK:›0V(rD0m‚o&g(6'ePR,P0TiPI’&gy„-)R

,P0Ti&¥m‚ﬁY·R,P0Ti{o’HR,P0Ti5†6˙’55~‘}5&xd&‹

,Y’æ&&¤C\m‚¯l=0V(r,"y„\D0{P5L.mSl?P1$

y5,¥/kº0?o ’+RR?8·

󲒵󶸁󶳖󲔩󴤮󴲮󳰡󱲡󱮭󳾾󴰭󵳴󶋌󱟗󹤆󸚰󳾸󸋳󱰠󳿑󴐊󽘜

󱿔󱙚󳴡󳊥󶶢󸊼󲙨󲒵󶐓󱾮󵵙󳛷󶻰󱺱󹀢󹫗󲀃󴯼󵮌

 C Rb{  1$  CnÆP

-k0m‚+˜='-.’¢/'5-L>{&¥{?‘Ly-L’+&g&¡zF

kO"o’›’“=‡u(/pn5/Æ ;&g‹sf&„¨¡wN]5

m‚C"vCS¯Qr{’›’-.-k0m‚+˜='  GVRc¡~

l?º0V+l}ˆ'4w xo  P&gs+~m‚l,

l;{&sf&„‡[^\kQ=l?·o  }ˆ&.JYßC"m‚

+ly„}aoB(Y’5~‘5B.-Dr•?r’GB5Im‚

 +˜uY6˙5}F/=pGtUJ>m‚F/,6˙5}F]5C‚

w xsds&gYU,]5{p`>A’+  GVRcf>Ax«

6 {sf&„ I o  J8¿

5P¡?¸Ly06˙5\[kº{5Y\[kºBs&¥{/k0(

L¿0  m‚C}H{0bC}H\⁄?}QT%Yßm‚ 

&x~‘5B‹º¤¨Eænl;=(

,0Z-/Dm‚ 系列播客Gˆ/œ

 26,000 名

=&O

HP,_‰blGe0’˜Rß{5~‘}5JﬁR'

&gnl8’5Jl-x\‘{C&5Oﬁ&¡lGR

¤Ko}o5,i  8·&¡5B>{5/0Kƒ

¡~‡(rk=o

󶴊󶴐󲔩 SARS-CoV-2󱾮󳐸󴏔󵷐󴳖

󳿑󹪸󱦿󱲡󱶷󱶣󳌨󲷫󵡂󱳐󳾾

]l;6˙5Ka{d,0_,D?C}H5(d,;oos+\[kºI

.5’¢“*D:$-/D’+&g&¡J8¿YßC"XﬁCOEKo  m‚+

ly„}ao’C{  C§r]’+’›m‚&r?Łk0P{’›h¡5P&g

&¡F/&n*4Dn]\`m‚?-=o 

&„’+C.L¿–’’?  0h¡Pw Rb Pxm‚

ØoC{5 Rb P5I  ,5)5IO8f¤›

UOiZæK&s{  &x5~‘}5ﬁCJﬁR'>= 

Jˇ-’+u&gioO¤&p0\UOi·w’˜/œ&g~Hm‚5~‘

}50B¤x&gpC§r]  m‚*4DI§¸{CL¿/.,(?6˙

5}F=’˜/œ,&J>JOV2⁄’x«*4Dm‚B›8—‘¶.m‚Øoo

’+RR?8·

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 r"~Jˇ4 0B¤/&x d.;J

>Jh¡ STEM O«,C

为社群助力

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ r"~Jˇ4 0B¤/&x d.;J

>Jh¡ STEM O«,C

IkP0ƒˇ&xEg1

战略方针与影响

我们致力于回馈社会，通过我们的业务

创造共同价值，并寻找机会为构建一个

更加平等、可持续、属于所有人的未来

做出贡献。

培养一种鼓励员工回馈社会的文化对于实现我

们的使命具有重要意义。我们在企业社会责任

重点领域的引导下，利用我们的技能、时间和

资源为社群带来积极影响。

提供有意义的战略性社群投资

鼓励员工回馈社会，为社群带来

积极影响

推动实现 STEM 教育公平

Gˆ/œ 500 万名

STEM 学习者

g˜ 100,000 多小时的

志愿服务时间

B5~‘}5,"FU‹na

50% 的员工参与志愿

服务

49,827

?-P 1

120 万

STEM =&O 1

,i,Rc 1,747 个

项目&E⁄OEKo

H 2019 C’˜Rß{/&x

KØP1$FHfRj.‹nam‚

0B¤’O¤ 增加了 10%

r"~Jˇ4»n7 46 个

国家 /地区

F“KØP›* 1,800 万

美元

50%

m‚0B¤B”/&x

1H 2019 Cw6˙,¥[Cx’˜Rß

员工参与KØP1$FHf

Rj.‹nam‚G,

志愿服务

捐赠

总参与率

2019 年

29%

40%

19%

2020 年

24%

20%

2021 年

10%

31%

26%

2022 年

39%

50%

28%

关键目标

I’m‚0B¤c“’55ﬁØr"(’˜/œ&„>Jh¡R?,

YßnR?03Ko}om‚R¢Rß§BC⁄{o&gc?I&g

nl^?0‚=”o

Sharon Vidal

企业社会责任全球负责人

联合国可持续发展目标

2030 年目标 2022 年进展

2022 年亮点

Future Kings =k0/5~‘}5B…

?7m‚M.,5J>o

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 0B¤/&x d.;J

>Jh¡ STEM O«,C

r"~Jˇ4

提供有意义的战略性社群投资

我们将社群影响力战略的重点放

在支持我们为患者、社群、员工

和地球所做的企业社会责任工作

的投资上。

I’BHy2⁄].&x«-DR…S,m‚0V(rRß0Kƒ'¸

(dEg1.{-Dk=I’m‚4_BRß_¨E251$,im‚

“=[o

社群投资关注领域

我们如何回馈社会

因美纳公司

因美纳企业基金会

员工捐赠和志愿服务

方法

Rc“=‡m‚GVOJ8¿0n$’56˙5}F

={L¿–6˙5}FO¤Lm‚8·TKFo

阅读“可及性”章节

了解详情 →

可持续性和环境正义

方法

Jˇ403Ko}o0?‹na1$B¤(r{’˜,

CP0D›0b([q+R¢RßB^o

阅读“可持续性”章节

了解详情 →

多元化、公平性和包容性

回馈当地社群

支持员工热衷的公益项目

方法

sdS’Jˇg’55ﬁØE25r"~m‚,n$’2

&{..E25r"~C?E2&t«&m‚

¤|‹1$KI{‚=. 1$OEKo0B¤/&x

’›’,"Eæ{c“m‚,n$‹nao

阅读“社群”章节

了解详情 →

方法

7.6˙5}F=O«COEKoCv&0

STEM O«R…(o

普及 STEM 教育

5I’m‚J>RcJˇ4&¥{8·+¸.˚n,CF1$.«>FPtlI’J>RcJˇ4m‚6˙R¥‡z{ 

o03p`)BI’:$}J(+L9u(f,C5Gˆ/œD.7~(d{.8—?’›’m‚OEKo.Co

阅读“员工”章节了解详情 →

阅读“社群”章节

了解详情 →

平等获取基因组学

项目示例

•

5~‘}56˙5}F=0h¡

• DNA Rp&

•

6˙5}F= 101

• SD STEM 8·TKFw SD2x

• ENLACE SDw7ﬂ1¥ x

•

7U#R¢Rßw5Bx

• CHRF STEMw=˘.K5Bx

•

k01s0=sT%5)w&¥5Bx

•

“CI?‘

项目示例

• iHope

•

l;/†(d6˙5}F=‹na

• Native BioData

• NYGC Polyethnic pGtU

•

}$/’=¶(§‚g}H-" →

项目示例

• iConserve

•

,Z&6˙5}F4.‹na

• STREAM

• CSUEB }k0f~EpG tUJ>

• GRID Alternatives

• Solutions Project

•

&kr¡k0k0f6˙¡(

•

‡k(^§¸[—m‚E˛u›·,n$KØP 

w.’iB’æ&>{h)B6˙¡(x

项目示例

•

b˙'…1C →

•

/6r"~KØY· →

•

&+,OEKo →

•

5~‘}5,"FU8—(“ →

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 r"~Jˇ4 d.;J

>Jh¡ STEM O«,C

0B¤/&x

鼓励员工回馈

社会，为社群

带来积极影响

我们努力创造一种以目标为导向的文

化，支持员工投身于他们最为关注的

本地公益项目，并与相应的外部机构

合作。

员工捐赠和志愿者福利

KØPKØ

500 美元

CFHfRj.)œw VTOx

16 小时

P0B¤s+='KØP

4¡

25 美元

FHf].5ﬁØ 

Z?-PFHf].Rj.?

5ﬁØ 10 ~‘+¸KØP4¡

10 美元

个人

圣迭戈课堂 —— ,i EHS

–})F“n/ Keith Rego 5,&

=='m‚h&s£’+’›m‚B¤

(r’˜/œ DNA JﬁR'CRßm‚03

JFo

家庭

清洁湿地 ——48 0\5~‘}58—&¥/6/FHfO/œ,&

>{’-xE&s]s@ØP¨&_Hd,)BJÆ//.’+u’3R

_*5^a\˙].o’›’,OP'¸’+ 250 ,PCP7UOæ

j1$\\A7UOæ{o’HOP'¸9im‚CDf?(-V(r

I035OP’a1wo

国际海岸清理 —— 5~‘}5 100 8·0\0

B¤w51$/p?,x/.’+E25]s

_^ai].o5Oﬁ&¡5/{ 4,000 8·0\

FHfO,^ai’+ 3.5 &pqH65⁄1$pæfYo

地区

志愿服务日 —— 5P.5&„R&g&¡Rbm‚5BC§KØP].w National Day Giving

CampaignxR¤{RßHP.5naL8—-D’GnPR¥n«œ5Bn/jC1$,&’›’G81$P

R¥5/5/m‚ 253 0\5~‘}50B¤5o&¡]s@6yBnqł5&gp{/.FHfRj.]

.{5ﬁØr"({’›’5&g8,;?‘/.’+’@&¡].oI’m‚0B¤&„5.+˜uYL¿(’+

STEM =&R…({&„–/mHC’L¿(’+4_BOEKo{CL¿–’+h7ﬂ03Ko}oFo

生命科学多样性 —— Z&¡ ERG Œ>$I&g&¡,(Rcr"(Eg1.

m‚‹nao iLatinX ERG I0>ARD?r"~LC].{&„=k0

L¿(˙?{0b’›’£ STEM VFA/œnq,"&{0ZPsdS’

/&x0Ps+nq,"‹na{(9u .-Dr•?r’GB Biocom pGtUJ>m‚

Generation STEAMo

阅读“员工”章节了解详情 →

ERG

团队办公室

Pedal the Cause—— 5

PP>PJ*I.5¤›&„/.+˜

uYHd¤dKIKw Pedal

Kids Challengexm‚=='-V(r

’+})'˘Ow{Y&¿P5OE

KoPedal the Cause{*}F}I

&„mSl?pGtUL¿(’+¡~‡m‚4

¡M.o

新加坡因美纳“散发希望”慈善活动 —— 5

~‘}5P.55/m‚ 27 0\0B¤B-m0{’˜

v'¸4¡CL¿–,(?+˜uYmSl?m‚Øo5

~‘}5Rc200 8·0\0B¤/.’+*].{&„P

.5+˜uYmSl?6˙¡(w Children’s Cancer

Foundation Singaporex,v'¸-L[ 3.8 &pP

.5+¸o

剑桥郡日 —— &„’+C§r]9Nhlmﬂ¡rªC{

5~‘}5(r&„&”‡N.2A/.’+-TP

w Cambridge County Dayx].oh¡5{ 

I’Rc&g5Te{’}O’+p:$’5-T

1950 C’¿m‚ DNA /07o

罕见病日活动 —— 5 2022 C~ l;P{5~‘}5¡~c?

OEKo’+~‘5Bm‚

SLC6A1 ConnectnPR¥m‚ ASridn~

i?r’Gm‚ NoRo 1$/B«~ l;}F }IoRßHZ&¡}F}Im‚

,’@&¡>{CKM’+~ l;GVOm‚PC"k0]dfYo

阅读“员工”章节了解详情 →

公司全球公益行动

Giving

“Twosday”—— 5~‘}5&¿.’+,

iF/)KØPKØ].Rß},FA‡}[’.PR’3· 

w Giving Tuesdayx].oI’RR[m‚

#GivingTWOsday22 ].v'¸’+B 23 &p~‘

+¸4¡{/&x0B¤’O¤[ 800 0\{»n7 29 &¡

5B>{/5/m‚ 580 >{Hy2⁄R…S,o

走遍世界，终结癌症 ——900 8·0\0B¤/.’+}A&sYdKIK‡e

&kr{}J}U¯lw walking the world for oncologyx·o I ’

&¤v<’+8·>{5B¤¯lHy2⁄R…S,/.*‡Yd}URmSl?w Walk

to End Cancerx·].{.«KM

ASARGA Fighting Sarcoman

KickCancer Curving Kidsn Zero – The End of Prostate Cancern

aL8—-D’G~ mSl?/8(w

Rare Cancers Australiax1$ BEABA

Cancer EducationoZ&¡Hy2⁄R…S,ŒOP-L’+5,000 ~‘+¸m‚KØY·{

Oﬁ5].,.k'¸2⁄Y· 2.5 &p~‘+¸o

我们支持员工通过多种方式回馈社会。员工可以个人名义，也可以与家人、团队、当地办公室、地区和员工资源小组一起参加

志愿者服务项目或参与到公司全球公益行动中来。

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 r"~Jˇ4 0B¤/&x d.;J

>Jh¡ STEM O«,C

引导教育工作者

ah. &t&g’¿Tu(I&„R¢Rßs0=>{n-/P>{1$DK*Om‚iG{“=‡

’¢O«B¤(rO,J[o,Œ)¶5~‘}50B¤1$«-D0V(r((6m‚&&o

{I’&„O«B¤(rOD0’+&¤vm‚B¤,(1$Cs{’˜R?6˙5}F

=C,C6o

•

因美纳基因组学发现 —— B&x.-Dr•?r’GB Blocom pGtUJ>0V

(r{I’,0ZDu(’+&g&¡O«>J(r"~{OB03’˜5r"~¡}=

&6˙5}F=o*‹naL¿(’˜6˙5}F=&„¡~c?m‚&&0?n>J¤C 

snC6].n 5~‘}5K>>J >T6˘¤|R…(’˜/œd&ºy„o

• DNA 解码 —— B&x Discovery Education Du(0V(r{ DNA

R p&P5C.O«B¤(rOCnÆ=k0&gpLrzI’y5Eæ,¥8m‚4

_Boo’H4_B1$Kw/B0bO«B¤(rOL¿(’+6˙5}F=V£{EH

’+6˙5}F=&xh¡>J&krm‚ºy„{’˜/œK}Ck=-x«m‚O«4_Bo

•

线上探访之旅 ——2022 C{ DNA Rp&‹naL-’+ 6˙5}F=;

Rp&k01&2w Genomics:Decoding the Language of Lifex

}A&sLr&PG]. oo5+)m‚}A&s=&(d].B}ł}^J

&kr0P5m‚O«B¤(rO1$=k0C-L’+I’(Y’5.-Dr•?r’GB5

Im‚>J>T{’›’’+RI’m‚&>{5h¡>J&kr&¥9u(f-Dk=

6˙5}Fm‚.¡OV2⁄’x«*4D{’˜/œR?9i5)BJÆ5iHd,4_Bo

’+RR?8·)LGC¤|5~‘}5 STEM 4_Bo

推动实现 STEM

教育公平 DNA 发现日活动：

The Future is Bright

&„’+C§r] 4Rb25 Pm‚ DNA 0h¡P{I’}F}I’+&„R&g&¡Rbm‚6˙5 

}F=O«-"‡ The Future Is Bright·o5~‘}50B¤B&¿.&0

?{L¿(6˙5}F=CsCf›8sd.J[>JRß&x=k0Du(ºy„o ’+RR?8·

90,000+ 名

学习者

2022 年影响力：

6个

国家 /地区受益

我们致力于提供平等的 STEM 教育机会，目标是帮

助学生和教育工作者提升相关知识，激励下一代树

立成为未来科学家、创新家和开拓者的理想。

R¢Rß{I’J0>$I(“10,’5&t&g’¿J0Ly0{9im‚O«{&„SLyR¢Rß*

9i,¥8oBnlLyD?].{&x«-D}F}I0V(r’˜/œ0B¤/&x{I’GD‚

?O«B¤(rOI&„6˙5}F=)‚?O{‚=. =k0Tu(I&„R¢Rß STEM ‹?O

m‚iGo

120 多万名

STEM =&O0n${

B,i 1

500 万名

STEM =&O0n${

B,i

2022 年进展

2030 年目标

因美纳 STEM 战略

结果

‚=. ,&Tu(I&„R¢

RßSTEM ‹?O

m‚iG

D‚?,&I&„6˙5}F

=)‚?O

学生

教育工作者

对象策略

直接开展活动

与非营利组织合作

让员工参与进来

1H 2019 Cw6˙}A[Cx’˜Rßo

..? STEM 1$6˙5}F=}5,O«k0FVy„}a{ 

O«B¤(rO1$=k0J8¿&E⁄4_Bo

53%

的美国课堂活动走进 Title

1 schools

（低收入家庭至

少占入学人数的 40%）

1,500+

小时的员工志愿服务时间

2,230

个捐赠的草莓 DNA

提取材料包

1,600+ 个

社群合作伙伴和学校

130+ 场

活动

O«B¤(rO

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 r"~Jˇ4 0B¤/&x d.;J

>Jh¡ STEM O«,C

激励下一代

我们致力于激励下一代基因组领导

者，以及为未来培养多元化、包容

性的 STEM 领域从业者。为此，我

们与一系列社群合作伙伴开展合作，

并让我们的员工参与进来，努力接

触和激励来自不同背景的学生。

Junior Achievement BizTown——

2022 C{I’55Im‚ Junior

Achievement (JA) BizTown D’+&g

&¡?05o Biztown P&g&¡·(y6yB{P

JA m‚(dD›?-=‹c?-"o5~‘}5?

05W•K>I’m‚>J>T{RcB¤(ru@{=k0J8¿+˛E2 “s0=>{ ”{Lr

zk01s0=1$k0fJﬁR'd&&¥m‚&o 了解更多

San Diego Squared（SD2）—— I’E 

HJ8¿-4Iu( San Diego Squared

w SD2xo*}F}I(Y’5I’F“¨J>55{&

\⁄’5>Jh¡ STEM &8·+¸.˚o 2021 C{

5~‘}5J‹?5&rC,;L¿( 50 &p~‘+¸4¡Rß

OEKo*}F}Io ’+R5~‘}5 2022 C9=¡

& E⁄O{ ’˜/œ,"’5*}F}IIu(m‚R?8·)LG o

斯克里普斯海洋生物技术和生物医学中

心—— 5~‘}50b.B8—=5I-T%

w University of California San Diego{

UCSDxP+¡}Q\P]s\=pGtUJ>w Scripps

Institution of Oceanography{ UCSDx

L¿(’+8ﬁ1$Hy2⁄4¡{(,& ]s\k0fJﬁR'1$k0f/=&¥Eæ

w Center for Marine Biotechnology and Biomedicine{ CMBBx m‚pG

tU’ 0*pGtU&k=o CMBB &\⁄’5]s\s0=&x’x«*4D’\/ł‹6m‚pG

tUo5~‘}5L¿(m‚ou·KØP?k=’5Du(H..˚&¥Eæ{’˜/œ&„=k0L¿(6˘

{C.=k0&„’¢’2k0fJﬁR'1$6˙5}F=B¤(r*9i,¥8o5~‘}5].’5

-/#-/P1$0V(rR…(oI’E–,#J8¿?o‹H..˚JﬁR'ﬁ-LR¢Rßs0=

>{&J[{’›’?(C‹I’e0b&t&g&¡8—0h¡P’¿oBoY8ﬁ

1$ 100 &p~‘+¸4.{I’BRJ8¿C-L=k0C.F/]s\k0f=pGtU{’¢

\OV2⁄5i1$’x«*4Do 了解更多

剑桥科学中心 —— Oﬁ&¡88{I’&x -Ts0=&¥Eæw Cambridge

Science Centerx N.’+ PopUpScience Roadshowo=k0/œ,&>{

’03’˜B>J(s0=?"1$’=.s0=sLrzs0=&kro

Future Kings——Future Kings B8·Cm‚>J(Cs1$&¤vKw?{

&„RßH4_B.ß&m‚r"~m‚-2&¥1$–&¥kQk0L¿(\]uD› STEM Cso

0%8“{=k0n(Ly0s0=(NDn-/&1$s0pG‹naP0«m‚6˘o 了解

其影响力

ENLACE——ENLACEwﬂhf2&„ “link”xP UCSD m‚&g&¡‹na{P

5-Dk=s0=1$B¤s=(r&„TT¿{C.7ﬂ1¥–&¥k01$8—=k0Du(&&º

y„1$&¡’/Oo5~‘}54. 14 0\=k0/.’+ 2022 C?B‹na{’›

’RcR…(LyX’¢]s\k0f=-Lfis0=v&v0Z‹6m‚B¤(r{k([RcR…(

/&xNJ,WC0Oo 了解更多

Genspace——Genspace P}?}(Bm‚&g&¡r"/k0f>J>T{&\⁄

’5L¿( STEAM O«Cso 2022 C{5~‘}51$5~‘}5’æ&6˙¡(

0b*>J>TL¿(’+F“’)ØB 10 &p~‘+¸m‚h¡¡1$>JfKØP{C.>

L¿–6˙5}F=pGtUJ.{&„&gnl’˜Rß}.˚~(dm‚=k0L¿(C.o

了解更多

米拉科斯塔社区学院生物技术专业 —— 5~‘}50b*='L¿(’+>JfKØ

P{’˜OEKor"/='?{«m‚6˙5}F=>J>To*r"/='Rck0fJﬁR'

Cs{L¿(-=8f=(Y1$=8f=(Y&{’˜/œ,"’5>J(nO=¶Csm‚

&o*‹na0b=k0L¿(LyXP&g’¿]5C‚JﬁR'm‚R…({CL¿(+sm‚&&

Cs{C.J>Rj.8·+¸.˚r"~0E⁄I.o

儿童健康研究基金会 —— 5~‘}51$5

~‘}5’æ&6˙¡(0b +˜uY*4DpGtU6˙(

w CHRFx L¿(’+’)ØB 30 &p~‘+¸m‚

h¡¡1$>JfKØP{ CHRF P=˘.K5B

&g&¡)s,,/ak01$ STEM O«m‚«

-D}F}Ioou·KØP?k=’5OEKo CHRF m‚=˘. K5Bs0=>{6˘,.-" {

>?&„,5B4_B&r"/&¥m‚C‰9NFQ\/œs0=o{C&„8—=k0

1$-2,5m‚&&’8fL¿(6˙5}F>J(6˘o 了解更多

移动式基因组学实验室 —— 5~‘}51$5~‘}5’æ&6˙¡(4.’ß-D?

’ß8—=/S?7 ·R· \\´6˙5}Fk0f=pG tUJ>w Carl R. Woese Institute

for Genomic Biology{ IGBx D1$Xst.D› STEM >J>T’˜/œ

K8’0oBst.D›>J>T{*5¤›03’˜-xE}Q]81$O«Rı’¯

Bm‚5/D?B¤(ro 了解更多

让学习者从好奇心到开启在 STEM 领域的职业发展

5=k00O«m‚Z&¡¤Zﬂ{I’ŒC.’›’Tu(I&„R¢Rßs0=>{n-/P>{1$DK*Om‚iGo

好奇心职业发展

格洛斯特海洋基因组学研究所（GMGI）

—— 5~‘}50b GMGI L¿(’+>JfKØP{

OEKo*pGtUJ>B-/Ps0=pGtU1$O«

R,]s\n’x«*4D1$h7ﬂ«&m‚&@

KIo&„’+L.R¥5r"~O«{ GMGI

-/D’+TT\ºPfk0fJﬁR'='{L¿(&„R&k&¡Rbm‚>J(6˘1$&r&¡

Rbm‚Ck0fJﬁR'>J& o 了解更多

大学及更高等级教育

中学教育小学教育

=k0

企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 r"~Jˇ4 0B¤/&x >Jh¡ STEM O«,C d.;J

行动赋能

支持乌克兰

8万美元

玛西玛公主小儿肿瘤中心

（Princess Maxima Centre

for Pediatric Oncology）

资助从乌克兰逃到荷兰和美

国各州的癌症患儿

乌克兰受惠范围

10 万美元

Eurordis

资助从乌克兰被安置到欧洲、

中东和非洲其他地区的罕见

病患者

10 万美元

剑桥大学

资助逃亡的乌克兰医学生

继续在剑桥大学学习

25 万美元

红十字国际委员会

向乌克兰提供人道主义

援助

12.8 万美元

红十字会、国际医疗团队、

联合国难民署、无国界医生

员工捐赠及配捐项目

§‚g}Hl;P~‘5BRRC"m‚(FN]˚l;o8—8·O¤§‚g}Hl;GVO

P«R{(F0Z&gs+P[ /[WP[(Om‚N]˚o5~‘}5&„*‹naL¿(’+&g

u·Hy2⁄4¡{k=’5OEKopGtU(5z?*4Dm‚Eg1o

ZC88{5~‘}5>J&k0Œ(&xI’m‚

«-DHy2⁄0V(r((6&gp>$I&g&¡,(Rc

r"(Eg1.m‚‹na{’˜>J¤d.(dI

’m‚5ﬁØr"(O.˚o’C{I’m‚ 实习

生贡献了 500 多个小时的志愿服务时

间{,>$I’+ 15 &¡‹naoI’ﬁY55B

¤&sJ?’+*‹na{?5~‘}55B5/

m‚>J&k0&}5,‹nao

基于实习生技能的志愿服务

-TP DNA ]5C‚m‚0_B5{&P

5Bs0=1$JﬁR'.¡RR>'¸m‚5

/&&g{o¡}}Q]8]{7§¸C

F/{ł'¸’+(8· STEM &&’J^o

(r&„-TE25m‚ STEM ’æ&&&g{

I’EHJ8¿5C.OBn=

k01$C‰’(d8—¡m‚&0?

R…({’˜/œC.8—-T5/5R¢

RßL¿/.JﬁJ/œ-/#R?8·B¤(rR…(

P0«0KƒnÆ¡~‡(rk=o

与英国剑桥 LaunchPad

合作

因美纳很自豪能为美国南加州红十字会的镰状

细胞项目提供支持

2022 年，我们签署了两封

公开信

向世界发出讯号，我们致力于

让人人都能享有 STEM 教育

I’m‚ﬁCJd>=&x Code.org /œ

,&’›800 8·(Y‹?Ov~-’+]~‘

5BB§¸1$O«‹?Om‚ CEOs for

Computer Science ,D)Loo?

,D)L10L0PBO_C˛)]Yß0PBm‚

K-12 Cs{Z&¡=T%m‚Z&¡=k0

ŒRcR…(=&vR…s0=o

5~‘}5n.,’+ STEMM R…(º

nEwSOAxo*ºnEkK~‘5Bs0=)s

(w American Association for the

Advancement of Sciencex1$8·&‰

& ·R+Hy2⁄6˙¡(w Doris Duke

Charitable Foundationx‹?{&x

mﬂ>as0JﬁO_v;.,>T0V(r{,0ZL

.>Jh¡5B>{HfQ^{BL¿–03/œF

1$-/#R?8·R…({L.~‘5Bs0=n

JﬁR'nB¤snO¤=1$/=w STEMMx

k0FVy„}a0« o*ºnEm‚naSßP]

'y„}aF'{p{L.0P5B¡~ CL¿

– STEMM O«,CFo

登上欧洲极具挑战性的山口之一，助力癌症慈善事业

&„’+L¿–,(?mSl?m‚Ø’˜/œ&„

mSl?pGtUv4{ Stelvio for Life 6˙

¡(5H8—-D.¨m‚P\†?7}v95?¸

0!&¿.’+].w&gC&gYxo

Stelvio for Life ].m‚nam‚P&„

mSl?pGtUL¿(OEKoo*pGtUkK&¡F

.˚mSl?\[kº6˙¡(&¥Eæw Center of

Personalized Cancer Treatment

Foundation{ CPCT Foundationx>J

P6o 2022 C{5~‘}5Rc,(Y.DOm‚

0B¤/.’+o5RcEg1.m‚].o5

~‘}5L¿(m‚N.’˜/œZ&¡J[v'¸m‚

Y·‹?B Stelvio for Life Hy2⁄R…S,

k=’5OEKo6˙’5DNA m‚&¡F.˚mSl?\[kº

pGtUo

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙

融入可持续理念

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

[^)«d. 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1 

战略方针与影响

我们致力于将环境管理融入我们的运营方式。

人类健康和环境健康息息相关，我们改善人类健康的使命与负责任、可持续发展

的企业目标紧密关联。

我们认识到，要想为所有人创造一个健康、可持续的未来，就必须要重视环境。

我们的环境可持续性方法优先考虑应对气候变化，并在我们的设施、产品和整个

价值链中实施可持续解决方案。

在全世界都在寻求能够应对气候挑战、保护自然资产的创新解决方案之际，我们

认识到基因组学领域和我们的技术提供了一个巨大的机遇。

我们站在持续改进的维度审视可持续发展，深知有大量的机会可以保护地球，并

积极贡献自己的一份力量。

联合国可持续发展目标

5I’m‚Oﬁ(d&.Ik&¥{}Q

Øm‚s0=[^)«d.naSßP&g&¡

¡~‡m‚}FI¨-{P5RR8—¤C

5,‚?1&x[^)«0.˚Rc,"m‚›e'n

L¿–«łF{0h¡§¸R03Ko}o7§¸

R…(o

-L  C>Jh¡ 净零排放w n 

1$ x

I’m‚nlLyX 减排 46%w n x

I’m‚’)Ø§F 减排 46%w x

.«3ROæ,‚?1 75% 

100% 的战略供应商J‹?RR8—¤C5,‚?1

h7ﬂ¨” 

503Ko}o0?1$h7ﬂYß&—)‚P0«Jˇ4

2,000 万美元 美元

共 万美元

TMEæB¤/实现 90% 的垃圾填埋转移率 

可再生电力比例达到 100% 



正在进行

1 推动气候行动

2 运营可持续设施

3 培养可持续价值链

4 开发可持续产品

5 发挥基因组学的力量让地球变得更健康

Kevin Pegels

全球运营总监  ’)Ø§F8“,‚LWo

¤|03Ko}o’a1w‹«{’+RR?8·)LGo

H  C’˜Rßo

关键目标

2030 年目标 2022 年进展

nlLyX>Jh¡ 碳中和w  1$

x{OEKo  ’)Ø§F8“

,‚LWw

x P0\

经认证的 SBTi 净零排放1$,‚LWnaSß100% 可再生电力

&x nqZæ{I’

L-m‚  ?[^)«m‚Eg

1 降低了 61%

2022 年亮点

↑

TMEæ.,5J>m‚k=[EC&t¤ 10% ↑

↓ 同比

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ [^)«d. 

我们的科学净零排放之路

&„’+p`)BI’5>Jh¡,“*LWO^m‚⁄&s*-L,"§v¡}spı{I’-V>A’+pRn&¥R1$§¸RnaSß{

o’HnaSßB”}QB  ØC&x º[^)«d.&)BKo&g]o

到2050 年实

现

净

零

排

放

目

标

短期减排目标



-L  C{ n  ^

>T[^(d}_?LWO^¡nq¯’5  C6˙

,¥[C,‚?1 

-L  C{  ¡~‡x«-Fm‚

^>T[^(d}_?LWO^¡nq¯’5 

 C6˙,¥[C,‚?1 

^>T[^(d

-L  C{5~‘}5m‚nlLyX

w n x1$’)Ø§F

w x>Jh¡^>T[^(d,“*LW

O^w6˙’5  Cm‚6˙,¥[Cx



-L  C{?03,Dk0kO.m‚

C¡wZæ(’¢  C6˙,¥

[CL¿/.[ 

长期减排目标



-L  C{ n 

^>T[^(d}_?LWO^¡nq¯’5  C 

6˙,¥[C,‚?1 

-L  C{  ¡~‡x«-Fm‚^

>T[^(d}_?LWO^¡nq¯’5  C

6˙,¥[C,‚?1 

推动气候行动

气候变化对人类健康、环境和全球经济构成威胁。

I’p`)BJ>RcB¤(r&x[^)«d.m‚+s>J(1$}F}I)BKo&g] ;

 ..*I?[^)«0QL}-V5  ·55,; 

 s0=q+naSß)‚}F}Iw x

 ,i2A&[^)«ºnE 

 º0V5B‡ ·X. 

 >JP6º0V5B03Ko}o0?naSß  ;[^)«0.˚ 

 [^)«)LGJŒ““B¤(r}Fw x

可再生电力

我们的气候行动进展

全球首批净零排放目标获得科学碳目标倡议组织（SBTi）

认证批准的公司之一

(r&„&g>{’˜s0Jﬁ&„R¥m‚,0@{I’BR¡wk=s0=TeSy-V>AI’m‚[^)«d.

naSßo

5~‘}5 -L  C>Jh¡^>T[^(d,“*LWO^m‚naSß &E⁄’+s0=q+naSß)‚

}F}Iw xm‚ØoI’&,¥I&„,iﬁJ s0=,“*LWO^naSß ’æ&&&g{

&Pﬁ>{}QØm‚6˙5}F=,0@o

  C{I’m‚ n  1$  LWO^naSß&kK

 s

d’+ 8“¨ Ø {C&xwB…•«/8>Axm‚>*([^)«naSß)BKo&g]{/p?,i0Q

C4CL}-V5 º’˜,;oI’P5Du(&gs+P0\{’˜P¨I’m‚§¸R,“*LW

O^[^)«naSßP)ØE⁄)LFm‚nRcJı1$RcKE2m‚o

SCOPE 1



,‚?1

SCOPE 2



,‚?1

SCOPE 3



7.

SCOPE 1 和SCOPE 2

碳中和 

503Ko}o0?1$h7ﬂYß&—)‚

P0« 投资

 万美元

 ,‚LW.«KMI’5  &8“m‚,‚LW

¡{?I’m‚8d,[^  ¡wk=

Øm‚q+*_o 

 m‚,‚LW.«KMh¡58¤Jn8“03,D

k0kO.1$03,Dk0kO.›Cm‚}F0Vo 

深入了解可持续发展的行动赋能→



[^)«0.˚u(58nP¨  O_v;

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ [^)«d. 

I’vi[^)«0.˚CRßm‚fi1$B^›e'&xR…m‚P0\{0Z

 TeSy)BKo&g]o9u“=s&gY’+RI’m‚[^)«GQ^\>¸{

</  KwO¤

 1$I’m‚  C[^)«  v78 o

探索我们的气候机遇

I’(ZC>NS¯h7ﬂviy„}aTeSy{(r&„5B¤1$Eg1RıY·m‚

&g¨-oo’HO¤Lm‚-(Eg1h)BIOj1$^>T[^(d,‚LWnaSßo

5~‘}5n?  h7ﬂvi(dy„(r&„n/]51$,‚?1^>T[^(dLW

O^m‚h7ﬂEg1m‚R…-V&&go

气候风险

?I’m‚IkEg1RR8—m‚[^)«0.˚5zPX«&m‚fi›e'n

(C§FEg11$8n›e'oI’B”}Q?o’H›e'}5,&.v}oF

-"nR¢Rßm‚’a1wD0n03JG,&tm‚(C§F,T(n’˜/œ&„_¨R¢Rß

7§¸“=[m‚5§BsoI’Yß5sdS’(.0Ps+R…({?[^)«¤|‹

s&gY}5,I’m‚](s1$0?&&¥{’˜s&gYL¿/.«łFo

I’B”}Q>JP6’+,T(n-"{C}vKo>,m‚C‰=‚{’˜L¿/.JßEG

.8[^’2’m‚J.o5.-"P0«{I’}5,’+BSß,¥‹ºv

-"sd(.m‚›e'&xR…o?’5“=‡4R¥OE-m‚J‹naJˇ4{

B4R¥:<0(m‚-"sC‚sd(.o&x(C§Fnq,"m‚‘¶5¤Ly

IR¥nR¢RßsOPIS’un8[^#Im‚XIR¥7.{&&xo’H,;¨

B¤(r](snq,"ºo

挑战

I’J‹?>Jh¡>*(m‚n’˜s0=&„6˙pm‚[^)«d.naSß{.«KM,“*

J‹?{*J‹?.«0I’m‚’)Ø§F1$}_?,‚LWnaSßo5~‘}5Ko}o)B

KoE."7§¸{(NI’&H-L‡>Jh¡}_?,‚LWnaSß{R¢Rß’d,«

&nÆ¡~¡~KIoY8“{I’(C§F&¥m‚&v0Z[^)«IdC1$¨-B

5m‚03,Dk0J_B&03JCRßKIoI’?}i}o..OY+Z‹KI{

5>Jh¡,“*LWO^m‚⁄&sg˜&g’.¡o

R,[^)«0.˚¤|‹P&„,’x«Jg#03Ko}on,Yß&Rc«łFm‚R¢Rßm‚

&g‹¡~‡&¿Lo 

'enÆ8“¨Rı’m‚OV0{I’?}i}o(.I’m‚P0\{H-LS’un8

[^vfi›e'’˜/œn/v1$JﬁR'0?vB^›e'Œ03J?,0@m‚X

#IEg1oI’B”?[^)«›e',I’m‚’æ&›e'vi‹nao

识别气候风险与机遇

&„’+^?,’+R[^)«0.˚m‚‘¶5›e'&xR…{I’-Dk= [^)«nq,".

)LGJŒ““B¤(r}Fw x m‚Dsd’+(.oI’&x2A.r"(

’ª5B¤/8(w x0V(r{-V>A’+&x  C,i0Qnq,"m‚&rs+

 C[^)«GQ^{’+R[^)«0.˚?I’&.m‚‘¶5Eg1{C-F

7E«łFm‚R…(o

[^)«GQ^-S@PB?I’R¢RßXh7ﬂm‚&rs+n(C0Vim‚L‰£

Rß>$Im‚{--F?C’5/.^C4C([’5 ºn º1$ ºoI’-D

k=Sß,¥.˚u&rP0[^)«W•6O¤L{9u,’gr"(}Q]8Ew x1$

O_C˛¤[^)«0.˚&¤v:<0(w x’¿F]=CEw x{ }Z

-VZs+“”m‚GG,o

管理气候风险与机遇

&„’+vi&x[^)«nq,"m‚¤|‹{I’B›e'vi}US,n  5¤›

viy„}an&.v}oF‹navin(C§F›e'>NS¯’˜/œnq,"](sm‚

>AR>N{?[^)««łF,X1$’)Ø§F&&¥oI’m‚h¡5CFv

iJ5¤›R,h¡5?{«m‚›e'{*5¤›?[^)«0.˚#Im‚

nlLynpRfi›e'sd-"1$1Co

气候风险与机遇

气候风险管理

8—Hd,PJ>Rc}Q]8].1$’x«k0=‚m‚6˙po>P&kr&sRR¡~

‡m‚4’ao5I’03Ko}o1$’ªm‚&.XBs&¥{I’

>NS¯’+'[^)«¨”’˜8“m‚,&’›‘¶5›e'1$R…{’˜,«>N

Hd,4R¥1$k0f8·TKFoHd,4R¥4’aPKwHd,kr&¥J8¿L¿

(}Q]8J>(Fm‚2A1w1$Rj.m‚‡zoI’>NS¯’+I’?Hd,

4R¥03J’ak0m‚nlLyEg1&x(FF&¤m‚ºy„o 

I’?Ko}on/]5Hd,nq,".)LGJŒ““B¤(r}F1$Pm‚,i

k0f8·TKFTeSym‚RRPs?G,o5~‘}5h¡Rcm‚h7ﬂnq,"na

Sß.«KM(+L,‚?1P6n(C§F1$’a1w?h7ﬂm‚Eg1oI

’?}i}on/]51$(.I’m‚h7ﬂ¨”&¥.«0m‚Hd,4’a‡zo 

'enÆk0f8·TKFnHd,4’a1$}Q]8&¤=‚5,"ºm‚L0

E⁄RßP¨p`{I’n-L’+Ck=6˙5}F=1$5~‘}5]5C‚JﬁR'

Rß)BJÆ1$-/PR¢Rßm‚Hd,Gˆn$6}Q]8PRcR…(0?m‚ona-x{

I’m‚JﬁR'k=’5D?s0pG‹na{P5’+R1$Kw?fs+)BJÆ

B¤(r{>JP6R?03Ko}om‚,Z&1$y›y>,0?EoY8“{o

’HJﬁR'nk=(r-/PB¤,(RßpG0Pm‚0VIROæ{RR8—¤C5

,‚?1Hd,4_Bm‚(“k={IO-/#&v.«0Hd,4’am‚RO’¿1wo 

自然资产和生物多样性

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}oP6 

绿化我们的实验室

I’&x  0V(r{,0ZL¿–&kr0P5

m‚5~‘}5>J>Tm‚03Ko}o

Fo  C{I’0.

’+/&x

Ø-"m‚](s{(r&„I’?‡,“*·R¢RßJ‹?

m‚&g¨-{nq,"B¤(r?Ko}o-L  Co 

运营可持续设施

我们在不断努力减少设施的环境足迹，包括专注于绿色建筑设计、优化能源、减少水资源使用和废弃物排放，

以及扩大可再生电力的使用。

减少排放

I’>AR(.JOjLP61$03,Dk0J_B‹na{P5,‚?1I’m‚Xq+LWO^¡o 

&„’+>Jh¡,‚LW{I’m‚0PB¤/ŒRc&gy„-)J_B‹nao

 .-Dr•?r’GB5I

 .-Dr•?r’GBr•Pf6y  &¥5B&s]s

 P.5

可再生电力 1

2019 2020 2021 2022

排放强度 2

2019 2020 2021 2022

0.6%

9.8

11.4

5.8

4.2

59%

100%

SBTi 净零排放层级 3

5~‘}5m‚,“*LWO^J‹?E˜’+Dm‚,‚LW?{})o  D-V>A’˜s0=&„6˙pm‚pR1$§¸RnaSß{’˜R,’)Ø§FLWO^¤|‹{C>JP6Ik{

?>Jh¡o’HnaSß(r&„ﬁ‡’ª.{d,0_Jˇ4’5’)Ø§F8“,‚LWLP6oTOL  ,“*LWO^Sß,¥m‚D{'’+pR1$§¸Rs0=naSß&8“{,0@n

CD?J8¿&„’x«1$Hd,0ZPCRßR?8·-Dn$m‚d.IJˇ4{s&gY}R[^)«0.˚o&„’+s&gYL.’)Ø§F8“,‚LW{5>Jh¡,“*LWO^m‚B

s&¥{5~‘}5Jˇ4’+6˙’5Hd,m‚  Øq+)Lk=})oI’B”}Q&„I’m‚8d,[^  kM<’+q+*_{(r&„&P,‚LWLP6o

停用蓄热式氧化炉（RTO）



 CC{I’D:$*"k=5IF“¨m‚tcD›[{

.˚bo'enÆI’m‚-V#B¤&vPOVs{Rc>r[S'f

Ko}o,‚?1{E258—[^[S'L}-V/Ø&„&v,D“=‡(“k=

Y3~(oZC{tcD›[{.˚bC5†eMc  N

:w xm‚8d,[^{IR¥&„  ~‘+¸{

’ak0–*  ,0m‚’3[{.˚q+LWO^o‹º?’5

 C>Jh¡,«*"k=o 

2022 年的各项计划

新加坡新生产工厂获得绿色建筑 LEED

金级认证

PB¤/’5  C0k={C&E⁄’+ 

¡})Ø{(dh¡’+,&5Jn[B¤(r1$

03Ko}oROæm‚-Dk=P0«0E⁄m‚ISSo 

2030 年目标 2022 年进展



03,Dk0kO. Bh¡50kOn8“03,Dk0kO.1$

03,Dk0J_B›C





 1$  ,‚LW



 1$  ,‚LW

绿色建筑设计 LEED 认证办公场所

h¡50kOn8“03,Dk0kO.n03,Dk0J_B›C1$  Øm‚6˙’5Hd,m‚q+)Lk=o

 1$  LWO^EC m&p~‘+¸OP,o

 ’)Ø§F8“,‚LW

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}oP6 

I’&vP?[R…({BL¿–XOjhg1$(.‘¶5

›e'Rß,‚?1[¨”{..)BJÆos+¡~‡m‚Hd,4_Bo

?’5W•RR8—n[›e'RR–m‚.,5J>{I’¡wk=

’+0Ps+[LP6oI’BZæ¯I’m‚.,5J>(Y

~(1$&kr4_BpGtUJ>/œ,&  55C'¸ (.I

’m‚k=[¡o?’5p`>A&„5}ˆ[/6Xdm‚.,5

J>{I’].’5?[vi-"*R?8·..o 

5Iw nF“¨n-§H&¥Eæxnr•Pf6yn

]s\En•Ln5B5~‘}5&¥Eæn,n 

P.5+˘,o

新加坡建筑用水效率（WEB）认证

I’m‚P.5B¤/&E⁄’+Dv0k=[OjhgØw x{*ØP5Ø

035,&.,5J>&x](s&¥¡w0[LP6m‚’æ&nd&1$Dv0oI’

&„*Dv0>3’+,  &¡L}-V¤](4<n[(H-4<1$[Dw3~({Z

Rbk=[¡,‚?1’+ {ZC03n  &p.’§m‚[o 

加利福尼亚州圣迭戈

荷兰斯坦奥文

英国剑桥

加利福尼亚州福斯特城

威斯康辛州麦迪逊

加利福尼亚州海沃德

新加坡

核心办公场所所在地的用水风险

按办公场所进行水风险评估

极高

高

中高

低

中低

水管理



0ZZæ&t¤



TMEæ.,5J>m‚k=[EC

nq¯’56˙,¥7.



TMEæ.,5J>m‚

k=[EC&t¤

2022 年进展

2030 年目标

再生水冷却塔

I’m‚5IF“¨>$I’+&g&¡‹na{7v⁄C?C[-](-L&g&¡

*[v&¥{**[v0b  ,/r7\o*‹naZC?}(  &p

.’§m‚[o 

220 万

‹º03}(m‚[¡

w.’§x

ZRbk=[¡,‚?1

2022 年水资源相关项目

利用再生水

I’55Im‚.,5J>?}i}o5Q^

n[Q^1$,/r7\&¥(“k=,Dk0[o

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}oP6 



J>RcTMEæ.,5J>“=>Jh¡m‚76u

ﬁsthg 

2030 年目标



76uﬁsthg



H  C’˜RßL¿/.

2022 年进展

5Inr•Pf6yn]s\En•Ln 

5B5~‘}5&¥Eæn,nP.5o

废弃物管理

I’¡w0-})CDfviP0\{,&&¥,‚?1Rß_BPRR030m‚‹{\76uPRR

&v030m‚‹o&„’+*I  C76uﬁstnaSß{I’?}i}o(+L-/P

CDfviB¤(ro

危险废弃物

I’m‚/m'CDfvi‹naP5RR8—¤C5,‚?1Eg1{’˜RRh)Bm‚P0D›vi

ROæo*BsE˜Kw>A’˜&t,;>m‚?{Y}US,;5OP ¡~8(“k=n,D-Dk=nCDf 

J_B5OPneMOæ^J0VnC[8inccn–/b£R’˜/œ,&’›RO’¿‹&v03k=

Psd76uo 

生产者责任

I’/&xk0’aO’ª‡[m‚0V(dy„{’˜p`)BYßp`m‚OP'¸nvi1$&DCD

f{.«KM,D-Dk=.«3nkO[’˜/œ CPkO[^kO=' 8w xoTOLYnEkO[

1$tkO[Kw’`/œ.«3CDfKw’`{’˜/œ8·&¡YnEI05Bm‚\{I’>‡

[{?’55I’m‚’a1wk010R}UR0_?¤ÆCm‚kO[1$.«3m‚OP'¸1$,D-Dk=

L¿(4.o

负责任的电子废弃物处理

I’m‚nam‚PBCDfvi‹na,‚?1kO='CDf?h7ﬂm‚Eg1{p`)B’˜

’ªm‚P0D›viJªC1woI’&x n  1$,&’›}QBØm‚5OP2A

0V(r:Pn¡~P}F31$¡~8(“k=0Ps+8{&„&kr0P5m‚}F}IL¿(C.o

塑料废弃物试点

&„’+L¿–I’’a1wm‚E˜hF{I’  CL-’+&g&¡c?‹na{Bu&r

P00V(rRß]5?]5C‚rRCDf¡~Pk=’5,&’›7UOæCk=o5I’c?‹na&¥

sdﬁ.˚Ck=m‚  qH7UOæw

 1$ x&¥{Rc  qH>Jh¡5OP{

nqE2’5,D-Dk=Bsm‚ROæL8hg&„ oI’-"s&gYLrz7UOæ5OPm‚,;

¨](so

最可取

最不可取

避免或减少

重复使用

回收

焚烧

填埋

我们如何处理废弃物

iRecycle

 PI’’G8/œPR¥w x5/&g‹kK0B¤&”?m‚‹na{P5?t03J,‚?1&x

h¡5Rj.B¤sB5¤›’ak0m‚CDfnq,"m‚h7ﬂ¨”o5aL8—-D’Gm‚c?¤Zﬂ{5~‘

}5Rj.5¤›?&s¤vRj.]5P(“k=m‚’a1w¨’C5.,>T{d,0_sd]Zº1$5OPoH

 C  ‹na0.’˜Rß{(.ZC}(Rc 5,000 kg 电子废弃物E⁄-L¡~P-Dk=n

5OPIh)B8ioc?‹na0E⁄I.0_{5¤›-"?‹naJ?[Oﬁ&¡5/{’˜’ak0R?

^?tm‚Eg1o

收集运输再生

维修

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}o’a1w 

开发可持续产品

我们不断创新，致力于减少我们的产品、技术和解决方案对环境的影响。

环境一体化设计

I’?h7ﬂ&g(d.˚w xP0\,-L’+’a1wD0m‚TMEæiFA&&¥{’˜?J“R?8·m‚

R…(ﬁ0bE˜h}Q]8{R,ROæm‚Oﬁ&¡k010R/œ(“k=?1}JYœm‚nq,"¤|‹oI’?h7ﬂ

Sß,¥Ck=’54_BKJnnJ_B(“k=nO¤L8iOjhgn?o?n¡~¡ns>AFn.«3n

)BRn^C‡[1$CDfvivP0«o

5~‘5B  03,Dk0{5,i·55,;6˙R¥03,Dk0o

使用寿命终止原材料

分销与包装

使用

可持续原材料

I’].’5¡w03Ko}oROæ{.«KM¤([P’a1w&¥

J>(“k=m‚p\X6˙7UOæo&xY0ZP{I’Ø&„8—s0=J

8¿CRß}s0={C?t03Jk=R?}m‚RO’¿1w’¿RO“=

‡D‚p\⁄Hm‚.˚=I-o

可持续生产

BI’m‚03Ko}oP6{I’BR¤([k0’aBs

m‚J_BEC{?t¡,‚?1RcZºROæm‚(“k={C?t03

J5OPk0’aBs&¥’ak0m‚CDfo

可持续分销与包装

I’].’5’a1wXR?–Oj&03Ko}ooI’sd’+

nq,"Jˇ4{(“I’m‚.«303,Dk0n035OPn03¡~8 

(“k=o

可持续利用

5K˝OyGVOk01m‚-/P

’a1wm‚Bs&¥{I’BR’a

1w&v’J8¿–Oj0Kƒ(rk={

0ZP&,(8h)Bm‚fc?o

可持续的使用寿命终止

I’D0m‚-/P’a1wJ8¿5R¢RßE

§¸&gZﬂP¤,;&„>PJ*Rj.{(NI’

m‚Bs&gnlD(=-L’a1wm‚(“k=

?1}JYœo



.«3ROæ,‚?1¡



m‚’3})1$&r}).«303

5OPn¡~8(“k=I03

¤R



&x C6˙,¥[CnqZæ

.«3,‚?1¡



m‚’3})1$&r}).«3035OPn

¡~8(“k=I03¤R

2022 年进展

2030 年目标

 可再生隔热运输箱：OVk=UˆfROæ-VIm‚}:'lcX

vL¿(’+&gs+  )-D5OP/œ03¤Rm‚R,P0Ti 

 可回收隔热运输箱：k=’5,Æ1$,,(d8“Pw x

’a1wXm‚'lcXv03E1nI’{k=’5¡~8-Dk=

 可重复使用大批量可持续解决方案：}Q{k=’5,

,1$,Æ’a1wm‚'lcJon9Xv038·Y(“k={&035

OPsd:P1$,D-Dk=oOEKo,;¨X}ł}^1$>PJ*8—>:



我们的目标是：

 

?h7ﬂ&g(d.˚w x,’a1wD0

 

(.˚]5C‚’Jr1$8iOjhg

 

¤([P’a1wJ>k=m‚p\X6˙7UOæ¡

 

?t03Jk=R?}m‚RO’¿1w’¿RO“=‡D‚p\⁄Hm‚.˚=I-

 

?[R?8·/&xE˜h}Q]8m‚R…(

可持续生产

深入了解我们的可持续设施 

深入了解我们的可持续价值链 

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}o’a1w 

无需干冰或

冰袋试剂可在环境

温度下运输

影响全世界，而非环境

 CC0Bm‚  y„-)y„}am‚P5,‚?1?h7ﬂm‚Eg

1o  -km‚03«F1$s>AFRcJ>L¿/.{035h7ﬂ^C&t

X{-krR7UOæPkKk%46˙k0fł0Vf-VIm‚o  m‚

¡~c?L’+03Ko}oF{P5^osD›m‚OV2⁄{n«Yß5OV0h¡g{

’¢\(“>PJ*0n$C)BJÆ5io 

TOL  -kn1&x  -kn1m‚?Zæo

了解 NovaSeqTM X 系列生命周期评估

k010R(.w xk=’5(.&gs+’a1w5,&k0

10R&¥’ak0m‚h7ﬂEg1 ;’¢/†ROæm‚&0-Lk0

’an(“k={,D-L(“k=?1}JYœw’¢8-L?uxo 

  C{I’:<Jou&rP0>$I’+v.˚m‚k01

0R(.{’˜s&gY¡.˚  -kn1

m‚h7ﬂEg1OV2⁄G,oI’? 

 E˜h-kn1&x  E˜

h-kn1sd’+Zæ¯(.{(“k=m‚.J/@(YPZ

 m‚(>p&o 

(.}USSP¨{  -kn1?[^)«0

.˚m‚Eg1¤([ oLMLª’+,"’5Oﬁ(dEg1m‚O¤

L{I’?-Dk=o’H)LGRßLrzR¢Rßh7ﬂCk=

&x03Ko}o’a1wOVsm‚PR…o 

NovaSeqTM X NovaSeqTM 6000

每Gb 排放

NovaSeqTM 6000 NovaSeqTM X

0.09 kg CO2 e 0.04 kg CO2 e

50%

试剂盒体积减少

50%

塑料使用量和体积减少

90%

包装重量和废弃物减少

植物性生物聚

合物塑料

优化数据储存，从而

降低存储和能耗要求

经过设计，无需工

具即可拆卸试剂盒

并回收利用

I’s%J‹03Ko}oFiFA{?JﬁR'1$.˚=’a1wsd’+ExCm‚¡~P1$OV#o

Alex Aravanis 博士

首席技术官，



科研与产品开发负责人

评估的功能单位

  E˜h-kn1&x

 E˜h-kn1 

 

]5C‚-2})-S@ ’3})-S@

  (>p&

 

‹nau0V  Sß,¥  1$ 

 ,"’5  m‚P0\‡[1$Kw/B{

’˜/œw^>T[^(dTMv(dy„ ;’a1w?10RTMv

1$Jª0˙Sß,¥xw { xod,\{

kK’5¡wk=m‚Pv.˚m‚  pGtU{5YCR¢_

¨o’HSß,¥>Am‚,¨Jª0˙‡[o 

61%气候影响降低 *

TOL~‘5B}?}(}JunB5(.

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}o’a1w 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}om‚’)Ø§F 

17% 类别 2：

资本货物

10% 类别 15：

投资

8% 类别 7：

员工通勤

8% 类别 6：

商务旅行

19% 类别 4：

上游运输与物流

31% 类别 1：

外购商品和服务

0.1% 类别 5：运营中产生的废弃物

0.6% 类别 8：上游租赁资产

1.0% 类别 12：售出产品的报废处理

3.0% 类别 3：燃料和能源相关活动

3.0% 类别 11：使用已售产品

Scope 3 87%

Scope 1 5%

Scope 2 8%

培养可持续价值链

作为一家全球性组织，我们认识到，我

们的环境足迹不止来源于我们的各种

设施。

我们关注的 Scope 3 重要类别包括：

 &s^•X&x— 

 8“2A1w1$Rj. 

 4R¥f

 Jˇ4 

 2A.PGd 

 0B¤.w

?’5Z&¡x«-F{I’Yß5&x‹nam‚0PJ¨¤v0V(r{ 

s&gY¤([’)Ø§Fm‚Eg1o 

Scope 3 排放

TOLI’  Csdm‚ﬁY  LWO^^a/@(.{

’˜  C&„6˙,¥{I’,iLWO^¡m‚  03E15’5I

’’)Ø§F&¥m‚0Ps+‡zoI’(.’+  m‚,¨ 

&¡x«-F{p`>A’+5LWO^^a/@&¥/QZæRR8—m‚x«-Fo/QZæ5

I’˜&sm‚x«-F>A&—&„¡~‡x«-F{5I’m‚  F“

¨”&¥/Q o 



H  C’˜Rß7.



 ,‚LW

2022 年进展

2030 年目标

运输方式从空运转变为海运

}i  CI’I.?’¢’G85/

-L~‘5Bm‚s0!,"§v/†ROæm‚XP0

D›’¢t_Xﬁ0&„]sX&0_{  C

I’?]sX(r&„,i&”‡X}A

m‚XP0D›{8—C4¤([  LW

O^{s&gYE.˚I’m‚J‹?o

可持续投资政策

I’)]OV’+Jˇ4O_v;{0]?J_B

1$,k=’2&¨¤v)-Zm‚Jˇ4{'«

nq,")-ZØ>A&„}nr"(I03

Ko}o0?w x)-ZoI’03’˜H

OﬁI’m‚P0\{\&v(?5Jª’ak0

’ª(f‹ºREg1o 

2022 年海运试点项目

 C{I’B &¡]sX

c?‹na{I.>$I’+’¢P.

5-L~‘5Bm‚k0’a-V1wXo'e

nÆc?‹nam‚I.{’C{I

’MhDp03ZRb>ARsd/6

¤]sXm‚C05o  C&0_{

I’m‚}ł}^Ik?5Ko}o7§¸

m‚-"&¥)st_Xs&gY0b]s

Xﬁ0o

2019 年Scope 1、Scope 2 和Scope 3 排放基准

可持续商务旅行

5~‘}5-Dk=&gy„-)}A&sB¤,(RßRcOj

5,‚?10B¤52A.(\-B{’¢

\,‚?1nq,"q+LWO^o?’5I’RRC"

k=m‚BPG}A{I’Yß5&x].’5

(“k=03Ko}ot_eMOæ{L¿–›wR…Oj

hgm‚t_,0@Du(ﬁ0V(r,"y„o

I’&x  kO.[¤ºnE0V(r{

(“I’m‚0B¤03’˜5C"-dm‚ˇ.

1¥Ee•L1$5IEe\ºRp

}A&¥&5´kO.[¤o 

可持续供应商

I’BIk(C2A-‹naRß

(.(C2A(r-m‚h7ﬂ03Ko}oFJ‹?o

I’m‚naSßP‡[(C2A,‚?1’›’

m‚'¸(dq+¨”{C‚=. ’›’’˜P¨

m‚P0D›Jª0˙Y‹B¤(rm‚s?o

可持续运输

 Cm‚trpvF-/P’a1w  

 OEKoC"^X{&v,D

“=‡,§FXo  C 

D:$sdﬁJ0o ’+RR?8· 

可持续员工通勤

I’&„0B¤L¿(’+&gy„-)/6.w

KJo ’+RR?8· 

减排工作示例

I’H-L'enÆ5~‘}5m‚&.C7.{>Jh¡}_?,‚LWnaSß«&nÆ0Ps+KIo

I’:$}J5ˇ>,“*LWO^&{CRc&gy„-)&¿L{'enÆo’H&¿Lm‚>JP61$>$2⁄{

?Eg1I’m‚h7ﬂ“”o

9u“=’+R,"’5  J>Rcx«-Fm‚,¨O¤L{</ ¤ÆE6o

2022 年Scope 31

关注的

重要类别

类别 1：外购商品和服务

39%贡献

↑81%自 年以来

↓5%同比

类别 15 ：投资

0%贡献

↓100% 自 年以来

↓0%同比

类别 4：上游运输与物流

26%贡献

↑86%自 年以来

↑25%同比

类别 7：员工通勤

4%贡献

↓17%自 年以来

↑97%同比

类别 2：资本货物

25%贡献

↑108%自 年以来

↑4%同比

类别 6：商务旅行

6%贡献

↑4%自 年以来

↑406%同比

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}o’a1w 0Kƒ6˙5}F=m‚.¡ d.;J

’æ&r"(’ªJª0˙ 03Ko}om‚’)Ø§F 

我们期待供应商：

 >E25\1$k=m‚~‘5B/œ5B¤\

 OEKo0B¤m‚’R1$ 5~‘}5’RO_v; 

 p`)B>,1$*4Dm‚B¤(rh7ﬂ 

 EeQr"(’ª1$h)B’ª 

 ’˜u0V(!im‚P0D›D?&. 

 J>RcP(C2A“=‡Ø03(C2Ad&„,¥--

J^J&xI’D?0V(r

¤@ ?tXuN  &¥m‚‡03«m‚(

C§F·¨-s&gY’+RI’m‚(C2A

/&x&¿Lo

 C{I’5w(C2Ad&„,¥--x&¥.,’+*‡[{C‡[I’m‚Ik(C2A5vOP’ª(f¡w/@PŒE‹Ly0*‡[o

可持续的供应链

I’Ø&„{&x’)Ø§F&¥a’H0ZTK].’5OV2⁄h7ﬂm‚(C2A1$0V(r((6D?0V(r?,0@m‚}Q[,"

¡~‡o 

I’&xIk(C2A1$&.0V(r((6?‘[^)«nq,"¤|‹sd\2{‡[’›’>I’&„HB„>Am‚

¯–m‚2A&d&„,¥--{0ZP‡[’›’J‹?,‚?1,&h7ﬂ¨”o5(.‘¶5(C2AP{I’m‚)LG<

[w xB¤,(&¥.«0r"(Eg11$h7ﬂ>NS¯o 

J>RcP(C2A“=‡Ø03(C2Ad&„,¥--J^J&xI’D?0V(roI’m‚ (C2Ad&„,¥-- &xI’(r

&„º0V5B,i9}(}F}I v~-P01$⁄iyP03Ko}oF,iKwO¤I0J>*m‚J‹?&g]o



Ik(C2AJ‹?RR8—¤C5,‚?1h7ﬂ¨”

2022 年进展

2030 年目标

携手 Amazon Web Services 共同作出可持续承诺

I’5’;un>,=‚*m‚P&g’¿]5C‚J>’ak0m‚6˙5

O¤L¡5pp,C,;’¢  ›w7.-L o

I’&x  MJ[0V(r{-Dk=,& 



 JﬁR'{B5¤|W•D›OV0Pst.O¤LRß

H.n=‚*IR¥{0ZP’d,p`)BO¤L>,on

(“k=&&„–Oj§¸R=‚*

m‚JﬁR'Rß=‚*0.

¯?1m‚O¤L{’¢\L¿–

’+03Ko}oFoH  C

‹na>JP6’˜Rß{I’&x

’;un6˙5}FO¤L=‚*nq,"m‚q+LWO^B”,‚?1 o

’+RR?8·

90%

&x6˙5}FO¤L=‚* 

nq,"m‚q+LWO^,‚?1



附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F d.;J

’æ&r"(’ªJª0˙ 0Kƒ6˙5}F=m‚.¡ 

发挥基因组学的力量，让地球变得更健康

基因组学的积极力量正在帮助我们发

现、衡量并解决全球一些最具挑战性、

最紧迫的问题。

如今，世界各地的科学家正利用我们的

技术和基因组学开展生物多样性、濒危

物种保护、生态系统保护、可持续农业

实践、气候变化研究和创新研究。

)BJÆ6˙5}F=&\⁄’5¢„>Aa/mfs+m‚(8·TKF{Ck=

5~‘}5]5C‚v-='B¤,(RßOEKoa/mfs+1$a/ms+~m‚03

Ko}ovio 

保护基因组学

农业基因组学

,Z&6˙5}F= B”}QC?}i}oL.03Ko}ok0’a.{&„,&

kr&vP7§¸m‚’0!J>CRßm‚KIL¿(R,P0Tio,Z[Wn

«s+&>{1$pGtU’003’˜-Dk=h¡’¿JﬁR'‰S -F-iG

Fgnq,"(Sßı{’¢\&„6˘«1$«s+,v;L¿()LGo 

 ]5C‚P&gs+=,#pm‚P0\{03pGtUk0f8·TKF

Cn/]5k0FVy„}am‚OV0ok0f(?  ¡zO^-L,&055h

7ﬂ&¥{ -S@035&vpv5`k0FVy„}am‚G,&tU,]5f

s+P0=‚5o  ‘¶5m‚Ck=Rc^ƒ0!n/]5nk0f8·TK

FHS¯n/¿[U,]5n5|8]U,]5vos0=>{’Yß5(“k=

I’m‚JﬁR'1$h7ﬂ  Rß&0Rc’)Øm‚)LG{k=’5D

0-/P6h7ﬂR,P0Tio ’+RR?8·

生物多样性与 eDNA 测序

农业基因组资助项目

,Z&6˙5}F4.‹na6˙¡ ’5  C0

.{ZC&gYo*4.P5ah. F

“=m‚nJL¿–¡~‡,Z(rf1$f¤kfs+03

Ko}oFn’a¡1$,.>Cm‚pGtUo4.

&E⁄O(OP-L5~‘}5&„OEKo,&‹naL¿(

m‚KØPo

2022 年获得者：

SENAI 生物合成创新研究所

 C,Z&6˙5}F4.‹na6˙¡m‚&E⁄O&„B…ﬂ¡}}(c

,;/Tm‚  k0f0VI-/PpGtUJ>w 

xo*pGtUJ>&\⁄’5B]sD

,.Zd{Lrz6˙5}F=5q+?=‚nh)B’˜/œy›y>,P0«

m‚‘¶.o

pGtUJ>-Dk=-='(=m‚.¡RßpGtUh7ﬂ0.˚?8—6

Dx«-B1$k0f8·TKFm‚Eg1{Cp`>A&xq+5?>Ank0f

-^ah-kn›y1wB¤&nkLc‹,‚LWnh)BvRc,"m‚’¿gEo 

]sD,.ZdJ8¿&“>¢]s\k0f8·TKF{C?[^)«0.˚{

)s5P0}Q]8{CRc.’5,.˚]s[{&„8·‹º0V5B03Ko

}o0?naSßL¿(’+OEKoo ’+RR?8·

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F d.;J

’æ&r"(’ªJª0˙ 0Kƒ6˙5}F=m‚.¡ 

海洋保护

C5~‘}5&x 6˙¡( >RB’+&g‹&„R&rCnJˇ, &p

~‘+¸m‚0V(r‹na{P5B5~‘}5–¡]5C‚JﬁR'OV2⁄]s\k0FVy„

}an/]5o 了解更多

利用基因组学监测海洋生态系统的健康状况

海水样本

采集过滤和 eDNA/eRNA

提取

eDNA/eRNA

检测方法

利用短 DNA 片段的序列信息来识别已知

的物种

鱼类基因组在过去二十年得

到测序

已报道的鱼类物种（32,000

种）已得到测序

OceanOmics 项目旨在

建立一个包含

鱼类基因组的基因组

参考文库

共同构建基因组

参考文库

物种鉴定与定量

不伤害任何鱼类

高通量测序

宏条形码

约600 种

约 20,000 个

约1.85%

保护生物多样性

iConserve 计划

 P5[¤łr"~.¡{)s¡k0.f)BJÆo

基因组学将如何

支持大猩猩保护

测序拯救狐猴宽吻海豚基因组

向科研人员公开

全新基因组图谱有望拯救濒危大象

o‹5B¤0V(rJ>&E⁄m‚O¤L?C.k0f=>{)BJÆ’›’pGtUm‚~

¡k0«]m‚O¤¡Yß5F-¢,‚?1{&„’+C?o&g¤|‹{5~‘}5m‚  ‹na

&x5I.f5)¡k0.fºnE’˜/œ1¥R¥1TO8—=1$’ß-D?’ß8—=?D0V(ropGtU

5¤›-Dk=RßH«]0P58—m‚  &¡ TKR¥m‚TKR¥C‰{B,6˙5}F]5C‚-/

D‡6˙5}F5Cv·{’˜?r1›’H~5f*Sgnk0Zd.&v¨1$&x’x«m‚,~tr&¥

«&RR8—m‚›e'oo‹0V(rnP5&„*‹6B¤(rm‚k0f=>{L¿(]5C‚B¤,({(“E2

5r"~J8¿0Kƒn«Yßm‚(rk=o 

c?- Y8{’+RRc,"  -"m‚R?8·,;> 

^?,’+RI’m‚,&’› iConserve B¤(r ;

通过 STREAM 研究流域健康状况

[S'nCP1$[^)«0.˚Yß&vP#IEg1{(“](6n/]50

E⁄Rß¡~‡o¡wk=  1$5~‘}5JﬁR'{D?‡?\N

](TKR¥]5C‚{’˜sdh7ﬂ(.1$n/]5·w 

{

x‹na{*‹na5.Km8—0P5m‚^[\N](sd

¡wTKo ‹na&x,"\⁄[6)BJÆm‚,[Ws0=>{nE255(d1$/†(^[W~(d

0V(r{C.OP'¸J>pGtU](6m‚[TKo/BRß{O¤L[W&”.˚?(“/†(^[W~(d&

E⁄¡~‡)LGo’›’&¥m‚8—8·O¤’(«K·&„k0{\  n/]5m‚k0f>J

¤&sP·x«m‚›yfo ’+RR?8·

分析濒危植物

.BBu(8—=&_)-T%&xI’m‚]s\EB¤/(Y’50Z&g5

/{*8—=B”Iu(’+ }k0f~EpGtU J>{0Kƒ6˙5}F

=m‚.¡?.-Dr•?r’GBm‚a/mUˆfsd-S@o*pGtU

J>P5&„[  s+a/mUˆfk0I-='5Cv{’˜L.)BJÆ

B¤(rm‚D?{CıE6,&k0ffEnk0FVnq’=(rk=1$‘¶5

m‚’x«-Dn$o

5~‘}5’æ&6˙¡(&„*pGtUJ>L¿(’+  ~‘+¸m‚4¡{B–&¥k0n

R¥s0k01$pGtUk0/&x6˙5}F=pGtU{L.6˙5}F=O«1$  O«{.E

?.-Dr•?r’Ga/mUˆfm‚’+R1$)BJÆo

保护考拉

G*?r8—=m‚aL8—-D’G¡k0.f6˙5}F=s0pG?-}FYß50

Kƒ6˙5}F=m‚.¡Rß)BJÆLKm‚(8·TKFo5~‘}5,

6˙5}F]5C‚JﬁR'&„s0pG’0L¿(\>¸{C.)BJÆfs++

0[^)«0.˚nl,l;1$,&’››e'm‚Eg1o 

’+RR?8·

附录



企业社会责任战略与管理可及性社群员工尽责运营

简介可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 [^)«d. 03Ko}oP6 03Ko}o’a1w 03Ko}om‚’)Ø§F 0Kƒ6˙5}F=m‚.¡

’æ&r"(’ªJª0˙ d.;J 

&„’+OEKo

wkK 

 &”.m‚CC].{P5L¿–•–’

5[^)«d.&¥m‚"2Rx{5~‘}5L¿(’+

 ~‘+¸m‚4.{’˜EekK•–’n/†(^

[W~(d1$Rc’s+‹?m‚D-/F[^)«R,P0

Ti1$h7ﬂYß&—B¤(ro

PR¥  pGtUJ>‹?m‚  P&g

&¡OP'¸Uˆf6˙5}Fm‚5}AO¤LC‰o&x,&’›0Zx«O¤LC‰

&v0Zm‚P{*O¤LC‰P5Z&¡’ŒJ&0nq,"O¤Lo

 C 05L¿(’+&gs+Pm‚R,

P0Ti{J8¿C.pGtU5¤›+Rj5[¤}Uˆf6˙5}FP

-Lm‚=8·KIopGtU’003’˜)¶.  

-FPm‚0(d{CpGtU>’58·s+Uˆf&¥m‚*1$.Jo 

’+RR?8·

以公平的方式向无碳未来过渡

行动赋能 Solutions Project

5~‘}5>PJ*  03’˜?^>T[^(dﬁ.˚&„&Øº1$,&’›Rck=m‚.˚=fo

 P&g>{(Y’5’ß-D?’ßBm‚k0fJﬁR',0@{P5?q+LWO^fﬁ.˚&„

Rc’)Øm‚f2A1wo  0h¡&gs+0\&„H’a&ØºURw 

xm‚/[{}HR{*UR,(Rc&gs+0"Hm‚E{03’˜0ZP0

¸  1$ {5E2m‚Rı’&t03RcOj5?,&ﬁ.˚&„&Øºo5~‘}5m‚]5C‚Jﬁ

R'C.  -FC)]OV’+-V#&…m‚E˛k0f6˙5o  B”

}Q’¢B¤&LWO^f&¥k0’a’+B  &p.’§m‚&Øº{onqE2’5¤Yœ’+  8·&p

0q+s,8—[^o ’+RR?8·

I’L¿(0Ps+/6F.wr•-D{

.«KMKh¤w

x-"n

EE25,,’\m‚+)kO.h

¤{’˜/œ,i  8·&¡+)kO.

¤+˛kOu@o

通过饥饿细菌进行碳捕获

可持续通勤计划

逐步壮大：植物 DNA 数据库

,‚?1  0m‚q+LWO^{nqE2

’5,‚?1(“k= 2,400 万磅煤炭

58¤J‹nam‚k010R,;{

&„5I1$_)/m‚>{Cn}(

270 万美元m‚)k=

J?5I1$/6n?‹m‚?‘&6˘

{ 迄今为止已经培训了 93 人

’+RR?8·

I’&x«-D}F}I 

D?0V(r{].’5&„,5B}QC"0-L

y„}aF/-Vm‚r"~L¿(^a\˙}Q]8m‚

03,Dk0J_Bn’\1$B¤(r@(Y{’˜

s&gY)s[^)«1$h7ﬂYß&—o5~‘

}5’æ&6˙¡(L¿(’+  ~‘+¸

m‚4¡{OEKo50P&¡&”‡.,5J>

D?nq,"‹na{&„5InP¡?¸_)n

/6n?‹f/1$:›PDPm‚([OP,~

(d1$¨Er"~L¿(^a\˙J_Bn8¤

Jd&?‘&6˘1$?‘&>~(o

I’KØ.m‚4¡OEKo  >Jh¡

’˜&tnaSß ;

I’P 地球生物基因组计划

m‚I0&&go*8—6-"P

5?5i&sJ>Rcfs+m‚6˙5

}Fsd]5C‚{C.Jg#k=’5

)BJÆ1$FŒ8k0f8·TKFm‚R

,P0Tio

观看

 9u(f.

.,i,Z&6˙5}F=



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙

培养员工 Y]n&¥&n«]’.4_B5¤›



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

I’m‚0B¤ Jˇ40B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1

Aimee Hoyt

首席人力官

战略方针与影响

联合国可持续发展目标

.«>PI’m‚TMEænaSßoo?’5I’m‚B¤

(rnI’Rj.m‚r"~nI’KJm‚0V(r((6

’˜/œI’Du(m‚5¤›S’&„¡~‡o

1 践行多元化、公平性和包容性

2 投资员工

3 建设关怀文化

我们致力于打造关注创新与关怀的工作环

境，珍视每位员工所具备的独特才能，充分

发挥集体的力量，在全球范围履行因美纳的

使命。

要实现伟大使命，公司各个层级都需要有优秀的员

工。通过培养包容与关怀文化，可以放大我们合作

和建设社群的价值。

我们携手并进，扩大我们的积极影响，激发我们的

无限潜力。

关键目标

41%

↑2%4

提高全球领导层中的性别均衡比例 1

13%

↑3%4

提高•–’n/†(^[Wn8C\@[WnﬂhfRI

K&hR~(dn &¡I’˜&ss+P[m‚’8f5 美国领

导层中的比例 1

18%

↑1%4

提高•–’n/†(^[Wn8C\@[WnﬂhfRI

K&hR~(dn &¡I’˜&ss+P[m‚’8f5 美国员

工中的比例

提高少数族裔在执行领导层中的比例w~‘5Bx 2,3

保持

)BKo净薪酬差距为零

0.23

↓从 0.564

¤([ 可记录伤病率

2030 年目标 2022 年进展

45% 的员工为女性

L-’+ 支持残疾人士的新 ERG

项目

~‘5B0B¤&¥少数族裔占比 52%

–v  6˘‹na&E⁄ 80 分的

净推荐值得分

B/Æ&rC&¥{9NF–v’O¤ 占比

提高 5%

‹?O?&&0?-"m‚ 平均满

意度为 85%

L-Pm‚ 心理健康福利-"

w~‘5Bx

2022 年亮点

30%

↑9%4

连续 4年

‹??{ ;}Qin0Zv})-F/œ’˜&so

?1O¤P[Rw~‘5Bx;’GRn•–’n/†(^[Wn8C\@[WnﬂhfR K&hRn &¡I’˜&s 

s+P[m‚’8fo

Jd‹??{ ;F“n/n0Zv})-F/œ’˜&so

H  Cw6˙,¥[Cx’˜Rßo



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 Jˇ40B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ I’m‚0B¤

受到基因组学力量的驱使，因美纳的每一位

员工都在为全球创造积极影响。我们寻求机

遇。我们不惧挑战。我们不懈努力，推动基

因组学和人类向前发展。

’G]1$ 

8C\5/

2,456

~‘]

6,342

Y]n 

&¥&1$

«]5/

1,459 性别比例（全球）

kQF



9NF ,&’› R¢JŒ““

ZN'{’8f˝(,Y’

员工年龄分布（全球）

–’5  ?Ł([’5  ?Ł 

我们的员工

其他身份（美国）

,i0B¤F“O¤w x



54%

45%

15%19% 66%



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 Jˇ40B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ I’m‚0B¤

提高全球领导层中的性别均衡比例 2

提高•–’n/†(^[Wn8C\@[WnﬂhfRIK&hR~(dn

&¡I’˜&ss+P[m‚’8f5 美国领导层中的比例 2

提高•–’n/†(^[Wn8C\@[WnﬂhfRIK&hR~(dn

&¡I’˜&ss+P[m‚’8f5 美国员工中的比例

增加美国执行领导层 3,4 中的少数族裔占比

2030 年目标 2022 年进展

41% | ↑2%1

13% | ↑3%1

18% | ↑1%1

30% | ↑9%1

5-/OPJ¨¤vK’ªvi(Ym‚9NFm-Zæ 35% 36% 42% 42%

K’ª-/OP(Ym‚9NFm-Zæ 41% 36% 48% 48%

K’ª  nq,"(Ym‚9NFm-Zæw/Q  (YF“O¤m‚m-Zæx 37% 37% 39% 39%

K’ª  (Ym‚9NFm-Zæ 24% 23% 24% 24%

K’ªB¤sB(Ym‚9NFm-Zæ 37% 36% 29% 29%

性别占比趋势（全球） 2019 2020 2021 2022

员工多元化

与占比数据

OEKo[-2})(Y

  

&¥})[–})(Y

F“n//œ’˜&s

}Qi[-F“n/

不同级别的少数族裔比例（美国）

mﬂ’ –.z’

’GR &¡I’˜&ss+P[m‚’8f

8:›8 ,&’›8C\@?5||

ﬂhfR K&hR

R¢JŒ““

/ju>’ ¤KP.5|| •–’ «R~‘5B’ 52%

44%

员工中的少数族裔比例（美国）

?1O¤P[R 

Zæ( 

K(}_

P¨s+P[

HØ&„Pmﬂ’

H  Cw6˙,¥[Cx’˜Rßo

‹??{ ;}Qin0Zv})-F/œ’˜&so ?1O¤P[Rw~‘5Bx;’GRn•–’n/†(^[Wn8C\@[WnﬂhfR K&hRn &¡I’˜&ss+P[m‚’8fo

Jd‹??{ ;F“n/n0Zv})-F/œ’˜&so

不同级别的性别比例（全球）

OEKo[-2})(Y

&¥})[–})(Y

}Qi[-F“n/

F“n/1$–})F“n/

-F“*

–})-F“* RR–vi?{

’2(

kQF 9NF ,&’› R¢JŒ““

  



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ D,"FUO.˚ d.;J

首席执行官寄语

’æ&r"(’ªJª0˙ (d8·+¸.˚n,CF1$.«>F

’˜&t?-}F03&„  viL¿(OEKoo

我们的 DEI 管理

践行多元化、

公平性和包容性

I’&v(n.55J>Rc].&¥(d8·+¸.˚1$.«>iFA{’˜

L.,C0?{L¿/.E1?'H-

董事会薪酬委员会

员工资源小组（ERG）

专职副总裁，DEI 负责人 CSR/ESG 执行指导委员会高管层多元化委员会

DEI 职能小组 CSR/ESG 职能小组

多元化委员会工作小组

我们的 DEI 战略员工之外的 DEI

I’].’56˘,.8·TK.˚n.«>m‚O.˚{J>Rc0B¤Œ

H-0-L¡~ 1$Ø03oos+h7ﬂJ8¿C.0B¤RR8—

.˚0Kƒ‘¶J{;’.,&Cvm‚R…({CB&¡(d.˚BD

ah0I§¸n*-I}kn&E⁄I.o

I’m‚  Ik&v’’?w¤’5,;¨0B¤n’01$O.˚{I’n?,&,Oﬁ&¡&.{

C&PI’Z&g&¡’æ&r"(’ª¡~c?‹6m‚6˙po

关键项目

 8—(“-"



(.76˘

 ‹na



H.  =&



‡P¨J^Qp·–v

 6˘



,iQpH·-"

  5¤›  6˘ 

I’m‚  -"’˜>J(&„6˙poI’<Z&¡’’¢h¡g-0{

&vP..B¤(rCØ-L=P}Yœ7ﬂo

Lisa Toppin 博士

全球 DEI 负责人

5I-.-..,5~‘}5P{,0@?‘Rc&g&¡5ˇ>Am‚)LFA{/p-/Ps&vD8·

+¸.˚ -oE2P{IC\5RcH-L,0@m‚o&g)LFA(?IR?9i5iR8·+¸

.˚.FVCI&„&g0\Rc.m‚  )‚?O’ak0(fv^?tm‚Eg1o5/.’+ 

8—(“-"0_{I0h¡HB„«C"Rc../Æ?J“D‚‹0« m‚PP0\{CF|LH

B„J8¿?1›’H‹6’ak0RR^?tm‚Eg1oI=(BHI/F|{R?,¥p`5i

R8“¨&kro

Jennifer Pellegrini

高级品牌经理

包容性领导力

透明沟通

强化公平的流程

吸纳并培养

多元化人才

作为我们对多元化、公平和包容（DEI）的承诺，我们非常自豪地签署了

以下文件：



º0V5Bw;R’.99N/†--x



8·+¸.˚1$.«>  d.



º0V5B,i9}( 

 v}(’

企业社会责任重点领域 DEI 关联

加速提高基因组学可及性更多信息请参阅

“可及性”→

提高基因组数据的多样性

为社群助力更多信息请参阅

“社群”→

支持多元化学习者成为未来的

STEM 领导者

融入可持续理念更多信息请参阅

“可持续性”→

在环境正义倡议方面投资

培养员工更多信息请参阅

“员工”→

在所有工作中践行 DEI 理念

尽责运营更多信息请参阅

“尽责运营”→

与不同的供应商合作



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ D,"FUO.˚ d.;J

首席执行官寄语

’æ&r"(’ªJª0˙ (d8·+¸.˚n,CF1$.«>F

2022 年ERG 亮点

L-

2个支持残疾人士的新 ERG 项目

/&xO/&x

5,400+

,i  -¨

17 个

员工资源小组（ERG）

ERG 构成职业发展和 DEI 参与度的基石

’›’BH.0B¤sdS’F{L¿(&x0Z’21$nE/’\](nC§r]1$

nq’==&m‚R…({.^?’+I’?#¡~n.«>m‚O.˚o  &P

0h¡n6˘,.1$k(^’J^m‚,"§vRR˝o 

我们的 ERG 项目理念

5~‘}5m‚Z&¡  5†55}W58—OESS,D ; 社群服务、职业发

展、教育1$商业影响力{p`)B‹na-"POEKo  I0“=[{

0ZP&u0V5~‘}5’)Øoo‹B¤(rnaSßP¨p`{03’˜I’

m‚5¤›’+RBD.˚m‚’)Ø{0Kƒ8·+¸.˚m‚.¡{&„I’m‚&

.L¿(-/PR,P0Tio’+RR?8·,"’5  L.I’Hy2⁄’2&

m‚)LG{</¤ 0B¤ d.;J uNn 03/œF uN1$ r"~ uNo

‹?  m‚r"(Eg1.‹naILyX-L’+&g&¡I«C"Rc

,#m‚}F}I{RR0_In0.,*}F}Im‚i’2(o  ‹na

&„/&xr"~Rj.1$&0?-/#’+R…(o

I«C"H-g5~‘}5B  ].8—>{Ø-L{

,0@h˙ 0B¤J>,(8m‚0P‹J^Jo

Alexa Tralla

资深 PCP 项目经理

Seki Norihiro

资深 EHS 专家

我们的员工资源小组

社群服务

通过与我们生活和工作地

的非营利组织合作来支持

我们的社群

职业发展

专注于培养多元化员工

成为未来领导者的职责

和技能

商业影响力

采用多元化团队发现和解

决业务难题，增强创新

员工资源小组（ERG）项目支柱

教育

促进更多理解的达成和

建立更深入的合作



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ D,"FUO.˚ d.;J

首席执行官寄语

’æ&r"(’ªJª0˙ (d8·+¸.˚n,CF1$.«>F

I’ZCn/]54CvgFV1$B5uJ’0. oI’«C"H5>RBB”

v}o5C,„B&„“* o

I’m‚„>J(P5TOL=9uB¤(rh¡n&&JﬁR'1$&xJ>5/6

nq,"m‚}Q&„0B¤L¿(Jª„oZ(Y0B¤ŒC&E⁄,Cm‚4E{

&vC*kK’5,&F-Fns+P[nC„AnP[~nF00bn5BxBI’ª(f&x,&

B¤(r1$g˜P},"m‚?'F\0-L/-F?Eo 

4CvKwkQ9N0ZB¤0Z„o 

0ZTKIx«(Cm‚B¤(r{P}F-F{[WP[Is+P[{5„P0«\5Rc}a=&sm‚Q|BDo 

提升薪资透明度

(r&„I’?„Cv1$,C](snDO^’\](1$‹?¤|-VJ‹?m‚&g

¨-{I’?,DJ>Rc~‘5B(Ym‚4·55{’¢  C RbPp

k0Ojo&„’+p`)B,CF&x&g]F{I’n?B’.4_By„}a&„J>

Rc0B¤L¿(E2-x(Y  Cm‚„·55o

薪酬平等

连续第 4年实现

)BKo,„B

&„“*

2022 年进展

2030 年目标

I’OEKo5&P0«]'Z d&„oI’].’5,Cn?#¡~5?EJ>Rc0B¤{5B¤(r5J>1$&.m‚

0P&¡P0«)sR…(5†v1$8·TKFoI’m‚O_v;rYœ?s+P[nnC„AnF-FnF00bn;u:gFVn

F-FØ0Z1$*nP[~n)L’ng(dIy5r_ZNl,ng(dg,n()LGn,%EvgFVnP[_BI’ª(f0

)BJÆm‚~(d>Jd/-F?Eo

机会均等和非歧视政策



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ Jˇ40B¤

投资员工

无论是对个人、团队还是组织而言，不断发展都是实现

成功、超越自我的催化剂。我们希望创造机会与环境来

帮助员工释放全部潜力。

I’].’50¤D‚S-’J^{C.’›’&vPI§¸o&„’+p`)BI’m‚0B¤55~‘}5

’g0§¸R\+˛>Jm‚&k0]˘{I’ ;

发展的脚步永不停歇

55~‘}5{Z&¡’ŒKFRc&Gm‚I§¸t_¤o?’5J>Rc(Y1$5/m‚0B¤{,

0@ŒL¿(’+Ko}o=&&x0?m‚R…(o0?P5~‘}5m‚&g‹¡~‡PC">J({&„0B¤

E2-xm‚&I.1$R¢Rßm‚R…(9->A6˙poJ>Rc0B¤ŒJ&E⁄0Ps+END›m‚0?R…({

’¢\55~‘}5&E⁄RcH&—m‚&}Q/o

F“n//œ’˜&s(Y

提供重要

发展机会

投资

人才

为员工提供

有意义的奖励

Z&g8{I’sdS’/&xEN7UI’m‚RRn,"y„1$}USS

m‚?"oI’_FU9i8&xahGRßD?B¤(r{COEKon«Yß

¡~‡m‚(“1{..0B¤trpvHI{>Jh¡I§¸o

Karen Wetherholt

全球人力资源负责人

员工全面掌控Hg0?{KFRcR…(L¿/.(.7{=&Hg&&

’˜8“m‚o{¯??'’5HB„m‚&¡’&x&I§¸⁄>

因美纳大力投入0Ps+(dnB¤,(1$‹na{’˜OEKo0

B¤>Jh¡JıC#0?O.˚

领导者引导COEKo0B¤0? ;C.0B¤

-"⁄>nL¿(4_B’˜/œBKw?L.

0B¤&¡’I§¸

发展

在每个阶段提供指导与支持

m‚(YkK,;¨)«’K’ª 

49%

m‚P'˛0RßH5~‘}50B¤L[

Z&¡0B¤m‚CC6˘C5†?-PO¤

28%

m‚–v(Y kK,;¨)«’K’ª

41%



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ Jˇ40B¤

发展计划、资源和解决方案

员工发展

人才讨论和继任󾗕‡>Jh¡I’m‚(“1{?‘E‹Ko}o6˘,.0Vm‚’J^o’J^(.1$}i’ª-"

p`)BI’?0Vm‚’0&x‹na>LW50Vm‚(Y~({’˜OEKo5~‘}5>Jh¡E2-x&xR¢Rßm‚HfQ^o

团队赋能󾗕–Ojm‚5¤›].’5-Dk=&¡’(.7{C+˛-0Kƒ5¤›(.7o5¤›;J&„5¤›L¿(

J>“=m‚HIKw?m‚4_B{7E5¤›,ł.{&„R¢Rßm‚I.9->A5ˇ>Jm‚6˙po

绩效赋能󾗕-m‚}kOj“=‡Ko}o\2{’˜’+R&¡’h¡’˜/œ,0@0?P00boI’m‚}kOjOE

Ko’¢CCLTMﬁ0&„L¿(Z=˝Cm‚&”.\2R…({P0)0B¤&x‹?O5(+’2‹&s)BKo&g]{

0?>E{CsdKw?&x/ﬁØ{o’HŒJ&„0B¤0E⁄I?‘&x0?L¿(..o

学习与领导力提升󾗕’¢PR&k0]˘-L–})‹??{m‚0P&¡¤Zﬂ{5~‘}50B¤?&E⁄«C"8·

m‚R…({’˜’¢R¢GBm‚P0D›>Jh¡0?o=&&x‹?.L¿/.‹naL¿(0Ps+B¤,(n4_B1$-"{

OEKo0B¤5&k0]˘m‚Z&¡¤Zﬂ0E⁄I.o

I’L¿(0Ps+-"nB¤,(1$R,P0Ti{&„5~‘}50B¤L¿(’¢PR&k0]˘-L–})‹??{m‚0P

&¡¤Zﬂm‚OEKoo

资源

y5Eæv;-"m‚=&&x&0?4_B{’˜)0B¤J8¿Lrzn

-’gn-"CD?d.{N&sRR0Vm‚&⁄>o

^?,’+R0B¤Rc.’55~‘}5&vPOVso)º00B¤w.«KM  HS¯x(“I’J8¿/œP’+R0B¤m‚I.n“=[1$Oﬁ(d(d{

’˜)I’¡w0LP6COV2⁄0B¤(do 



8“¨&‹C 



DO^&?-}F 

wJﬁR'O«ox‘5 



’ª(fP)«{«YßD›/ﬁØB¤,(&xYßD›(.



B¤(rnq,"O«m‚=) 4¡4. 

 =&n‹w x=&1$,&’›K}“==&4_B

 C1$  C(.n  1$‡5¤›(.7·w 

x03k=’5&¡’1$5¤›/ﬁØo

=˝C 职业发展和绩效?" =˝C 晋升周期

m‚0B¤RcR…(Ly0>AR}kOj1$&0?(. 

100%

95%

E*´&„5~‘}5B¤(r

90%

Ø&„,&}QiOEKoCB¤(r&x&¡’k0]

J>*m‚..

86%

/&xCKwO¤

81%

?5~‘}5m‚Ko}o0?1$I.+˛_)LEæ 

81%

)L’ª1$)LEæKwO¤

86%

HfHL[5~‘}5(r&„iGm‚B¤(r5J> 

83%

Ø&„5~‘}5«C","Eæ0B¤m‚r•r8 83%

55~‘}5RcE1?'H- 87%

Ø&„03’˜““ZDG}l 

I’‡[0B¤>$I>AR  HpGo  C{I’D?’+&g‹(.o

倾听员工



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ Jˇ40B¤

激励时间󾗕&g}A‹?O‹?.L¿/.‹na{kK=s0&>{

X{’˜&0RcOj‹?5¤›J>“=m‚JﬁJ1$o 

讨论和 Lean In Circles󾗕I’m‚&.‹?’?¡~‡

‹m‚-x\‘{(9u‡N,vi&>·1$‡vi&

k0]˘·oI’nB5~‘}59NF}ł}^w x0B¤4_B

?-}FOEKo

导师项目󾗕 &”Ko

 ((6

‹na{?&PR&&’J^&x4^?0B¤ºy„pRß{0ZP

 0B¤4_B?-}FL¿(0\&„  m‚?B‹na 

指导文化󾗕I’m‚Kw?=&EEH0Ps+KJ{C.

‹?O=&n>J(CDu(HB„m‚Kw?JﬁJ

领导者在行动󾗕‹?OC.‹?OL¿–JﬁJ{J8—Eg

1.

新领导者定位培训󾗕ƒˇ?5~‘}5P,1$&E⁄Q%/.m‚

‹?O{*‹na’˜I’m‚,iP‹?O&„&¥Eæ{^?,’+

R55}5~‘9u(fC‹5¤›1$I’m‚‹?iFA

因美纳领导力提升

‹?OB&gy„-)YßD›m‚0?Cs{sdS’&„R¢Rß*,¥8o

认可成功

I’’+8·&¡‹na{Ø030B¤m‚

/>I?‘{.«KM ;

倍

5~‘}59NF0P¨’&x~‘5B,5B

9NF&-D&E⁄hgm‚Zæ¯ 



P.50P¨’ 

&„9NF



5B0P¨’

&„9NF



~‘5B0P¨’

&„9NF

0P¨’F“O¤ 





0P¨’&„9NF 



~‘5B0P¨’&„ 

?1O¤P[R 



P0P¨’

因美纳发明家的数量

 C{5~‘}50B¤L¿’\’+ 193 项新专利申请{

,D-/P–o5~‘}55,i,>KFRc 9,178 项专利o



B 1,000 人参与’+(.76˘-" 

 70% m‚‹?OZC[?1/.&g‹0?-"{C5†_HC

超过 85%



‹?O03¤|B 18,000 &¡K}“==&Cs

激发󾗕o&g‹?.y„-)5‹?.&”‹&¥D‚,’+8“¨F|

G‹{’˜>Jh¡Ko}o1$>AR0?

高层领导提升项目󾗕5&„RO¤0m‚PGs&¥{F“n/1$–

})F“n/&x,i0P5m‚0Z’2&gp’g0-x\‘m‚r"’\1$’=.=

&(do‹?OB].1$Kw?F0b,&’›–?{‹?=

&{&x&¤vm‚–?{‹?O}E-’g&&o{E.˚\>¸. 

优势培训计划󾗕(“k=+-D8‹(.7-F(.B¤,({*

-"P5(“0B¤Ø-LHg(.7CH-g0Z’2m‚g˜{5

I’m‚B¤(r&¥,  iFA

“聪明才智”高管 DEI 培训󾗕oP&&„–vm‚&g‹

-"{C.’›’=&9u(f5’J^k010RD‚N~m‚0P&¡P0

«D‚‹0«



创新奖4BZCØ03I’m‚+

§Ss0=>{m‚«,g˜{^?.˚-/P(r

&„,0@O.˚1$I.m‚TMEæ‡z 



发明人奖49. ZC?I’m‚

&-DkM<(r-g˜m‚0B¤0P¨’ 



价值奖4‹Ł0}[kK0Z’2L¿0\

m‚&¡’0B¤1$5¤›hg 



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ D,"FUO.˚ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ Jˇ40B¤

吸引出色人才

5~‘}5m‚’J^K8Ik5OEKoI’m‚(“1P0«pnÆ,"§v(rk=oI’? 

/†--,K8B¤(r&¥{’˜0¤D‚&xI’KFRcnq0Z’)ØnRßH&v0ZQ^C,(

8g]fJﬁJm‚‹})’J^.,{C.¡zO^6˙5}F=m‚0« F.¡o

深入了解I’m‚0B¤O¢&C1$6˙’5>J&k0JﬁJm‚FHfO-"{

<c?- Y8o

实习队列



转化率

（美国）



少数族裔

（美国）



美洲地区女性占比



欧洲、中东和

非洲地区女性占比

吸引多元化的未来人才

(r&„&g&¡,iF}F}I{RßH&v0ZQ^1$}Qm‚c??I’m‚’

J^Ik[,"¡~‡o5ƒˇ?R¢Rßm‚Jˇ4P0«{OEKo’¿F&v¨m‚

=k05(dC&x’›’Du({9i,"y„’d,P,"§v(+’2‹oox«=

k0}F}I.«KM9NFB¤sB/8(n,5B•–’B¤sB/8(1$ﬂhfR

&&B¤sB/8(m‚T%5)-(vo  C{I’B&”‡m‚8·

+¸.˚=k0}F}I{’˜h¡5].nT%5)¤|1$K>(m‚END›{&x

,~‘5B  8·0\=k0sd’+’\](o

实习项目

I’^?o{=k01$Z&k0?I&„-/POn-/#O{0ZP&P

5~‘}5m‚R¢RßoZC{I’Œ(5,i·55,;SLy&gJ(s

m‚>J&k0nRcB¤(r}Qm‚=k01$=Eoo’H&Eæ]Fm‚=k0

5o¡}=&1$I§¸{,5¤›{>Jh¡&Gm‚J.L¿/.o

I’m‚‹naL¿(’+&v,&O¤

m‚R…({.«KMRcEg1.m‚B¤

(r@(Yn&0?1$FHfO

‹naoI’OEKo>J&k0sd

‹?.>J({’+R,&B¤(rC

Rßm‚nlLyEg1{+RjKIC

C?0Ps+PG,o 

因美纳校友网络

I’P5J8—6˙5}F=k0FVy„}a{-/

Dr"~Rß,>0ZJg#6˙5}F=m‚R¢Rßo

.,5~‘}5/pH1nÆG‘I&„5~‘}58—

>{Cm‚&g0o/p(“G‘5&0?m‚B

s&¥sD,0@{I’’d,YSG‘B

T%/}ł}^)BKoºy„o  8·0\5~‘

}5T%/B,i  8·>{,0@{I’

Ø-LT%/5L.F|G‹?.1$&„k0

fJﬁR'krK8}58fP0«,(Rc«C"8—m‚

‘¶.o  C0.m‚T%/}ł}^&„-x0

B¤L¿(’+R…(Rß&x,&’›T%/sdº}^{

-’gd&.7nF|G‹?.{CJ?

6˙5}F=H‹m‚r"’\}ł}^o

实习生、毕业生和职业生涯早期人才

6˘,.1$Jˇ4R¢Rß’J^?5~‘}5m‚0?Ik[,"¡~‡oI’&x¡~c?8—=>-0V

(r{5\RcR…(&x=k0nZ&k0nOLG1$8—=OBDu(§¸R,"y„oI’B

0Px«f-F].n&0?pG(nJﬁR'C1$T%5)8—(“-"{&„=k0-/#Rc

H&—(doI’}F}IP/m‚K>1$h¡5({Rß_¨&kr0P5=k0m‚“=[o 

>J&k0 Z&k0 &k0]˘PR 0B¤ T%/



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ D,"FUO.˚

建设关怀文化

打造优秀团队并实现突破性创新，从关爱员工开始，我们在各方面将员工福祉放

在核心地位。

Yß9uI’S’,(-/PFm‚B¤(r&gTK{I’&&„0B¤L¿(&gy„-)r•-D{.«KM/kº)B*4n6˙5}F]5C‚Rj.1$>{Ck0«-"o

I’P5&„J>Rc0B¤/œ,&’u’L¿(RcH&—m‚r•-Do

员工福利

I’L¿(0Ps+-m‚r•-D1$*4D-"{C?r•-D·55J

?-L0B¤n*Pn>{C(6(1$0J,.='9No

Z8{I’m‚JﬁR'Œk=’5OV2⁄’x«*4D{>Jh¡,C

-x&v03J>Jh¡m‚sYoI’m‚0B¤03’˜-Dk=o’HPJﬁR'{

9uB¤(rh7ﬂ6˙5}F=nk0Zd*4D‹na1$mSl?U,]5{RßC

.’›’R?9i5*-/kº,v;o 

I’m‚0B¤r•-D55B>{1$5/\D{P5B&gy„-)

RcH&—m‚‹naH-g0B¤&„’æ&CRßm‚B›8—’)Øo 

工作环境基因组学项目 *

I’&x0V(r((6  D?0V(r{B,&

(&>{&„0B¤/œ,&>{’L¿(1P’nKw?CC.U,]5oY

8“{I’&„mSl?U,]5nk0Zd*4DU,]51$~ l;/œR¢p`

l,l;m‚&Cﬂ,6˙5}F]5C‚w xL¿(4¡OEKoo 

癌症早期检测（美国）

(r&„I’B¤(rh7ﬂ6˙5}F=‹nam‚&g¨-{I’?

 \mSs+PRU,]5’a1w+)L¿(}[u0VRı’m‚~‘

5B0B¤/œ,&>{?'o 

家庭发展援助 *

0B¤/œ,&*P1$>{C(6(03JRc4TTB)B'I.OE

Ko/.,0@N.m‚k0Zd*4D‹na ;



(d8“0y5



ßUˆ,-x6˙5U,]5



P}-/’a-xU,]5

I’B0V(r((6  &„u0VRı’m‚~‘5B0B¤L¿(

,«m‚k0«r•-D‹na{»n7k0«)B'{{&„I’m‚0Ps+0B¤

L¿(Cvm‚?‘/R…({.«KM?[«(}a’u=',"y„m‚0B¤o

提供充电时间



b‡]m‚()œ 

 8CFHfRj.)œ 



[?1  8C)œR

 Rb1$ Rb,,0@()œ



JF)œ

培养身心健康



/kºnfs01$ .)B' 



s-xOE-J* 



0B¤M.‹naw x



*4D>Tk=’51˜’n,jG1$r6r 



2A.PGd/kº)B' 



*4gJ;(“k=R¤I(0/S 



’(dB¤=.,P6n+˛-m‚Hd,+’˜/œ5J*8“B¤(rm‚

R…(



›y6L¿(03Ko}on*4Dm‚›yfKJ{.«KMz›y 



6˙51P’ 



,i*4D]. 

健康解决方案（美国）



B  L¿(mSl?OEKo1$&>{1P’>NS¯ 



&>{Kw?{k=’5Pn\[kºIB 

?J“RR9im‚/k0w~‘5Bx 



B  L¿(O¤=¶.˚]X§w x

fi\[kºJÆiR,P0Ti 



B  &„0B¤n>{?'1$J>Rc>{CI0L¿(,

«m‚Eæi*4D‹na 

投资未来



0B¤‹na 



˝(*t-" 



,.H¡wY]n&¥&1$«]5/x 



’g1$H8“)B' 



(>ZN' 



g]u(4¡D 



=). 

其他津贴和福利



.,P6{.«KM\¤nC\nst.0D$n˙›yRj.n

YßFA1$HIL¿/.Cs 



0B¤L[‹na 



KØPKØ‹na 



fZK,#)a&¨ 



.wOEKo 



>C$w^J0V ts0B¤x 

¨-Rj.’¤~‘5Bo



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ d.;J(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ D,"FUO.˚

I’].’5&„,(d0B¤nJ‹.«2A1$I’XJ>55m‚r"

~L¿(>,1$*4Dm‚B¤(rh7ﬂoB6˙’5›e'm‚P0\{

I’m‚O_v;V£’+(.n’n]'1$¤([  ›e'm‚

](s{0ZPL¿/.I’,i&.m‚’)Ø1$Ojhgo

全球 EHS 管理系统

I’}i}oTOLh7ﬂ1$&*4D/œ>,viy„}am‚5B¤

HHfSß,¥-V>A,i](soI’m‚P.5B¤/&E⁄’+ 

 1$  ,DØ{C&E⁄’+ B¤(rh7ﬂ>,*4

D-/P9o

I’BDu(n>JP61$}vKoOﬁ0Vm‚  viy„}a>$I(“

1o R?8·)LG</¤I’m‚  O_v;o

预防和预案

 m‚,i  L‰£’+I’m‚0B¤&„’+)BKo>,1$0Vm‚B¤(rh7ﬂ03¡wk=m‚6˙R¥

sC‚oI’m‚CFd.5¤›,>0Z..{L¿–¤¨·H{f›8>ARD?¤¨·‘5&1$

].o*‹º¤¨FP0\ B”}5,I’m‚›e'(.nh7ﬂ5z Eg1n  O_v;n’a

1wvi1$0B¤m‚/&xo

EHS 项目

I’m‚HfQ^PZ&g(Y5~‘}50B¤ŒI&„h7ﬂn*4D1$

>,m‚‹?Oo’C{I’0p’+&gy„-)>,‹na1$)‚{

’˜L.Ko}oOVs1$>$2⁄‹nao

>$IJ>RcTMEæ.,5J>m‚  n/v(. 

>JP6RRPm‚’(dB¤=›e'¤([-"{(“I’m‚0B¤J

8¿s&gY0h¡CR,’(dB¤=›e'5z{’¢\L.}

RLP6

/m'1wvi,i](sSß,¥.˚{.«KM?/m'1w¡wsd

 >NS¯{’˜/œ5J>RcTMEæ.,5J>sd.˚=1wn9c? 

TMEæ.,5J>45Iw nF“¨n-§H&¥Eæxnr•Pf6yn]s\En•Ln5B5~‘}5&¥Eæn,’˜/œP.5+˘,o 

º0V5B,i9}(u Rı1$u  RıP¨{&„)BJÆh7ﬂ{C¡wk=‹º¤¨FP0\o

工作环境健康与安全

,‚?1)Ø&„  C1$  C&¤m‚0ZRZæ¯o

2022 年安全绩效

¤¨·Jª0˙

 w

,i  ›e'(.

 Y

’(dB¤=(.

 Y

03ıE6(>l;hg



 nq,"6˘

>  ?-P 

PB¤n0¤IHhg¤([ 



了解更多

 O_v;  Ø  Ø (>l;‹º¤¨‹naw x

环境、健康和安全趋势

可记录伤病率

2019

0.52

2020

0.34

2021

0.53

2022

0.23

2020

0.18

2021

0.22

2022

0.12

误工患病率

2019

0.74

2020

0.18

2022

0.17

旷工、受限或调职率（DART）

2021

0.43

0.34

2019



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

IkP0ƒˇ&xEg1 I’m‚0B¤ Jˇ40B¤ D,"FUO.˚(d8·+¸.˚n,CF1$.«>F

首席执行官寄语

’æ&r"(’ªJª0˙ d.;J

5~‘}5,Œ)¶5P&g’¿

]5C‚w xJﬁR'P0

«m‚Ko}o-/P{’˜/œ

5,i·55,;J- P

,_lGm‚&vIn..{

5(8·5B,0@&¥·‹\-{C,w•niB¤s0Jﬁ

x&¥5B  Eo

&„’+Jg#«0bJ>Rc’m‚.«>FB¤(rh7ﬂ{I’&¿.’+,"’5c¤vP’2m‚].{’˜

)s’\]({s\L.kºH n=&C.^?I’r"~&¤m‚º}^o’CRR,(Eg1.m‚(

&&gP‡9NFnk01nHkK·w x{’˜/œ[Rm‚’2’?I’

’ßR}r"~m‚Eg1o0B¤’sdS’-’g’+&¡’}Q/{*’+?r"~m‚OEKo{C&E⁄’+4

_B’˜^?,’+R’ßR}9NF/'¡~n.DOm‚/07o

o&gC{I’&„0B¤}F}I’+&gy„-)*4D].{.«KM,

i ,¡}*4e1$ıY].n*4DPR&rn*4D/G"({

’˜/œBI’m‚*4D*4gC05}F}Im‚K>*4eHy2⁄

].o

I’m‚Y]n&¥&1$«]’.4_B5¤›J8—’+].

·55{¡~c?,"\⁄Eæi*4D1$r•-DB¤(r{9uEæi*4D)‚

?O-"n‹?OEæi*4DHCsnN.CC*4D

P{’˜/œ&x5BHy2⁄R…S,0V(rL¿(0B¤*4DCso 

5~‘}5P.5,0@&E⁄’+B¤(rh7ﬂ*4D

&x>,-/P9o*‹na.«KMH..˚pG0{

’˜OEKo¡~68m‚}F31$-V#o¤([›e

'{]'p¡~/m'{L¿–Ojhg1$>,F{

&E⁄’+RßHB¤(rh7ﬂ>,&x*4D:<0(

1$P.5’.¨w xm‚Ø03o

(r&„ ‹naOESm‚&g¨-{

Z&¡?-}F>$I&g&¡r"~Rj.r"

(Eg1.‹nao  C{,((d

&¿L.«KM.E?’¿F&v¨m‚

r"~m‚  >R({&„-h¡F

-FØ0Z'{pm‚“?1C-V(r,"FU

.«1$)Rı{&„ﬁ6Rm‚˝(

,Y’L¿(&Kw?vo  ?

I’m‚5ﬁØO.˚’=d.{?

I’m‚(“1n  ¡~c?&xr"~

Rj.ºy„pRßo

健康自拍活动

ERG 社群影响力项目

行动赋能关怀与交流讨论活动

因美纳获评 2021 年度《麻省理工科技评论》

“50 家聪明公司”

新加坡工作环境安全健康创新奖

&„’+s&gY,"f60B¤/œ,&’u’{I’0b,iJ>Rc0B¤L¿( 500 美元

的健康和生活方式津贴o&„’+.E,i0Z’2&¤m‚vLy{I’&¿.

’+ #健康自拍w x].{0B¤-’go?’›’m‚*4

Dk0]P0D›CRßm‚sdS’Eg1o

培养关注员工健康的关怀文化



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙

尽责运营



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ IkP0ƒˇ&xEg1

Gwen Chapman

首席合规官

1 实行强有力的企业管理

3 我们所做的一切都以公正诚信为基础

5 打造可靠的供应链

2 保持合规文化

4 坚持数据安全和隐私的最高标准

6 参与积极的公共政策

战略方针与影响

我们致力于以诚实、公正、尊重的方式待人行事。

做正确的事情是我们成就自我的核心。作为基因组学领域内的先驱者，

我们肩负着以技术推动创新，为人类造福的责任，确保我们创造的技

术始终是以安全、合乎伦理和负责任的方式被使用。

联合国可持续发展目标

?I’Rß9{*Yßp`m‚’2&v’’H1nÆp`)B0V

{nH1nÆTOUˆ’5,;Eæm‚>)LH*{&vÆ0B¤n

GVOn>PJ*n&1$r"~?I’m‚)L’ªo

?5~‘}5>A(Y&„5\⁄¡~6˙5}F='gs1$u0V(!

iP0« 最值得信赖的公司正在进行

&E⁄ 行业内最高的  }) 正在进行

100% 战略供应商J‹?RR8—¤C5,‚?1,&h

7ﬂ¨” 100%

(C2A8·+¸.˚P0«m‚ 支出的占比达到 20%

w~‘5Bx 18%

&E⁄RßH  &¡n/vR…S,m‚

72 项批准

>$IﬁY 人权影响评估

5~‘}5m‚TMEæP6 100% /&x

u&rP0>N‹na 

58·&¡  })1$LWdKwO¤

&¥8’5 行业领先地位{.«KM⁄

iyP03Ko}oFKwO¤w xn

 1$ 

33% ’2(I0&„9NF 

2.69 亿美元（美国）



8·+¸.˚(C2AOE- 

33% ’2(I0(dh¡s+P[ [WP[

8·TKF

5~‘}5m‚,Y·’;un)LG=sC‚ 

5 隐私信息管理方面获得了 ISO

27701 认证

关键目标

2030 年目标 2022 年进展

2022 年亮点

TMEæP6m‚>A&—&„5In_)/n•Ln5B-T’˜/œP.5o

* 5~‘}5’50P5B\E+¨m‚Rı’&tsdnq,"B¤(ro



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 0VF (!i1$,Yß O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ ’æ&vi

Robert S. Epstein，医学博士 Scott Gottlieb，医学博士

Caroline Dorsa

Frances Arnold 博士

Francis deSouza

Sue SiegelGary S. Guthart 博士

John W. Thompson

（主席）

Philip Schiller

董事会

董事会概况

Rc,"’2(m‚R?8·+}H)LG{/I’m‚  1$,0@}łu@o

9NFZæ(

33%

?1O¤P[RZæ(

33%

C5†’2(’ªR

6.6 C

实施强有力的企业管理

通过强大的企业管理能力，我们努力激发公众对我们的事业和公司未来

发展的信心。

董事会

I’m‚ ’2( P8·+¸.˚m‚‹?*~(d{OEKos0=-/Po

’2(m‚naSßPp`)B,0@8Rc.>¡zO^6˙5}F=.¡m‚

J>“=B¤,(o’2(¡wk=’+ ’æ&viKw /B{EH’+’ª

m‚vioo’HKw/B’˜/œ d&„,¥-- 1$’2:< 0(uNs &„5

~‘}5m‚’æ&viL¿(’+TeSyo

董事会 ESG 管理

,(d’2(L¿(  n/o{/ÆCI’J8—’+L¿0\ ,

0@vi:<0(m‚R·55{’˜/8.’2(n/o,0@m‚¡~

8—h7ﬂnr"(1$\[i’2‹w x{(Nf-FLGR}[,&’›

’2(:<0(m‚'8“o„:<0(}i}on/o8·+¸.˚

1$.«>F’2.C0bvi?{L¿(nq,"H{\>N:<0(

--}i}on/o}ł}^>,’2.o 阅读“管理”一节了解更多

内容 →

多元化和独立的董事会

TOLI’m‚’æ&viKw/B{I’].’5}FDQ^/œ}Q

8·+¸.˚m‚’2({.«KMC„AnF-Fn5B¤Q^ns+P[1$

&&}Qo 

’æ&viKw/B‡[g]u(’2/Q’2(m‚8·O¤o,0@m‚

g]u(’2E‹u0V}5P*+rpB5-V>Am‚’2g]u(F

Sß,¥o 

I’m‚’2(u(’+5*&¡C":<0(o/¤0P:<0(uN

s’+R+G ; 

>N:<0(

„:<0( 

L¿0\ ,0@vi:<0(

s0=&xJﬁR':<0(

g]u(’2

89%



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi (!i1$,Yß O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ 0VF

保持合规文化

我们以诚实和透明的方式开展运营，符

合法律标准和伦理原则，对此我们十分

骄傲。

I’m‚0V1$(!iO.˚:$’5’2(})-F{CD}o[I’

&.m‚0P&¡})-FoI’m‚O_v;Kw?*0B¤5PC"B¤(r&¥C

k=0VO.˚o

因美纳行为准则

5~‘}5d&„,¥-- P5)s>>Jnu0V(!im‚d&„{>

k=\E1$\{C)BJÆI’m‚2A&-Dn$o*,¥--k=

’55~‘}5,(d0B¤n‹¤|n&PB¤n–vn’2(I0{

&v,&B¤(r5c?n4/[Cn&.¨¤vnB¤(rJIJ>

55/od&„,¥--&¥m‚¡~‡&”‹.«KM¤¨YœY‹n/21$

æn¤¨YœZ n¤¨YœJn’Rn8·+¸.˚1$.«>n0

B¤>,n’æ&r"(’ªn§H8nP¨’˜/œO_C˛’=.1$O_\[

].o 

5~‘}50B¤1$u&rP00V(r((65†03B  ?-P0V

&xY‹‹º¤¨c}AInlLy 5}A &¿Jªo

培训

0ZP{I’n&„,iJ>Rc0B¤L¿(Rc,"d&„,¥--’˜/œ/

/21$/æO_v;m‚CC6˘{Cƒˇ?,&’›5~‘}50V

nq,"O_v;L¿(R?'¸&¥m‚6˘o

J>Rc0B¤5,E2C’˜/œ&0_ZCŒ‡BI’m‚’æ

&=&viy„}aLy06˘ØoZC{I’m‚J>Rc0B¤

Œ(BI’m‚’æ&=&viy„}aLy0d&„,¥--6˘{

C“=‡’˜kO='P0D›p`Ø,&B”¤@niRC>I’m‚d

&„,¥--o 

扩大对临床环境的监督

5~‘}5u@56˙5}F=’¢}1s0pG0b(d8“Pw x/kº

4<UCk=m‚RR-x\‘o5YBs&¥{I’5&vP0.˚nn/

v&TTm‚  B5&¥X{}QC"&x/kº&&’8fnO_C˛

>=0n’¿’˜/œI’&.J>5B5m‚n/vR…S,nq’=’\](

0V(ro5~‘}5].’5p`)B}Qd&„u0V–Sß,¥m‚2A&⁄

Ed&„{.«KM>J>Rck=m‚//2 /æ1$/5J~

\E’˜/œnq,"m‚/kº4<Ud&,¥--o

合规委员会

5~‘}5m‚0V:<0(P&g&¡C":<0({p`)B,0@

:$}J’˜0V&(!im‚P0D›’˜/œRR–[Cm‚>)LRßD?&.

1$].{Cu0VJ>Rc\E1$n/v‡[o0V:<0(

n/o,iFm‚n0V\m‚n>J¤m‚1$03Ko}om‚‹naw}asf 

‡0V‹na·xm‚D0n}vJÆ1$n/]5{P5_¨,0@m‚\

E0V&—.‡[{C6˘,.>\En\nd&Sß,¥1$

,0@O_v;m‚O.˚o 

伦理与合规问题报告

I’].’50B¤J8¿O^Eæ5L¿-&x0V1$(!iRc,"m‚

¤|‹{P}“=KEæŁ-LJª8oI’LdDO^O_v;{‚=. I

’m‚0B¤nlLy0b,&}Qin  1$0V¨¤vJª0˙¤|‹oI

’nD’+u&rP00V&xY‹‹º¤¨c}AkO"1$}łu@{P0

)5~‘}50B¤1$,&’›’05†03(“k=o’HE/"0\&¿JªY

x«d&„o

5~‘}5«*C"¡~ ?‘¶5u\d&„nu/5~‘}5d&„,¥

--1$,0@O_v;’˜/œ&v⁄Ed&„m‚Jª0˙sdHS¯m‚&—.o

,0@].’55E‡P?J>RcYx«Jª0˙sd,Yßm‚HS¯{

C’˜,C&g]m‚P0D›}"Yß’ª(fYx«ud&„o5~‘}5?

¡w0*&g-0ViLP6{)BJÆ&¿Jª’I0V(rP0+0Jª8o 

d&„,¥-- 

0V‹naTeSy 

/æ1$//2

/uJ’0d&„

&x/kº&& ’8f&¤m‚’=.

0V)LG

(!inq,")LG 

(!i1P’:<0(uNs

(!i1P’:<0(I0

关键政策

.«KM,'˛0w xnJ‹.«2An‹¤|1$>J&k0

98% 完成了网络培训CP¨’›’B”¤@CiR,¥--

w  Cx

100% 的员工 ZCLy06˘

培训

12 种2

行为准则



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi (!i1$,Yß O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ 0VF

业务和资金

运营

法律法规

品牌和声誉

产品质量

员工

环境、健康和安全

气候（物理和过渡）

^?,’+R I’  TT&¥m‚›e'5z o

气候韧性

55~‘}5{I’nq)LR,[^)«0.˚¤|‹{P&„,’x«Jg#03Ko}on,Yß&Rc

«łFm‚R¢Rßm‚¡~‡B¤(roI’].’5¡w0*[^)«d.{?[^)««łF-",I

’m‚›e'vi‹nao9u“=’+RR?8·)LG{<S¯n 03Ko}oF→{9u“=’+RI

’m‚[^)«nq,".)LGJŒ““f-FB¤(r}Fw xKwO¤m‚R?8·+G{<S¯n

¤ÆE6

→o

反贿赂和反腐败

I’rYœ’ª(fEND›m‚/21$æd&„oI’>I’D

?&.m‚5B>{ 5/m‚nqC/æ\E{.«KMrYœ/2

O_C˛>=01$2A&}F}I'˛0m‚\Eo5,i·55,;{5~‘

}50B¤1$I’m‚§H2^⁄0V(r((6&vE⁄nlLyI¤Ly0b’ª

(f,&’›&¡’I}F}IL¿(nJ‹?nOE’nP’.ILGRP’.

’ª(f.I,&’›9i8{I’ª(fRc’)Øm‚&ﬂ{’˜?LyOP

OP6.&vE2Eg1{6(“LyOPOu/{&„,0@P0*&v

E2-Dn${I?LyOPOB/Æm‚d&„sd&vE29. oI’‡

[I’m‚&.0V(r((6w(9u{^⁄0V(r((61$‹¤|x

5’¿I’d’2P>nq0Zm‚Sß,¥o 

风险管理

5~‘}5¡wk=’+&g‹»n7,,0@m‚P0\{B0Ps+R…-VRß(.1$vi›e'o

I’..p`)BJ>Rc0B¤>I’m‚(!i1$0VFP0TioI’m‚’æ&›e'v

iw xTeSyP5‹º]5n(.nn/L}nvi1$Jª0˙03J9˛p&.0?m‚

›e'{’˜/œ*-FP-h¡m‚¤|‹1$R…o 

I’>JP6’+’æ&,i&.v}oF-"w x‹na{’˜¤([›e'Q—““{

,‚?1&.X&¥m‚«’2’o  Sß,¥k=(r*‹nam‚&.v

}oFTeSyoY8“{,;¨>N¨Z=˝CŒ(g]u(n>P5(.›e'C0b’2

(>N:<0(Jª0˙Rc’)Øm‚)LGo

我们的风险评估考虑各种定量和定性因素，包括：

反竞争行为

I’..5,C>>Jm‚B5&¥sduJ’0C0*E⁄I.oI

’&v&xuJ’0?J[sd&v⁄En&v,CI«*\\2oI’

:$}J,C5?E>PJ*n(C2AnuJ’0?J[1$0B¤oI’

&v(BN|}7n'gojn_k=fR)LGn)œ¤£I’ª(f

,&’›&v,Cm‚’\Pd&„Rß&0*&v,Cm‚uJ’0(.7oI’

&v&xuJ’0?J[*IYßD›I«*YßD›/8{&v/&x’ª(f/uJ

’0d&„{.«KM>A’TTI-"->PJ*n(C2AIB5oI

’>J>Rc&xuJ’0n/6P1$uJ’0)LGOP'¸Rc,"m‚\Eo

&„’+)s,C1$>>Jm‚uJ’0{I’?t¡,‚?1&xuJ’0?J[

m‚LyX{:$}J+OuH-"‹{.«KMuJ1w,0@1$,&’›,0@

&¤uJ’0Rc,"m‚"‹o 



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ (!i1$,Yß

公正行事

我们致力于反映我们的人员、活动和目标的最佳形象。公正和平等是我们开展工作以及在市

场立足的根本。

伦理咨询委员会

I’(?‘&gy„-)Ik¤|‹0b (!i1P’ :<0( ?[Kw?*{.«KM

ƒˇ?&x6˙5}F=d&nq,"m‚nP-h¡m‚(!i¤|‹nO_v;1$\

L¿-m‚DoI’Z=˝CŒ(&x(!i1P’:<0(\2o,&

B¤(r.«KM0b5~‘}5L¿(’˜&tP0«m‚IkD ;

基因组学技术的伦理应用

5~‘}55ˇ>A?¶dJ‹?{].’5?6˙5}F=JﬁR'Ck=Gˆ

/œ’x«{I’0+&x)s>$I*(“1m‚((60V(roI’

m‚’RO_v;1$>PJ*/8V£’+I’?0V&(!im‚2A&

d&„m‚RR{?JﬁR'm‚(“k={’˜/œ503Jm‚uG,

&tI’03’˜¡w0*m‚LP6oI’J?CE.˚’+I’m‚n/

o1$¤|sC‚{’˜n/o1$Jdo’HJ‹?{’2+¤¨Yœ03

J#I_k=I’R¤|‹m‚§H2o5~‘}5J‹?HS¯Rc,"

’a1w_k=m‚‘¶5Jª0˙{?’5p`Ø]/œ(!iI’R¤|‹

m‚&.((6?u(/p*"Yœ?,&m‚§H2d&„o

与基因组学行业和公司利益

相关的新的政策和法规

特定技术或产品产生的伦理

问题



(!i1P’:<0(



’Rn/o1$¤|TeSy



’a1w_k=m‚’RC?v;

kJ[,C 



’REg1(.



 Eg1(.w.«

KM’B¤QpJ(!in'gs

1$’R-S@x



6˙5}FO¤L,>’gm‚5B¤

RR(>J(



6˙5}F(!iıE6fYy„-)

Nita Farahany，

博士，法学博士

Charmaine Royal，

理学硕士，博士

Freda Lewis-Hall，

医学博士，DFAPA，

MFPM

Glenn Cohen，

法学博士

Leslie Biesecker，

医学博士

Clement Adebamowo，

医学博士，外科博士，

理学博士，FWACS，FACS

伦理业务与基因组学应用



P¨F 



8·TKFn«*Z F 

1$,CF 



’)Øn.m‚ 



¤|-V

人工智能伦理规范

5~‘}5].’5’˜6˙5m‚.¡OV2⁄’x«*4DoI’m‚(“

1PI’’2&0_m‚L..{.«KMI’D0m‚JﬁR'o

5~‘}5B-/DC(“k=’B¤QpJw xy„}aRß>Jh¡d

&‹+m‚]5C‚¡{L.O¤L\>¸{L¿–’’?&x*4

D1$l,l;nq,"m‚6˙50Dm‚iR{L.6˙5}F=s0=

0?oTOLI’m‚>A&—{’B¤QpJy„}a.«KMR…4<=&n

^?C=&1$‹º]5DW•o5~‘}5].’5TOLk=\E1$

’˜&tKw?*/†--RßD0C(“k=  ;



了解更多

'gsO_v;

'gs/†--

'gsP¨CJª0˙

’ªm‚C}H(“k=u(58n P¨

.f]5u(58nP¨ 

’B¤QpJ(!i·

关键举措



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ (!i1$,Yß

I’?’a1wJ>*m‚8nP¨E‹n«>J,¥p`oI’0b>PJ*L¿(

m‚,"’5I’’a1wm‚J>Rc)LG{.«KM]/œL¿(/kºRj.m‚

)LG{E‹&xk=m‚Sßv&g]{Cu0VE25\E1$n/v

‡[o 

道德营销可负担性和定价透明度

5~‘}5].’5L¿(J8¿)s6˙5}FJﬁR'C\Ck=m‚’

TToI’¡wk=’ªm‚P0D›?I’m‚’a1w>A’oI’&x

/ak0y„}anOE’P01$s0pGR…S,M-<1$0V(r{’˜,Cm‚,

’TTL¿(I’m‚’a1wo 

为了支持客户并提高可及性，因美纳采取了以下行动：



L-’+ {oP&gY·Pm‚8—W•]5C‚’{

?trpv6˙5}F/=m‚03JFS’¤{>Jh¡R?F/nR?E8—n

R?03Ko}om‚]5C‚



&x 0V(r{L¿/.0}UTMl;Eg1m‚5B>{ 5

/m‚¤¨\[J.{’˜)R?RcOj5U,]5CJ- c8·}UTM

l;w xoo?Rc.’5Ls&kr/ak0}F}Iw x

-L  C}JYœ,i}UTMl;](dm‚naSß



}i}oJ8—,DJª’-"{p`)B&„&Cﬂ¯l  B5

#&g&¡,Cm‚uJ’0h7ﬂ

5~‘}5TOL8·&¡5z~(1$HOﬁnaE6’TT{.«KM(N&v

¤’5IR¥n†˘1$B5.FVo’TTB5~‘}5>PJ*

}QiI5  5}A0b>PJ*L¿(o>PJ*&03

50rp1$/@8nP¨&¥n-L’TTo 

&xB/Æ,C&gTK{5~‘}5m‚’TT]»C4([’5†˘Kw

O¤I&x&KoC{0ZP0¤OP’+8·kK,i(C§F¤|‹?*]

m‚&PIR¥7§¸o(9u{  C{5~‘}55~‘5Bm‚C

C’TT0.˚([’5~‘5B])O’TTKwO¤w xo 

5~‘}5m‚>A’/P’+,&’)Ø0*0b{OEKo,0@}i}o&„>P

J*>Jh¡-/P{.>L¿–6˙5}F=03/œFo

我们的责任



,Cnn«>Jn,¥p`5£I’m‚’a1w1$Rj.o’?,&

J,¥m‚k=sdLC



&v5’ª(fC0˙n§HI§H2ROæI’ª(f‘5r&¥B¤

£I‘)#I’ª(f4?*F/j



&v8Ø8—I’’a1wm‚.Oj{?&xI’’a1wRc,"m‚›e'‰

L‰^,W{I?uJ’0?J[m‚’a1wIRj.sd)œI«*\

m‚>R(IZæ¯



J>RcC0˙1$>R(ROæE‹>I’m‚C0˙1$>R(ROæ

,¥--1$O_v;



rYœ(“k=R¢E˜,0@O_v;1$sC‚&E⁄nqC>NS¯1$J,¥

m‚)LGI§HROæ



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF O¤L>,1$'gs 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ (!i1$,Yß

I’].’5?#¡~’R{?#¡~Z&g&¡-Dn$nq,"Oo 

I’J‹ØC?#¡~w5B¤’R>‘uNxw/pº0V5Bw&kr’

R>Rxnw,[WR-D1$O_\[R-D5B¤,}(x1$w}Q]8n

r"(/œO.˚R-D5B¤,}(xxn5B¤.#B¤}F}IwB¤(r&¥6˙

R¥/†--1$R-D>Rx’˜/œº0V5BwB¤2A&&x’RKw?*/†--x

&¥m‚6˙R¥/†--o(r&„º0V5B,i9}(}F}Im‚I0{5~‘

}5].’5?o’H/†--,I’m‚IknO.˚nX’˜/œ

2A&((6,"y„&&¥o

关键政策

’RO_v;

’RO_v; —— P2f\

P},~trp$’aO_v;

.-Dr• ?r’GB(C§FP¨C\Tin5Bh¡’¿9Q'‹-V\ Ti/œaL8—-D’G

h¡’¿9Q'‹-V\Ti  CJŒ““8nP¨

维护所有利益相关者的人权

我们人权政策的关键承诺



u0V(!im‚&.d&„ 



(C2Ad&„,¥-- 



d(“}Ur"HkKm‚R-D 



,Cm‚41$B¤(rP¤ 



)BJÆ'gs 



>,m‚B¤(rh7ﬂ 



]'uYB¤1$E.#. 



R…(5†v

<5Y8¤@ ’RO_v; ,O

 C{I’TOLº0V5BKw?*/†--

0.’+’REg1(.oY‹(.5

 C}i}osd{&xY0ZP{I’

&(.’+,;¨O_v;1$8“¨JŒ““{’+

R>J¤1$‘¶5m‚Q|’REg1o

  C{I’}i}osd(.{P

5p`>A5~‘}5¡~‡m‚’REg1{5

~‘}5)BJÆ1$)so’HR-Dm‚h¡d>J

({’˜/œ5~‘}503’˜}i}o.E’R

>J(m‚P0\o

I’5‹’+w5B¤’R>‘uNxn5B

¤.#B¤}F}IwB¤(r&¥6˙R¥/†--1$R

-D>Rx’˜/œº0V5BwB¤2A&&x’

RKw?*/†--xo

I’p`>A’+5*‹¡~‡m‚’REg1 ;



Cv1$«*Z R-D



'gsR



Z&¡’ŒRc>Jh¡03&E⁄m‚RR–Sß

,¥m‚*4Dg,’˜/œ’g0s0=sY

/œ,&Ck=CRßm‚n$8m‚R-D



M·h¡’¿9Q'‹-V1$E.#.

I’&x5~‘}50P¨¤vm‚,;¨-Dn$

nq,"Osd’+LyX{’+R5~‘}59u

(fEg1o’H¡~‡m‚’R{Cp`>A&x

Z&¡‹6nq,"m‚0?R…(o

I’?}i}o5Oﬁ&¡’æ&,;D?B¤

(r{&vPOVs1$OEKoh¡Rcm‚B¤(ro

人权影响评估



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ O¤L>,1$'gs

我们的隐私原则

I’m‚'gsO_v;L‰£’+5~‘}55L¿(’a1w1$Rj.P9u(f(“k=n}vJÆn

)BJÆnJŒ““IﬁstS⁄’Hx«6m‚&¡’)LG *oI’?&¡’)LGm‚8i

u0VI’m‚5*‹6˙R¥'gsKw?*/†-- ; 



透明性



以合乎伦理的方式使用



负责任的管理



问责制

2022 年关键举措



Jm‚'gsTMEæ5¤›1$'gsKw?*:<0([¤'¸’+RßHOﬁ&¡’æ&m‚

‹?*O{’˜Ls5~‘}5m‚'gs-"



L¿’\’+YnE}(RF’æ&--kM<wL}-VO1$8iOx{(r&„'¸5

,;¨7ﬂO¤L* (m‚'gs-"IdCB¤(r



5~‘}5m‚,Y·’;un)LG=sC‚5'gs)LGviP0«&E⁄’+ 

 Ø



)]’+5~‘}5'gs1$0B¤'gsO_v;{’˜u0V.-Dr•?r’GB'gsR

-D\Ti1$&vP0?m‚,i'gs\m‚‡[

坚持数据安全和隐私的

最高标准

当我们在全球范围内提升基因组学可

及性时，我们必须尊重并妥善保护相关

数据 *。

6˙5}F=O¤LYß5L.,i>Jh¡sdS’s?oI’].’5

D0nOEKo1$LC6˙5}F=O¤L'gsFm‚RR–Sß,¥oI

’-V>An>JP61$>NS¯&x'gsnq,"m‚O_v;n>J(1$/8 

2{Cp`)B?'gs(r&„,,0@m‚(+’2‹oI’m‚'g

sO_v;>A’+I’(“k=n}vJÆn)BJÆnJŒ““1$(ND&¡’

)LG* m‚P0D›o

了解更多

'gsO_v;

'gs/†--

'gsP¨CJª0˙

* 5~‘}5’50P5B\E+¨m‚Rı’&tsdnq,"B¤(ro



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß 03«m‚(C§F ,,O_v;

’æ&r"(’ªJª0˙ O¤L>,1$'gs

我们网络安全承诺的五大支柱

项目管理



kKﬁC)LG>,>=w x‹?*

 [?1Z=˝C0b’2(>N:<0(

[¤Jª



TOL~‘5B5B>{Sß,¥&xJﬁR'pGtU'

w x}ł}^>,TeSysdCC(.



0B¤1$J‹.«2AZCsd6˘



u&rP0B¤(r‡[/&x-xD?}ł}^>,

›e'(.

安全的产品设计和布局



’a1w1$y„}a5,&,k010RE⁄-L)BJÆ

1$}vJÆ





5’a1w1$¨~-m‚RRPR¤Zﬂ,‚?1

›e' 



>,‡[ 



’;un’a1wu0V 



¡wk='gs 



ERc.m‚.>Sß,¥ 



&TTm‚O¤L * ¤|L}-V

合作



/kº)B*4)LG,>’g1$-S@&¥Eæ

w x



5B,;>,ºnEi’2(w x



5B¤)LGy„}a>,/8(w x



5I)LGvi/8(w x



ﬁC)LG>,>=5PTq(



风险分析和安全测试



Ko}o(.}ł}^>,›e' 



?J>Rc’;un–’’a1wsd,;¨1$8“¨

>,]5 



>AR?’;un–’’a1wsd“FV-S@ 



-V>A’2’1C-"{}FDnq,"5¤›{

8i}ł}^nq,"¤|‹{)B&.v}oF{

-V>ACF-" 



sd,;¨‘)\-S@ 



¨~-,;¨]5{W•K>•–>POY-

数据保护



K}dJ>Rck=\E1$}ł}^>,RR(>J

(Rß)BJÆO¤L 



O¤L'gs1$O¤L)BJÆ&TTE˜ n

n n,&’›E25\E\1$

I’m‚'gsO_v;>Am‚Sß,¥ 

 >J>TB&x  1$C"m‚

 TeSy(.)BKo&g]{p`)B’+O¤

Lm‚¡1$>,F 



8’.J03¡wk=&v0m‚TTD›Rß.>1$*

=‚O¤L{)BO¤Lm‚R…>F1$>$OﬁF 

w xJ‹¿

{C,(8›

8“m‚>,fF

网络安全框架

I’m‚JﬁR'1$Rj.R¥g]/œ-L8i8—¡E‹0-L)BJÆm‚6˙5}F=1$*4DO¤L *{

o(“E⁄}ł}^>,I&„>Jh¡I’,0@(“1m‚¡~‡¨-o 

主要参考文献

 }ł}^>,TeSy 







k=O¤L)BJÆ\w x



.-Dr•?r’G])O'gs\Ti

w x



*4D)B')MF&x’ª\Ti

w x



&Cﬂ>J>TOVs\Ti)]YßTi

w x

ZC/’Rb{I’Œ(&¿. 网络安

全意识月w x].{.E0

B¤?}ł}^>,’2’n:›˙nOY-

1$03E˜m‚RR(>J(P0\m‚Ø*{

].’5)BJÆ5~‘}5/œ,&O¤L+0

}ł}^:›˙o

2,486 0\

0B¤/&x’+I’m‚‡}ł}^>

,H*Rb·].

10%

F“/&x’O¤7.m-Zæog]u(

w x>P/&x 同比增长 35%

网络安全意识月

深入了解

}ł}^>,5~‘}5>,4_B1$RR(>J(

Carissa Rolins

首席信息官

E8—m‚}ł}^>,LP6Ph¡’¿  y„}am‚E‡}FI¨-o&„I’m‚>PJ*

1$J>Rj.m‚r"~}vJÆ>,n)ØE⁄)LFm‚C05{PI’&.m‚TO6˙ o 

* 5~‘}5’50P5B\E+¨m‚Rı’&tsdnq,"B¤(ro



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs ,,O_v;

’æ&r"(’ªJª0˙ 03«m‚(C§F

建立可靠的供应链

供应商是我们在践行公司使命的过程中，不可或缺的伙伴。我们共同努力扩大我

们对客户以及公司运营所在地的社群的积极影响。

供应链概览

5~‘}5m‚,i(C§F.«KM(C2An-.«2An^⁄0V(r

((6nk0’aB¤/n-§H&¥Eæ1$>PJ*oI’Ø&„&x,>0Z

].’5,YßnOEKo(!i1$0VO.˚m‚(C2A0V(r?’5

&.D?,(Rc¡~‡H&—oI’?(C2A &„0V(r((6{

..&„J>Rc’-/#&g&¡R?.,CnR?03Ko}om‚R¢Rßo 

I’?(C2AL¿-&xI’Hg&g]m‚&.d&„Sß,¥o

I’‡[’›’> (C2Ad&„,¥-- -)-m‚d&„Sß,¥{

?¶dr"(’ª{>JP6h7ﬂvio

5~‘}5(C2Ad&„,¥--&xI’(r&„ º0V5B,i9}(}F

}Iv~-P01$⁄iyP03Ko}oF,iKwO¤I0J>*m‚J‹?

&g]o

I’RE(C2A ; 



>E25\1$k=m‚~‘5B5B¤\ 



OEKo0B¤m‚’R1$5~‘}5 ’RO_v; 



p`)B>,1$*4Dm‚B¤(rh7ﬂ 



EeQr"(’ª1$h)B’ª 



’˜u0V(!im‚P0D›D?&. 

5(.‘¶5(C2AP{I’m‚)LG<[w xB¤,(&¥.«

0r"(Eg11$h7ﬂ>NS¯o 

J>RcP(C2A“=‡Ø03(C2Ad&„,¥--J^J&xI’D?

0V(ro

 C{I’5w(C2Ad&„,¥--x&¥.,’+(C2A

C].’5,‚?1,&h7ﬂ¨”m‚‡[{C‡[I’m‚Ik(

C2A5vOP’ª(f¡w/@PŒE‹Ly0*‡[o

I’Rc&v0Zx«6m‚(C2A{.«KMh¡.«3ROæ(C2An

8R˙-k(C2AvvoI’Bx«-Fn}H-1$-x«Rß>A

&—(C2A~(doo’Hx«-F.«KMnlLy1$¤Ly(C2A{,&&¥

nRc='x«-F{9u-)&„Ik(C2Am‚¨-(C2Ao(C

2Am‚-x«0*,’5’›’L¿(m‚’a1wIRj.{9uI1w/kº4<

UnTT’a1wnh¡I’a1w1$Rj.(C2AoI’’¢,i

 &¡5B>{5/¡w}F’n–’n81$Rj.o

919 家

]m‚8·+¸.˚(C2A

2.69 亿美元

(C2A8·+¸.˚P0«m‚OE-

6.94 亿美元

(C2AP0«m‚nlLyOE-

> 10 亿美元

0b(C2AOE’m‚‹º(.)k= 

3,323 家

Oﬁ&¡(C§F&¥m‚(C2AF“O¤

我们的供应链



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs ,,O_v;

’æ&r"(’ªJª0˙ 03«m‚(C§F

供应链透明度法案及英国现代奴隶制法案

5~‘}5].’5’˜0V\1$,Yßm‚P0D›D?&.oI’..

(.˚>J({p`)B5I’(C§F1$,iXm‚’ª(f¨-&v

=‚5’0!/An9QEvnEIE-V.#.m‚¤|‹oI’&

5Cp`)BI’m‚,i&.0V(r((65L¿(2A1w1$Rj.P

&v(¡wk=’ª(fEND›m‚h¡’¿9Q'‹-Vo  C{I’R?P

’+w.-Dr•?r’GB(C§FP¨C\Tix1$w5Bh¡’¿9Q

'‹-V\Tixm‚JŒ““8nP¨{7.’+w  CaL8—-D’Gh¡’¿

9Q'‹-V\TixoR?8·)LG<¤@I’m‚ .-Dr•?r’GB(C

§FP¨C\Tin5Bh¡’¿9Q'‹-V\Ti/œaL8—-D’G h¡’¿9Q

'‹-V\TiJŒ““8nP¨ o

无冲突矿产

5~‘}5OEKo5B¤r"(,>0Z..{p`)B-.SS[W&”,>1$5BI

Zł5B>{m‚Z3}F}I&vnlLyI¤Ly0n$’5,~trp$’ao&„

Y{5~‘}5‡[J>Rc(C2A> ’ª2A&º nEwx

d&„,¥-- oBI’m‚ P},~trp$’aO_ v; ‡[(C2A-V>A

HB„m‚?tHS¯‹na{’˜p`)B(C§F\5Rc,~trp$’a{C

K}‡[0b5~‘}5L¿(,&?tHS¯LP6o5~‘}5?>AR?

(C2Asd(.{’˜p`)B,&u0VI’m‚RR1$’)Øo

验证和尽职调查过程

I’’&xJ‹??¶dJ>Rc\E1$(!i&—.m‚&.0V(r((6

Du(0V(r,"y„oI’}_&v(5oQ/m‚G,&t&x'˛k=R¢I

C’nE.#.IB(d~RßG—I0B¤m‚&.0V(r((6

0V(r{P}\EP0+¨Yx«*\o 

I’(?P&.0V(r((6sd?tHS¯{’›’P

0u0VI’m‚Sß,¥oYBs]/œ5.,P(C2APsd

-2:$›e'(.{C?,&h¡D?>AR(.oY8“{?’5

›e'¯–m‚(C§F‹6{I’¡w0*nq,"LP6{E.˚I’

m‚›e'}RIko5&x’ª(f(C2AD?&.&-x{I’

Œ(-Dk=B¤,(Rß&0*&kr0P5O_C˛0Bm‚RRP-V*0\/@{

’˜*-F/&x\ƒłn4.,¥,Y’25(dvg~!].m‚,0@1$

&¡’oY8“{I’&(-Dk=8·s+B¤,(RßKo}on/L}I’m‚

(C2A~(d{’+R‘¶5m‚›e'5z{9u.s>AFn‹

?*?{0.n,i‡¤vvo 

I’‚=. J>Rc0B¤1$&.0V(r((6B0Ps+YßD›^⁄

w.«KMI’m‚\E5¤›1$ I0V&xY‹‹º¤¨Jª0˙}łu@I

c}AxJª0˙‘¶5m‚ud&„I¤|‹o

渠道合作伙伴

I’m‚’a1wBI’03«m‚^⁄0V(r((6}ł}^§HE,io

I’m‚0V(r((6&v’?I’m‚’a1wL0b,i{&L¿(§H

2n§HnRj.1$OEKo{,&[C&xI’nlLy0b>PJ*L¿(

’a1wm‚[Cnq0Zo 5~‘}50V(r((6d&„,¥-- ‡[^⁄0V

(r((60ZTK>&.,YßFnB51$(!id&„J‹?{

>J>Rck=\E’˜/œ’R6˙R¥‡zo5~‘}5P+s/kº

JﬁR'/8(w x1$Y]  I0o^⁄0V

(r((6E‹_¨k=m‚  (!i ,¥-- 1$ 

Y]0V(!i&.>J(,¥-- m‚>Ao

供应商可持续性

 C{5sd  O¤LOP'¸P{I’?(C§F03

Ko}oFsd’+  m‚(.o

^?,’+R 供应商可持续性→

了解更多

^⁄0V(r((6d&„,¥--

.-Dr•?r’GB(C§FP¨C \Ti/œ5B h¡’¿9Q'‹-V\Ti

JŒ““8nP¨

P},~trp$’aO_v;



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs ,,O_v;

’æ&r"(’ªJª0˙ 03«m‚(C§F

供应商多元化

I’m‚(C2A8·+¸.˚B¤(rP56˘,./PI’m‚r"~n>PJ*n

0B¤1$XJ>558·+¸.˚m‚(C2A6˙po 

I’Ø&„{8·+¸.˚m‚(C2A6˙pB-Dk=(C2Am‚g]f}Q

1$-/#FR,P0TiL¿(uJ’0F2A&(.7oI’-"5(C

2A8·+¸.˚n/v:<0(m‚n/o&t{&x&t£~‘5B(C2AD?0V(r{

o’H(C2A[?1Rc  PkK0VTTm‚8·+¸.˚~(dKFRcnvi1$

L}-Vo

我们的供应商包括但不限于：



9NF-/.m‚’æ& 



?1O¤P[R-/.m‚’æ& 



˝(,Y’-/.m‚’æ& 



ZNl,’-/.m‚’æ& 

 -/.m‚’æ&



5r"(1$}Q]8P0«8’5D.7

m‚~(d-/.m‚’æ& 



&E⁄Øm‚?-’æ& 



5,i{I’‚=. ?t03J(“k=E25&.{OEKoI’0B¤J>

55m‚}Q]8oI’m‚‹naYß5^oJ8—{?.«KM’G85/m‚

9NF-/.’æ&1$5Bm‚?-E˛’æ&o 

(r&„I’5(C2Avi&¥,(C2A8·+¸.˚m‚XL}-Vm‚

&g¨-{I’‡[¡w}QiB=&viy„}aw x>$I

,"’5(C2A8·+¸.˚m‚E-VF,;¨6˘Øo  C{I’

-"?8·+¸.˚vC}5,I’m‚)LG<[1$P0TikM<](s{s

&gY.EXL}-V{’˜OEKo8·+¸.˚m‚(C2Ao 

了解更多

(C2Ad&„,¥--

(C2A8·+¸.˚‹na

5(C2A8·+¸.˚P0«m‚F“OE

-&¥{ 女性创办企业/QZæ

25%

活跃的多元化供应商

 ; 

2022 ：

919

多元化供应商支出

w~‘5Bx

 ;  ’~‘+¸

2022 ; 2.69 亿美元

20%

(C2A8·+¸.˚P0«m‚

OE-/QZæw~‘5Bx 

2030 年目标 2022 年进展

18%

OE-

5(C2A8·+¸.˚P0«m‚F“OE

-&¥{ 少数族裔创办企业/Q

Zæ35%



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs ,,O_v;

’æ&r"(’ªJª0˙ 03«m‚(C§F

供应商质量愿景和价值观

&„’+p`)B’a1w¡{I’E‹)BI’¡wm‚0Ps+}F’m‚

¡o5~‘}5(C2A¡HfQ^0_m‚6˙R¥/†iPS,D1$6˘

,.‹+m‚(C2A~(d{:$}Jp`)B’a1wm‚>,1$–¡o 

(C2A¡vik010R.«0’˜&t¤Zﬂ ; 

•

初始风险评估

•

验收

•

审计

•

监测

B&x(C2A0V(r{I’,"\⁄>PJ*(dnKo}oOVsn

¡viy„}am‚Oj.1$0VFoJ>Rc5~‘}5&g})nlLy(C

2AŒ“=‡TOL5~‘}5¡wL}-VLP6Rß,¥.,1$sd

OPoJ>Rc’a1w5†03¯_w{\&n03’˜BI’m‚C‰=‚v

iy„}a  ¯v’a1wC‰=‚o’a1w03J¤ÆCRıENp&nJ0?

1$ I2&gSß*uo

产品质量

5~‘}5].’5)s’x«?(*4Dm‚iR{I&„*‹6

}~0VR,P0Tim‚‹+(C2AoI’B,"\⁄k=J*(dn

RßKo}oOVsn}vKo¡viy„}aOj.n>\{Rß>J

h¡*naSßo 

  C{I’R¢0p’ª(f“=‡0b  Jª0˙m‚/kº4<

U’a1w0.5oR¥C0k0’+&gYP}“=0b  Jª0˙m‚/kº4<

U&”.0.5’2’{,>0k0’+’@Y“=‡0b'~‘5B’˜8“m‚,&

’›5B>{m‚n/vR…S,Jª0˙{C’¢B5&sN55I?’a1wsd

nq,")]YßB¤(ro

了解更多

(C2A¡J[,C

¡O_v;8nP¨

质量管理系统

’˜&tB¤/B”B  /kº4<U¡Sß,¥Ø ; 

•

加利福尼亚州福斯特城

•

加利福尼亚州圣迭戈

•

加利福尼亚州海沃德

•

威斯康辛州麦迪逊

•

荷兰

•

新加坡

•

英国剑桥

供应商质量管理周期

¡vi(dy„5’a1wk010Rm‚Z&¡¤ZﬂŒ,(Rc¡~‡(r

k={03’˜p`)B>JP6nq,"O_v;{Tu(nq,"naSß{¡wk=RR–

’a1w¡Sß,¥o

•

供应商选择和评估

•

供应商验收

•

供应商监督

•

组件验收



5~‘}5TMEæP6 /&x’+u&rP0>N‹na

TMEæP6m‚>A&—&„5In_)/n•Ln5B-T’˜/œP.5o



企业社会责任战略与管理可及性社群员工尽责运营

简介附录可持续性

首席执行官寄语

IkP0ƒˇ&xEg1 ’æ&vi 0VF (!i1$,Yß O¤L>,1$'gs 03«m‚(C§F

’æ&r"(’ªJª0˙ ,,O_v;

做出负责任的公共政策决定

5~‘}5/&x,iO_C˛1$R…S,m‚O_\[1$,,>O_v;Bs{&x

O_v;-V>AO1$,"§v-Dn$nq,"O?‘Eg1I’m‚(“11$&.

m‚¤|‹sd’\]({D?O«o 

I’&xO_v;-V>AO&¤m‚’=.&xI’m‚TMEæ’)Øn

(!i’ª1$\E&—.)BKo&g]o5~‘}5’2(m‚L¿0\ 

,0@vi:<0(n/oI’m‚O_\[O_v;’˜/œ5~‘}5m‚

KØPg˜o*:<0(p`)B5~‘}5O_\[].)s(!i

1$P¨/&x{L.’æ&naSß{>k=m‚\E1$Jª0˙‡

[o5~‘}5ZCL¿(,0@ ,,>O_v;(+}) nO_\[FKØY·n

^•9)k=1$¡~‡I0g’)LGm‚RRPG,oI’m‚,i

O_C˛’2.5¤›D?>R(].o5~‘}5\5Rcu(O_\[

d.:<0({(N)Bk’+8“¨Ik‹¤|{P5OEKoI’&x

,iO_v;-V>AO1$,"§v-Dn$nq,"OD?’\](oo’H‹¤|

?‘O_v;1$f>A5/¤|‹L¿(&&o*o 

5~‘}5>&x,&,iO_\[1$,,>O_v;].nq,"m‚J>Rc

k=m‚\E\oo’H\E&g‡[Jª0˙^•9].C>

k=m‚P&x\Eo 

’¿5~‘}5L¿’\m‚Jª0˙5’˜&tO_C˛O¤LC‰03,D&0* ; 

~‘5B( '&ı>=.,>T 

~‘5B/'/'s=&. ,>T

^•9JŒ““{.-Dr•?r’GB./.,>T

P¨ıE6{YnE:<0(

EB(!i:<0(

)‚?*,,>O_v;’˜p`)B1$>Jh¡6˙5}F=JﬁR'C\(“k=PE2.

&Fo  C{I’¡~c??‘’˜&tP0«&x,,>O_v;-Dn$nq

,"O?D0V(r ; 

•

Lsy5,¥/kº 

•

¡wk=1$Jª§H(U,]5 

•

¡wk=1$Jª§H 

•

¡wk=1$4.6˙5}F=(S'l;n/]5 

•

-/#  R…(

积极地与公共政策利益相关者开展交流，准确可靠地分享有关基因

组学的信息，推动相关政策，确保和促进该技术的可及性。

了解更多

O_\[g˜¡O_v;

O_\[g˜¡OE-Jª0˙n(P}F}I1$¡~‡I0Jª0˙ →

贸易组织和成员身份

5~‘}5/&x0Ps+(P}F}I{D?0V(r{’\](F|GoI’0b

8·&¡(P1$d&}F}IOE’C){,&&¥&g’H}F}I?¨-(0

)k=’5&v03J~'m‚B1$ºe^•9/œO_\[)k=oI’(JŒ““

5-x&gCg˜B  ~‘+¸m‚(P}F}II0g’{’˜

/œYx«)k=m‚F“¡›o 

?’5B  ~‘+¸m‚(P}F}I)k={I’n(JŒ““

w5B,;sOP\xu  Rı>Am‚&v03J~'m‚)k=

¨-{(9uTOLu  1$  Rı0bR…S,OE’

m‚Y·‹o

John Frank

首席公共事务官

'enÆ5~‘}55&Cﬂ/kº‹6m‚Eg1Pn$^?

t{O_C˛1$d&-Dn$nq,"OBR8·P0sdS’0V

(r{Lr6˙5}F=9u(fJR?9i5&„&¡’1$,

i·55,;m‚GVORj.o

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Appendix

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

About this Report







Boundaries and Exclusions













Reporting Period



Baseline Year



Materiality



Currency References



Signatory Participation















Reporting Frameworks

























Relevant Memberships

















Learn More





Contact







Re-statements





Assurance







 



ESG Appendix Contents

83 

84 

85 

86 

86 

86 

86 

87 

90 

97 

100

103

104

105

106

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Our 2030 Targets

Accelerate

Access to

Genomics

Target 17.6:





Target 3.d:

 Target 17.7:



Target 17.16:





Operate

Responsibly Target 9.2:



Target 10.3: 



Target 17.16:





Empower Our

Communities

Target 5.b:



Target 10.3: 



Integrate

Sustainability

Target 12.2:





Target 12.5:



Target 13.2:





Nurture

Our People

Target 10.3:

Our Focus Areas

$100 genome

50,000 patients

2 billion covered lives

 200+ genomic startups



$60 million commitments

25,000 medical education learners

Ensure 100% strategic suppliers



 20% spend

top industry ESG ratings

5 million STEM learners

100,000+ volunteer hours

50% employee participation 

net zero emissions



Reduce emissions by 46%



Reduce emissions by 46%



100% renewable

electricity

90% landfill diversion



10% reduction



packaging

by 75%

 gender representation

zero net pay gap

 minority representation

representation of Black, Native, Pacific Islander,

Hispanic or Latino, 2 or more

recordable injury and illness rate

2030 Targets

1. 

2. 

3. 

4. 

5. 

6. 



1. 

2. 

3. 

4. 

5. 

6. 

1. 

2. 

3. 

1. 

2. 

3. 

4. 

5. 

1. 

2. 

3. 

Objectives UN SDG Target Alignment

$20 million





100% of strategic

suppliers



Achieved In Progress

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Recognition 2022

Workplace















Regional













Leadership









1 | 1 | 3

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Key Performance Indicator Summary

Introduction

General 2022

Name of organization Illumina, Inc.

Location of headquarters San Diego, California, US

Number of global locations 33

Nature of ownership and legal form Public Corporation

Revenue $4.55 billion

Total capitalization (stockholder’s equity) market value as of 12/31/2021 $6.6 billion

5Y CAGR 11%

10Y CAGR 15%

R&D % revenue investment 22%

R&D spend $1 billion

Building footprint12,649,068 square feet

Facility additions27

Facility closures32

Expand Access to Genomics

Access to Genomics 2022

Cost per genome4

iHope™ patients supported in 2021 439

Total iHope™ patients supported since program inception 1,704

Clinical iHope™ network sites 28

Professional healthcare learners 

Illumina Accelerator companies funded through December 2021 74

NGS coverage outlook: total insured lives 1.2 billion

Footnotes:





















Empower Our Communities

Total Giving 2019 2020 2021 2022

 $1,185,088 $13,829,496 $14,966,331 $18,239,858

 $873,088 $13,255,768 $14,446,500 $17,676,194

Number of causes supported51,021 1,034 1,345 1,747

Illumina, Inc. Giving 2019 2020 2021 2022

 $560,088 $7,146,450 $9,409,966 $12,379,381

Illumina Corporate Foundation Giving 2019 2020 2021 2022

Employee giving $312,000 $573,728 $519,831 $563,664

Employee participation (giving) 19% 20% 26% 28%

 $208,000 $721,111 $546,884 $606,597

Charitable grants $105,000 $5,388,207 $4,489,650 $4,887,885

Total Foundation giving (not including employees) $313,000 $6,109,318 $5,036,534 $5,860,477

Volunteer Hours 2019 2020 2021 2022

Employee hours 13,980 4,236 8,772 20,142

Employee volunteering 29% 5% 10% 39%

Intern hours 140 1,237 800 520

Employee Participation 2019 2020 2021 2022

 40% 24% 31% 50%

 2019 2020 2021 2022

Illumina, Inc. NA $2,894,129 $7,044,842 $5,994,599

Illumina Corporate Foundation NA $635,126 $1,089,892 $1,980,646

Number of countries 24 29 44 46

STEM 2019 2020 2021 2022

Number of teachers and students engaged in Illumina STEM programs 306,170 195,000 315,000 396,865

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Footnotes:



General Notes:











Energy Consumption  2019 2020*2021*2022*

Total fuel consumption from non-renewable sources 247,576 390,564 403,211 375,516

Total fuel consumption from renewable sources 0000

Generation from renewable sources consumed by the organization 1,566 3,333 2,417 2,966

Total energy consumption from non-renewable sources 503,658 561,258 581,067 228,712

Total energy consumption from renewable sources 1,566 3,333 9,077 375,516

Total energy consumption 505,224 564,591 590,144 604,228

Energy Consumption by Activity and Region  2019 2020* 2021* 2022*

 257,648 174,028 187,297 231,678

Purchased electricity 256,082 170,694 184,882 228,711.6

Generated electricity (on-site solar) 1,566 3,333 2,417 2,966.4

Total fuel 247,576 390,564 403,211 375,516

Natural gas 247,576 390,564 403,211 375,516

Total steam 0000

Electricity, heating, cooling, steam sold 0000

Total energy consumption AMR region 380,106 445,190 469,104 473,893

Total energy consumption EMEA region 47,779 35,072 36,358 36,308

Total energy consumption APAC region 75,752 80,996 84,681 94,026

Renewable Electricity Consumption 2019 2020 2021* 2022*

Percentage of global electricity consumption that is renewable 0.6% 2% 59% 100%

On-site solar generation 0.6% 2% 1% 1%

Renewable electricity purchased 0% 0% 3% 37%

Covered by Renewable Energy Credits 0% 0% 55% 62%

Emissions 2e) w2019 2020* 2021* 2022*

Total Scope 1 & 2 (market-based) GHG emissions 34,404 36,573 26,265 18,902

Total Scope 1 & 2 (location-based) GHG emissions 34,404 36,573 36,914 39,924

 12,489 19,701 20,296 18,902

 21,915 16,872 5,968 21,022

 21,915 16,872 16,618 0

Regional Emissions Market-Based e) 2019 2020* 2021* 2022*

Scope 1 & 2 AMR region 22,903 25,207 25,060 18,159

Scope 1 & 2 EMEA region 3,014 2,253 864 743

Scope 1 & 2 APAC region 8,488 9,113 341 743

Country-Specific Scope 1 Emissions e) 2019 2020* 2021* 2022*

China 000 0

Netherlands 73 73 74 55

Singapore 000 0

United Kingdom of Great Britain and Northern Ireland 1,132 801 768 688

United States of America 11,284 18,827 19,454 18,159

Country-Specific Scope 2 Market-Based Emissions 2019 2020* 2021* 2022*

China 388 518 0 0

Netherlands 384 368 8 0

Singapore 8,099 8,595 341 0

United Kingdom of Great Britain and Northern Ireland 1,425 1,011 14 0

United States of America 11,619 6,380 5,605 0

Integrate Sustainability

Key Performance Indicators

e)

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Greenhouse Gas Breakdown e) 2019 2020* 2021* 2022*

CO2 Scope 1 12,475 19,681 19,884 18,518

CH4 Scope1 710 375 349

N20 Scope 1 610 37 35

Emission Intensity Ratios  2019 2020* 2021* 2022*

GHG emission intensity per million dollars revenue 9.8 11.4 5.8 4.2

GHG emission intensity kgCO2e/square feet 13.8 15.1 10.4 7.5

GHG emission intensity per employee 4.4 4.7 2.9 1.8

Emission Intensity Ratio  2019 2020* 2021* 2022*

GHG emission intensity per million dollars revenue 72.6 71.3 66.1 78.8

Facility-Specific Emissions1,2

e)

Scope 1 Scope 2

Market-Based Scope 2

Location-Based

2021*2022*2021*

2022

2021

2022

Cambridge, United Kingdom 749 681 0 0 903 971

Eindhoven, Netherlands 72 040 0203 0

Foster City, California 1,359 1,506 1,403 1,403 1,906

Hayward, California 634 624 592 0592 673

Madison, Wisconsin 1,458 1,554 2,138 02,138 2,695

Northcoast, Singapore N/A 0N/A 00247

San Diego Headquarters, California 15,248 13,910 1,291 01,580 3,443

San Diego i3, California 756 564 134 0200 325

San Diego Warehouse, California 0 0 47 074 96

Shanghai, China 0 0 0 0 358 220

Steenoven, Netherlands 255 8 0 218 541

Watson, United Kingdom 19 714 023 26

Woodlands, Singapore 0 0 341 08,927 9,556

Scope 3 Emissions e) 2019 2020 2021* 2022*

372,915 100,351 138,563 131,929

339,940 44,057 79,530 83,071

 6,956 5,785 9,048 8,590

346,327 48,256 68,934 85,993

 236 617 1,055 1,275

319,350 8,913 3,959 20,040

318,012 7,567 7,616 15,027

 1,480 733 547 830

 Assessed, not relevant

 Assessed, not relevant

 6,968 4,850 9,221 11,865

 2,368 2,245 5,230 31

 Assessed, not relevant

 Assessed, not relevant

323,559 19,038 0 0

Total Scope 3 Emissions 238,110 242,411 323,702 358,651

Scope 3 Emissions: % of Total Scope 3 Emissions 2019 2020 2021* 2022*

331% 41% 43% 37%

317% 18% 25% 23%

 3% 2% 3% 2%

319% 20% 21% 24%

 0.1% 0.3% 0.3% 0%

38% 4% 1% 6%

38% 3% 2% 4%

 0.6% 0.3% 0.2% 0%

 3% 2% 3% 3%

 1% 0.9% 2% 0%

310% 8% 0% 0%

Footnotes:













General Notes:















Integrate Sustainability continued

Key Performance Indicators

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Water  2019 2020 2021* 2022*

 225 294 268 256

Water withdrawal (potable) 147 208 195 213

Water withdrawal (recycled) 78 86 74 43

Percentage of total water withdrawal in water stressed regions163% 62% 70% 66%

Water intensity (kiloliters by rentable square feet for core locations)20.10 0.12 0.11 0.10

% water consumption in AMR 97% 97% 97% 92%

% water consumption in EMEA 2% 1% 1% 2%

% water consumption in APAC 1% 2% 2% 6%

Total Waste  2019 2020 2021 2022*

 4,934 4,979 5,975 7,503

Global average non-hazardous diversion from landfill 51% 49% 49% 64%

Regional Waste Data AMR  2019 2020 2021 2022*

Non-hazardous waste total 2,619 2,869 3,326 4,802

Hazardous waste total 902 699 605 594

Madison Site % diversion339% 43% 43% 43%

Foster City % diversion354% 48% 49% 66%

Hayward % diversion332% 22% 22% 70%

San Diego % diversion333% 36% 31% 42%

Regional Waste Data EMEA  2019 2020 2021 2022*

Non-hazardous waste total 451 397 590 569

Hazardous waste total 67 35 55 79

Cambridge, UK % diversion3100% 100% 100% 100%

Netherlands % diversion3100% 100% 100% 100%

Regional Waste Data APAC  2019 2020 2021 2022*

Non-hazardous waste total 424 437 504 750

Hazardous waste total 471 542 894 710

Singapore % diversion3100% 100% 100% 100%

General Notes:



Effluent & Waste by Type and Disposal Method 2019 2020 2021 2022*

Non-Hazardous Waste

Non-hazardous waste total 3,494 3,703 4,421 6,119

Reuse 0000

Recycling 887 872 937 3,338

Composting 149 203 259 267

Recovery (including energy recovery) 760 729 977 366

Incineration 0000

 0000

Landfill 1,698 1,899 2,247 2,224

On-site storage 0000

Other 0000

Hazardous Waste

Hazardous waste total 1,440 1,276 1,554 1,383

Reuse 0000

Recycling 413 489 332 65

Composting 0000

Recovery (including energy recovery) 850 707 1,169 943

Incineration 62 34 41 47

 0000

Landfill 37 20 6 8

On-site storage 0000

Other 77 26 412

Integrate Sustainability continued

Key Performance Indicators



Footnotes:







CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Footnotes:







Workforce Data 2019 2020 2021* 2022*

Total employees    

Full-time employees 7,749 7,782 9,137 10,195

Part-time employees 53 46 54 62

Contingent workers 1,247 1,459 1,647 1,578

Age Group

Employees under 30 1,527 1,363 1,820 1,963

20% 17% 20% 19%

 5,090 5,235 5,992 6,748

65% 67% 65% 66%

Employees over 50 1,185 1,230 1,379 1,546

15% 16% 15% 15%

AMR

Total employees 4,973 4,937 5,668 6,342

Full-time employees 4,954 4,918 5,650 6,324

Part-time employees 19 19 18 18

Contingent workers 971 1,182 884 726

APAC

Total employees 1,883 1,871 2,238 2,456

Full-time employees 1,882 1,871 2,238 2,456

Part-time employees 1 0 0 0

Contingent workers 164 146 588 726

EMEA

Total employees 946 1,020 1,285 1,459

Full-time employees 913 993 1,249 1,415

Part-time employees 33 27 36 44

Contingent workers 112 131 175 186

Gender Data 2019 2020 2021* 2022*

Workforce

    

43% 43% 45% 45%

Full-time women 3,293 3,305 4,036 4,543

43% 43% 45% 45%

Part-time women141 37 40 53

79% 80% 76% 86%

Temporary women N/A N/A N/A N/A

N/A N/A N/A N/A

Leadership

Women in leadership2571 610 746 898

39% 40% 42% 41%

Women in executive leadership3112 136 174 217

33% 36% 38% 38%

Women on Board of Directors 3333

33% 30% 33% 33%

Total Women by Region

AMR 2,071 2,067 2,474 2,813

APAC 847 826 1,037 1,124

EMEA 416 449 565 659

Women in Leadership by Region

AMR 404 421 506 613

APAC 95 104 135 153

EMEA 72 85 105 132

Functional Group

Women in revenue-generating roles 41% 36% 48% 48%

Women in revenue-generating roles—management 35% 36% 42% 42%

 37% 37% 39% 39%

Women in IT roles 24% 23% 24% 24%

Women in engineering roles 37% 36% 29% 29%

Nurture Our People

Key Performance Indicators

General Notes:







CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Footnotes:







General Notes:





Percentage Female of Each EEOC Category  2019 2020 2021* 2022*

White/Caucasian 41% 41% 43% 44%

Native Hawaiian or Other Pacific Islander 31% 27% 33% 31%

American Indian or Native Alaskan 50% 45% 50% 50%

Asian 44% 44% 45% 46%

Hispanic or Latino 39% 40% 44% 43%

Black or African American 37% 41% 45% 46%

2 or More 45% 46% 51% 51%

Choose not to self disclose 40% 40% 41% 37%

Percentage Male of Each EEOC Category  2019 2020 2021* 2022*

White/Caucasian 59% 59% 57% 56%

Native Hawaiian or Other Pacific Islander 69% 73% 67% 69%

American Indian or Native Alaskan 50% 55% 50% 50%

Asian 56% 56% 55% 54%

Hispanic or Latino 61% 60% 56% 57%

Black or African American 63% 60% 55% 54%

2 or More 55% 54% 49% 49%

Choose not to self disclose 60% 60% 59% 63%

EEOC Minority Summary  2019 2020 2021* 2022*

Total employees identifying in minority race and ethnicity statistics2,429 2,422 2,830 3,213

Minority of total employees49% 49% 50% 52%

Non-Minority of total employees46% 46% 45% 44%

Decline to state of total employees 5% 5% 5% 4%

Representation of Black, Native, Pacific Islander,

Hispanic or Latino, 2 or more communities in workforce 17% 17% 17% 18%

Representation of Black, Native, Pacific Islander,

Hispanic or Latino, 2 or more communities in leadership10% 11% 12% 13%

Minority representation in executive leadership 21% 23% 27% 30%

EEOC Minority by Category  2019 2020 2021* 2022*

White/Caucasian 2,284 2,253 2,514 2,756

46% 46% 45% 44%

Native Hawaiian or Other Pacific Islander 62 56 67 64

1% 1% 1% 1%

American Indian or Native Alaskan 10 11 13 15

   0%

Asian 1,601 1,601 1,863 2,097

32% 33% 33% 34%

Hispanic or Latino 447 435 510 588

9% 9% 9% 9%

Black or African American 121 121 130 146

2% 2% 2% 2%

2 or More 188 198 248 303

4% 4% 4% 5%

Choose not to self disclose 240 238 294 241

5% 5% 5% 4%

Veteran 143 141 145 157

3% 3% 3% 3%

Disabled 248 235 230 223

5% 5% 4% 4%

Nurture Our People continued

Key Performance Indicators

Percentage Gender by Level 2022* Male 2022*Female 2022*Undisclosed 2022*

Support to Entry Professional 51% 49% 1%

Intermediate to Senior Professional 55% 44% 1%

Supervisor to Assoc Director 56% 44% 1%

Director and Senior Director 59% 41% 1%

VP 63% 37% 0%

SVP / C suite 64% 36% 0%

Board of Directors 67% 33% 0%

Learn More: 

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

EEOC Data by Level  2019 2020 2021*2022*

Support to Entry Professional

White/Caucasian 261 226 264 255

24% 23% 23% 23%

Native Hawaiian or Other Pacific Islander 29 31 34 29

3% 3% 3% 3%

American Indian or Native Alaskan 3 2 3 4

   

Asian 489 452 514 485

45% 45% 45% 44%

Hispanic or Latino 173 160 185 191

16% 16% 16% 17%

Black or African American 48 38 38 36

4% 4% 3% 3%

2 or More 57 56 65 83

5% 6% 6% 7%

Choose not to self disclose 38 34 35 26

3% 3% 3% 2%

Intermediate to Senior Professional

White/Caucasian 1,403 1,389 1,555 1,721

50% 48% 48% 46%

Native Hawaiian or Other Pacific Islander 22 16 21 22

1% 1% 1% 1%

American Indian or Native Alaskan 4 6 7 9

   

Asian 895 938 1,078 1,292

32% 33% 33% 34%

Hispanic or Latino 199 201 243 300

7% 7% 7% 8%

Black or African American 51 56 63 75

2% 2% 2% 2%

2 or More 105 115 150 181

4% 4% 5% 5%

Choose not to self disclose 143 146 191 147

5% 5% 6% 4%

EEOC Data by Level  2019 2020 2021*2022*

Manager to Associate Director

White/Caucasian 413 421 452 508

54% 56% 55% 54%

Native Hawaiian or Other Pacific Islander 11 911 12

1% 1% 1% 1%

American Indian or Native Alaskan 2 2 1 0

   0%

Asian 182 174 214 243

24% 23% 26% 26%

Hispanic or Latino 65 61 70 82

9% 8% 8% 9%

Black or African American 17 21 22 26

2% 3% 3% 3%

2 or More 22 21 23 28

3% 3% 3% 3%

Choose not to self disclose 46 48 51 49

6% 6% 6% 5%

Director and Above

White/Caucasian 207 217 243 272

75% 75% 70% 67%

Native Hawaiian or Other Pacific Islander 0 0 1 1

0% 0%  

American Indian or Native Alaskan 1 1 2 2

  1% 

Asian 35 37 57 77

13% 13% 16% 19%

Hispanic or Latino 10 13 12 15

4% 4% 3% 4%

Black or African American 5 6 7 9

2% 2% 2% 2%

2 or More 4 6 10 11

1% 2% 3% 3%

Choose not to self disclose 13 10 17 19

5% 3% 5% 5%

General Notes: 

Learn More: 

Nurture Our People continued

Key Performance Indicators

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

New Hire Data 2019 2020 2021*2022*

New Hire by Age Group1

Employees under 30 458 380 990 860

30% 28% 54% 44%

 716 586 1,358 1,320

14% 11% 23% 20%

Employees over 50 89 88 156 140

8% 7% 11% 9%

New Hire by Gender2

New female employee hires 566 490 1,185 1,049

17% 15% 29% 23%

New male employee hires 684 560 1,262 1,240

15% 12% 25% 22%

New Hire by Region

AMR new employee hires 707 629 1,479 1,315

14% 13% 26% 21%

APAC new employee hires 376 249 621 621

20% 13% 28% 25%

EMEA new employee hires 180 176 404 384

19% 17% 31% 26%



White/Caucasian 44% 47% 40% 39%

Native Hawaiian or Other Pacific Islander 1%  1% 1%

American Indian or Native Alaskan    

Asian 32% 33% 34% 35%

Hispanic or Latino 10% 7% 10% 11%

Black or African American 2% 4% 2% 3%

2 or More 7% 6% 7% 6%

Choose not to self disclose 5% 3% 6% 4%

Promotion Data 2019 2020 2021*2022*

Total number of employees promoted 1,502 1,568 2,583 2,436

Promotion Rate by EEOC  2019 2020 2021*2022*

White/Caucasian 22% 20% 34% 26%

Native Hawaiian or Other Pacific Islander 19% 10% 34% 24%

American Indian or Native Alaskan 0% 29% 33% 21%

Asian 23% 20% 37% 25%

Hispanic or Latino 19% 19% 34% 17%

Black or African American 14% 15% 33% 25%

2 or More 20% 18% 37% 38%

Choose not to self disclose 21% 22% 35% 21%

Veteran Data  2019 2020 2021*2022*

Number of US employees, regardless of whether

they have any military connection 4,908 4,866 5,561 6,210

Number of employees as defined by the federal government

as meeting the criteria for protected veteran status 87 87 90 92

Number of veteran and active duty employees,

regardless of protected status 143 141 145 157

Number of disabled veteran employees 2 2 3 3

Number of women veteran employees 24 20 26 27

Number of minority veteran employees—minority veterans include,



religious minorities

67 68 75 80

 3% 3% 3% 3%

 2019 2020 2021*2022*

 1% 1% 2% 3%

 3% 5% 4% 4%

Footnotes:





Nurture Our People continued

Key Performance Indicators

General Notes:







CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Employee Turnover Data 2019 2020 2021* 2022*

Total Turnover

Total number of employee turnover    

Rate of employee turnover 11% 14% 14% 13%

Total number of voluntary turnover 644 714 1,048 1,050

Rate of voluntary turnover 9% 9% 12% 11%

Turnover by Age

Employees under 30 229 224 246 308

15% 16% 15% 16%

 489 638 749 787

10% 12% 13% 12%

Employees over 50 138 166 159 151

12% 14% 12% 10%

Voluntary employee turnover under 30 195 182 233 279

13% 13% 15% 15%

 366 456 686 654

7% 9% 12% 10%

Voluntary employee turnover over 50 82 76 129 117

7% 6% 10% 8%

Turnover by Level

Voluntary turnover support to entry professional 11% 11% 14% 16%

Involuntary turnover support to entry professional 3% 5% 1% 2%

Voluntary turnover intermediate to senior professional 8% 8% 12% 9%

Involuntary turnover intermediate to senior professional 2% 4% 1% 2%

Voluntary turnover manager to associate director 6% 8% 11% 10%

Involuntary turnover manager to associate director 4% 4% 2% 1%

Voluntary turnover director and above 6% 13% 17% 9%

Involuntary turnover director and above 4% 4% 3% 2%

General Notes:





Employee Turnover Data 2019 2020 2021* 2022*

Total Turnover by Region

AMR 530 666 763 646

11% 13% 14% 11%

APAC 223 261 251 405

12% 14% 12% 17%

EMEA 103 101 140 195

11% 10% 12% 14%

Voluntary Turnover by Region

AMR 384 442 701 586

8% 9% 13% 10%

APAC 188 207 224 315

10% 11% 11% 13%

EMEA 72 65 123 149

8% 7% 11% 11%



White/Caucasian 8% 10% 13% 9%

Native Hawaiian or Other Pacific Islander 11% 10% 5% 17%

American Indian or Native Alaskan 0% 0% 25% 7%

Asian 7% 8% 13% 11%

Hispanic or Latino 8% 7% 14% 10%

Black or African American 11% 12% 16% 12%

2 or More 6% 11% 21% 9%

Choose not to self disclose 6% 8% 13% 13%

Nurture Our People continued

Key Performance Indicators

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Parental Leave 2019 2020 2021 2022

Total number of employees who were entitled to

parental leave 4,714 4,900 5,302 5,916

Total number of employees who took parental leave,

by gender

Female 116

Male 65

Female 181

Male 121

Blank 1

Female 173

Male 89

Female 236

Male 128

Blank 1

Total number of employees who returned to work in the

reporting period after parental leave ended, by gender

Female 116

Male 65

Female 191

Male 138

Blank 1

Female 166

Male 123

Female 226

Male 121

Blank 1

Total number of employees who returned to work after

parental leave ended that were still employed 12 months

after their return to work, by gender

Female 100

Male 54

Female 177

Male 123

Blank 1

Female 150

Male 107

Female 192

Male 102

Blank 1

Return to work and retention rates of employees who

took parental leave, by gender

Return to Work:

Female 100%

Male 98%

Retention:

Female 86%

Male 83%

Return to Work:

Female 100%

Male 98%

Retention:

Female 86%

Male 83%

Return to Work:

Female 98%

Male 99%

Retention:

Female 93%

Male 89%

Return to Work:

Female 97%

Male 100%

Retention:

Female 85%

Male 84%

Benefit Plan and Other Retirement 2019 2020 2021 2022

Percentage of salary contributed by employee

or employer





Level of participation in retirement plans, such as

participation in mandatory or voluntary schemes,

regional or country-based schemes, or those with

financial impact

US 401(k): 97% employee

voluntary participation

US 401(k): 98% employee

voluntary participation

Employee Bonus and Stock Program 2019 2020 2021 2022

Employees eligible for annual VCP bonus All employees

Employees eligible to participate in employee stock

purchase plan All employees

Average Compensation Ratio—Women to Men 2019 2020 2021 2022

Across all employee categories 100% 100% 100% 99%

Support to entry professional 102% 102% 101% 100%

Intermediate to senior professional 100% 100% 99% 99%

Supervisor to associate director 98% 99% 100% 99%

Director and above 101% 98% 99% 98%

Annual Compensation Ratio 2019 2020 2021 2022

Ratio of annual total compensation for the organization's highest-paid

individual in each region to the median annual total compensation for

all employees

Refer to

Proxy Filing

Refer to

Proxy Filing

Refer to

Proxy Filing

Refer to

Proxy Filing

Training 2019 2020 2021 2022

Average hours of training per employee per year 60 64 64 62

Hours of training by gender: Male 60 66 66 63

Hours of training by gender: Female 61 61 63 60

Hours of training by employee category: Individual Contributor 64 68 68 66

Hours of training by employee category: Middle Management 71 76 76 70

Hours of training by employee category: Senior Management 38 38 44 39

Hours of training by employee category: Executive Leadership 22 24 30 26

Hours of training by functional category: Commercial Operations 50 46 52 51

Hours of training by functional category: General Operations 23 25 27 25

Hours of training by functional category: Manufacturing 91 104 98 96

Hours of training by functional category: Research & Development 53 57 62 58

Total number of hours devoted to training on human rights 1,737 5,578 3,333 4,726

Applicable employees certified to Code of Conduct 99% 98% 97% 97%

Footnotes:















General Notes:



Nurture Our People continued

Key Performance Indicators

Performance & Career Development Review 2019 2020 2021 2022

Percentage of employees receiving regular

performance and career development reviews

(includes all administrative, production, technical,

middle management, and senior management)

100% 100% 100% 100%

Employee Survey22019 2020 2021 2022

Participation rate for employee iPulse survey 89% 79% 80% 86%

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Health & Safety 2019 2020 2021 2022



100 employees) 0.52 0.34 0.54 0.23

Lost time incident rate 0.74 0.18 0.23 0.12

 0.34 0.18 0.43 0.17

Environment, Health & Safety notices of violations 0 0 0 0

Environmental fines 0 0 0 0

Prevention reporting statistics 3,611 3,018 1,452 2,054

Employee Safety 2019 2020 2021 2022

Number of work-related fatalities 0 0 0 0

Rate of work-related fatalities 0 0 0 0



illnesses (excluding fatalities) 49 29 51 23



illnesses (excluding fatalities) 0.62 0.39 0.16 0.24

 49 29 51 23

 0.62 0.39 0.16 0.24



Ergonomics,

strains,

contusions,

and sprains

Ergonomics,

strains,

contusions,

and sprains

Ergonomics

and strains

Ergonomics,

strains,

contusions,

and sprains

The number of hours worked 15,647,395 15,344,520 15,946,780 19,462,592

Safety Workers Who Are Not Employees but Whose Work

and/or Workplace is Controlled by the Organization 2019 2020 2021 2022

Number of work-related fatalities 0 0 0 0

Rate of work-related fatalities 0 0 0 0



illnesses (excluding fatalities) 0 3 2 3



(excluding fatalities) 00.07 0.13 0.18

 0 3 2 3

 00.07 0.13 0.18



Ergonomics,

Strains,

Contusions,

and Sprains

Ergonomics,

Strains,

Contusions,

and Sprains

Fractures

and strains

Ergonomics,

strains,

contusions,

and sprains

The number of hours worked 2,741,396 2,798,888 2,986,473 3,296,423

General Notes:















Nurture Our People continued

Key Performance Indicators

Environmental, Health & Safety Training

Total hours of EHS training 26,758 30,054 43,066 45,022

Average hours per employee 3.7 3.4 4.1 4

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Governance 2019 2020 2021 2022

Non-compliance with environmental laws and regulations; Significant

fines and non-monetary sanctions for non-compliance with

environmental laws and/or regulations

0 0 0 0

# of FDA recalls 0 0 0 0

Number of substantiated complaints concerning breaches of customer

privacy and losses of customer data 0 0 0 0

Number of public legal cases regarding corruption brought against the

organization or its employees during the reporting period 0 0 0 0

Antitrust Cases 2 0 See notes See notes

Nature and total number of critical concerns communicated to highest

governance body regarding CSR topics 0 0 0 0

Total employees covered by collective bargaining agreements 0 0 0 0

Incidents of discrimination and corrective actions taken See note 3 See note 3 See note 3 See note 3

Transparency Reporting Law Enforcement & National Security Requests N/A

2020 Privacy

Transparency

Report

2021 Privacy

Transparency

Report

2022 Privacy

Transparency

Report

Security personnel are trained in organization’s policies or procedures

concerning aspects of human rights that are relevant to operations. N/A N/A N/A Yes

The organization is unaware of any operations in which there is a

significant risk for incidents of child labor. N/A N/A N/A Confirmed

The organization is unaware in which there is a significant risk for

incidents of forced or compulsory labor. N/A N/A N/A Confirmed



US District Court for the Northern District of California alleging that Illumina violated federal antitrust and state unfair competition laws,

based on a patent infringement suit Illumina filed against BGI in the same court. Illumina denies the allegations, which are without merit.

In July 2022, Illumina and BGI settled all US litigation, and the case was dismissed.



acquisition of GRAIL, Inc. violates federal antitrust law. Following a full trial on the merits, in September 2022 the FTC’s Chief





petition for expedited review with a US Court of Appeals, and the FTC’s order to unwind the acquisition will be automatically stayed

pending appeal.

3. During the past thirteen years, neither the EEOC nor any court or administrative agency has issued a finding against Illumina in a

claim involving discrimination. There was one claim of discrimination filed during the reporting period. Illumina denies the allegation.

The matters that were pending during the last reporting period have been resolved. We do not tolerate acts of discrimination, and

promote an open culture to report concerns (including anonymously). Illumina takes all reports of misconduct seriously and has a strict

non-retaliation policy. If a report is substantiated, the company would respond as it deems appropriate or necessary, consistent with

the law, and will act swiftly to correct the problem and deter future occurrences. Depending on the circumstances, this may include



violating the law.

ESG Governance Topics Position Level from CEO Level from Board

Corporate Social Responsibility / ESG SVP, Chief Public Affairs Officer 1 2

Environment, Health & Safety, Supply Chain,

Facilities, Operations SVP, Chief of Global Operations 1 2

People, Employment, Diversity, Equity, and Inclusion SVP, Chief People Officer 1 2

Compliance, Ethics, Legal SVP, General Counsel 1 2

Product SVP, Chief Technology Officer 1 2

Cybersecurity SVP, Chief Information Officer 1 2

Finance, Investor Relations, Internal Audit SVP, Chief Financial Officer 1 2

 2022

BoD level oversight for CSR and ESG (including themes of sustainability and climate action; diversity, equity, and

inclusion; human rights; cybersecurity; data privacy; and ethical and responsible business practices) Yes

Clawback provision Yes

Commitment to gender diversity on BoD Yes

 33%

BoD composition by racial/ethnic minority representation 33%

Number of Directors 9

Number of Indepenent Directors 8

Average Board Tenure 6.6 years

Operate Responsibly

Key Performance Indicators

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Supply Chain 2019 2020 2021 2022

Quantity of product shipped 3,118,142 units 3,297,561 units 3,862,839 units 3,752,857 units

Spend with direct suppliers $440 million $396 million $585 million $694 million

Supplier Code of Conduct in place Yes Yes

Geographic location of suppliers Countries: AE, AM, AR, AT, AU, BE, BS, CA, CH, CL,

CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, ID,

IE, IL, IN, IS, IT, JP, KR, LT, LU, MO, MX, MY, NL, NO,

NZ, PA, PE, PH, PL, PT, RO, RU, SE, SG, SI, TH, TR,

TW, UA, US, UY, VN, ZA

Countries: AE, AM, AR, AU, AU, BE, BR, BY,

CA, CH, CL, CN, CR, CZ, DE, DK, EE, ES, FI, FR,

GB, GH, HK, ID, IE, IL, IND, IS, IT, JP, KR, LT,

LU, MY, MX, NL, NO, NZ, PE, PH, PL, PT, RU,

SA, SE, SG, TH, TR, TW, UA, US,

UY, ZA

Countries: AE, AM, AR, AT, AU, BE, BG, BR, CA,

CH, CN, CO, CZ, DE, DK, ES, FI, FR, GB, GH,

HK, ID, IE, IL, IN, IT, JP, KR, LK, LT, LU, LV, MY,

NL, NO, NZ, PL, RO, RU, SA, SE, SG, SI, TH,

TR, TW, US, ZA

Countries: US, DE, CA, GB, SG, CH, JP, PL, FR,

AU, ZA, BE, NZ, IT, CN, NL, DK, NO, MY, IN,

ES, IS, SE, IL, PT, AR, HK, AM, KR, UA, IE, BN,

ID, BD, EC, AT, FI, TW, MO, LU, VN, TR, LK, AE,

MX, CZ, RU, RO, TH, BR, LV, CR, PH, BY, UY,

SA, HU, SI, GR, PK, CY, BG, LT, RS, BO, PY, NG,

KY, GT, PA, SV, KE, EE, PE, CL, CO

A description of the organization’s supply chain Illumina’s global supply chain consists of suppliers, sub-contractors, channel partners, manufacturing sites, distribution centers, and customers

Types of suppliers Direct, indirect, strategic, finished medical device, custom spec, off the shelf, and services

Number of suppliers engaged by organization 3,891 3,704 3,798 3,323

Estimated monetary value of payments made to suppliers  $935 million  

  334 517 919

Diverse supplier spend $190 million $152 million $209 million $269 million

 19% 16% 17% 18%

Percentage of strategic suppliers that have committed to minimizing their

environmental footprint N/A 75% 84% 89

 N/A N/A N/A 13%

Key Performance Indicators

Operate Responsibly continued

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Political Contributions 2019 2020 2021 2022

Total monetary value of financial and in-kind political contributions

made directly and indirectly by the organization by country and

recipient/beneficiary

$50,000 $0 $0 $0

Trade Association & Memberships 2021 2022

Illumina participates in various trade associations and industry memberships for collaboration and exchange of ideas. Some of these organizations may

utilize a portion of membership fees for non-deductible state and federal lobbying and political expenditures. As part of our transparency practices, we

disclose trade memberships for which we contribute at least $5,000 annually in fees.

Trade and Industry Group Memberships Above $5,000 Threshold Annually

Global

World Economic Forum $330,000 $330,000

EMEA Trade Association Memberships

 $35,000 $32,204

EUCOPE $27,892 $19,322

US Qatar Business Council $10,000 $10,000

US Saudi Arabian Business Council $10,000 $10,000

US UAE Business Council $10,000 $10,000

 $5,000 $0

APJ and Greater China Trade Association Memberships

US India Business Council $27,500 $20,000

Pathology Technology Australia $7,309 $20,868

 $25,000 $25,000

 $15,000 $15,000

 $11,686 $14,500

AmCham China $7,413 $4,026

U.S. Trade Association Memberships

World 50, Inc. $393,766 $240,850

US Chamber of Commerce $150,000 $160,000

 $100,000 $100,000

Access to Comprehensive Genomic Profiling Coalition $80,813 $75,000

Procurement Leaders $57,000 $58,710

Biocom $56,300 $57,500

 $50,000 $50,000

Coalition for 21st Century Medicine $50,000 $50,000

 $32,000 $32,000

California Chamber of Commerce $25,000 $0

 $25,000 $25,000

 $24,500 $24,500

AdvaMed $19,950 $19,950

 $10,000 $0

 $7,650 $7,650

 $6,000 $6,000

 $5,000 $5,000

For the trade associations with membership fees greater than $50,000, the portion of such payments that is non-deductible under Section 162(e)(1)



efforts annually.

Organization Total Annual Membership Fee % Membership Fees Used for

State or Federal Lobbying

Dollars Applied to State

or Federal Lobbying From

Membership Fees

2021 2022 2021 2022 2021 2022

US Chamber of Commerce $161,625 $160,000 25% 35% $40,406 $56,000

Coalition for Access to

 $100,000 $100,000 25% $0 $25,000 $0

American Clinical Laboratory

 $50,000 $50,000 33% 30% $16,500 $29,500

Biocom $56,300 $57,500 10% 10% $5,630 $5,750

Coalition for 21st

Century Medicine $50,000 $50,000 45%30% $22,500$15,000

Operate Responsibly continued

Key Performance Indicators



GRI Description GRI Section Illumina Report



Statement of use Illumina has reported in accordance with the GRI Standards for

the period 1st January 2022 to 31st December 2022

GRI 1 reference GRI 1 



Organizational details  Pages: 8, 9, 89

Entities included in the organization, sustainability reporting  Page: 86

Reporting period, frequency and contact point  Page: 86

Restatements of information  Page: 86

External assurance  Page: 108

Activities, value chain and other business relationships  

89, 101

Employees  

Workers who are not employees  Page: 93

Governance structure and composition  

Nomination and selection of the highest governance body  Pages: 16, 72, 100

Chair of the highest governance body  Pages: 16, 72, 100

Role of the highest governance body in overseeing the management

of impacts  Pages: 16, 72, 100

Delegation of responsibility for managing impacts  Page: 16

Role of the highest governance body in sustainability reporting  Pages: 16, 72, 100

Conflicts of interest  

Communication of critical concerns  Page: 100

Collective knowledge of the highest governance body  

Evaluation of the performance of the highest governance body  Page: 72

Remuneration policies  Page: 72, Proxy

Process to determine remuneration  Page: 72

Annual total compensation ratio  Page: 72

Statement on sustainable development strategy  

Policy commitments  



Embedding policy commitments  



Processes to remediate negative impacts  

Mechanisms for seeking advice and raising concerns  

Compliance with laws and regulations  

Membership associations  Page: 17, 22, 29, 31, 41, 44, 86

Approach to stakeholder engagement  Page: 17

Collective bargaining agreements  Page: 100

GRI Description GRI Section Illumina Report



Process to determine material topics  

List of material topics  Page: 14,17

Management of material topics  



Management of material topics  

Direct economic value generated and distributed  Page: Proxy

Financial implications and other risks and opportunities due to

climate change  

Defined benefit plan obligations and other retirement plans  Page: 67, 98



Management approach: Market Presence  

Ratios of standard entry level wage by gender compared to local

minimum wage  Page: 62, 98

Proportion of senior management hired from the local community  Page: 63



Management approach: Indirect Economic Impacts  

Infrastructure investments and services supported  

Significant indirect economic impacts  



Management approach: Procurement Practice  

Proportion of spending on local suppliers  Page: 82, 101



Management approach: Anti-corruption  

Operations assessed for risks related to corruption  

Communication and training about anti-corruption policies

and procedures  

Confirmed incidents of corruption and actions taken  Page: 100



Management approach: Anti-competitive  

Legal actions for anti-competitive behavior, anti-trust, and

monopoly practices  Page: 100

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

GRI Index

GRI Description GRI Section Illumina Report



Statement of use Illumina has reported in accordance with the GRI Standards for

the period 1st January 2022 to 31st December 2022

GRI 1 reference GRI 1 



Organizational details  Pages: 8, 9, 86

Entities included in the organization, sustainability reporting  Page: 83

Reporting period, frequency and contact point  Page: 83

Restatements of information  Page: 83

External assurance  Page: 105

Activities, value chain and other business relationships  Pages: 8, , , , , ,

86, 98

Employees  Pages: , 

Workers who are not employees  Page: 90

Governance structure and composition  Pages: , 69, 97

Nomination and selection of the highest governance body  Pages: 15, 69, 97

Chair of the highest governance body  Pages: 15, 69, 97

Role of the highest governance body in overseeing the management

of impacts  Pages: 15, 69, 97

Delegation of responsibility for managing impacts  Page: 15

Role of the highest governance body in sustainability reporting  Pages: 15, 69, 97

Conflicts of interest  Pages: 

Communication of critical concerns  Page: 97

Collective knowledge of the highest governance body  Pages: 15, , 97

Evaluation of the performance of the highest governance body  Page: 69

Remuneration policies  Page: 69, Proxy

Process to determine remuneration  Page: 69

Annual total compensation ratio  Page: 69

Statement on sustainable development strategy  Page: , 

Policy commitments  Pages: , 41, 49, 59, 65, 69, 70, 71, 74, 75,



Embedding policy commitments  Pages: , 41, 49, 59, 65, 69, 70, 71, 74, 75,



Processes to remediate negative impacts  Page: , 97, 103

Mechanisms for seeking advice and raising concerns  Page: , 103

Compliance with laws and regulations  Page: 65, , 97

Membership associations  Page: 16, 21, 28, 30, 38, 41, 83

Approach to stakeholder engagement  Page: 16

Collective bargaining agreements  Page: 97

GRI Description GRI Section Illumina Report



Process to determine material topics  Pages: 

List of material topics  Pages: 13,16

Management of material topics  Pages: , 69



Management of material topics  Pages: 

Direct economic value generated and distributed  Proxy

Financial implications and other risks and opportunities due to

climate change  Pages: , 48, , 104

Defined benefit plan obligations and other retirement plans  Pages: 64, 95



Management approach: Market Presence  Pages: 

Ratios of standard entry level wage by gender compared to local

minimum wage  Pages: 59, 95

Proportion of senior management hired from the local community  Page: 60



Management approach: Indirect Economic Impacts  Pages: , 18, 33, 54, 68

Infrastructure investments and services supported  Pages: 18, , 24, 25, 29, 34, , 2

Significant indirect economic impacts  Pages: 18, , 24, 25, 29, 34, , 2



Management approach: Procurement Practice  Pages: , 68, 

Proportion of spending on local suppliers  Pages: 79, 98



Management approach: Anti-corruption  Pages: , 68

Operations assessed for risks related to corruption  Pages: , , 97

Communication and training about anti-corruption policies

and procedures  Pages: , 77, 78, 97

Confirmed incidents of corruption and actions taken  Pages: 97



Management approach: Anti-competitive  Pages: 

Legal actions for anti-competitive behavior, anti-trust, and

monopoly practices  Pages: 97

GRI Description GRI Section Illumina Report



Management approach: Materials  

Reclaimed products and their packaging materials  Page: 49



Management approach: Energy  

Energy consumption within the organization  

Energy consumption outside of the organization  

Energy intensity  Pages: 46, 91

Reduction of energy consumption  

Reductions in energy requirements of products and services  



Management approach: Water and Effluents  

Interactions with water as a shared resource  Pages: 47, 92

Management of water discharge-related impacts  Pages: 47, 92

Water withdrawal  Pages: 47, 92

Water discharge  Pages: 47, 92

Water consumption  Pages: 47, 92



Management approach: Biodiversity  



protected areas and areas of high biodiversity value outside

protected areas

 

Significant impacts of activities, products and services on biodiversity  Page: 45

Habitats protected or restored  

IUCN Red List species and national conservation list species with

habitats in areas affected by operations  Page: 45, 46



Management approach: Emissions  

  

  

  

GHG emissions intensity  Page: 46, 91

Reduction of GHG emissions  

  Page: 91

Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant

air emissions  Page: 91

GRI Description GRI Section Illumina Report



Management approach: Waste  

Waste generation and significant waste-related impacts  

Management of significant waste-related impacts  

Waste generated  Pages: 48, 92

Waste diverted from disposal  Pages: 48, 92

Waste directed to disposal  Pages: 48, 92



Management approach: Supplier Environmental Assessment  

New suppliers that were screened using environmental criteria  Pages: 81, 89

Negative environmental impacts in the supply chain and actions taken  



Management approach: Employment  

New employee hires and employee turnover  Page: 96

Benefits provided to full-time employees that are not provided to

temporary or part-time employees  Pages: 67, 98

Parental leave  Page: 98



Management approach: Health and Safety  

Occupational health and safety management system  Pages: 68, 99

Hazard identification, risk assessment, and incident investigation  Pages: 68, 99

Occupational health services  

Worker participation, consultation, and communication on

occupational health and safety  Page: 68

Worker training on occupational health and safety  Pages: 68, 99

Promotion of worker health  

Prevention and mitigation of occupational health and safety impacts

directly linked by business relationships  

Workers covered by an occupational health and safety

management system  Pages: 68, 99

  Pages: 68, 99

Work-related ill health  Pages: 68, 99

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

GRI Index continued

GRI Description GRI Section Illumina Report



Management approach: Materials  Pages: , 40, 46

Reclaimed products and their packaging materials  Page: 46



Management approach: Energy  Pages: , , 43

Energy consumption within the organization  Pages: , 43, 48, 87, 88, 104

Energy consumption outside of the organization  Pages: , 43, 48, 87, 88, 104

Energy intensity  Pages: 43, 88

Reduction of energy consumption  Pages: , 43, , 52, 

Reductions in energy requirements of products and services  Pages: , 



Management approach: Water and Effluents  Pages: , 40, 44

Interactions with water as a shared resource  Pages: 44, 89

Management of water discharge-related impacts  Pages: 44, 89

Water withdrawal  Pages: 44, 89

Water discharge  Pages: 44, 89

Water consumption  Pages: 44, 89



Management approach: Biodiversity  Page: , 



protected areas and areas of high biodiversity value outside

protected areas

 Page: 

Significant impacts of activities, products and services on biodiversity  Page: 42

Habitats protected or restored  Page: , 

IUCN Red List species and national conservation list species with

habitats in areas affected by operations  Page: 



Management approach: Emissions  Page: , 

  Page: , 43, 

  Page: , 43, 

  Page: , 48, 88

GHG emissions intensity  Page: 43, 88

Reduction of GHG emissions  Page: , 43, , 52, 

  Page: 88

Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant

air emissions  Page: 88

GRI Description GRI Section Illumina Report



Management approach: Waste  Pages: , 40, 45

Waste generation and significant waste-related impacts  Pages: 40, , 89

Management of significant waste-related impacts  Pages: 40, 

Waste generated  Pages: 45, 89

Waste diverted from disposal  Pages: 45, 89

Waste directed to disposal  Pages: 45, 89



Management approach: Supplier Environmental Assessment  Pages: , 40, 49, 68

New suppliers that were screened using environmental criteria  Pages: 78, 86

Negative environmental impacts in the supply chain and actions taken  Pages: 



Management approach: Employment  Pages: , 54

New employee hires and employee turnover  Page: 93

Benefits provided to full-time employees that are not provided to

temporary or part-time employees  Pages: 64, 95

Parental leave  Page: 95



Management approach: Health and Safety  Pages: , 54

Occupational health and safety management system  Pages: 65, 96

Hazard identification, risk assessment, and incident investigation  Pages: 65, 96

Occupational health services  Pages: , 96

Worker participation, consultation, and communication on

occupational health and safety  Page: 65

Worker training on occupational health and safety  Pages: 65, 96

Promotion of worker health  Pages: 

Prevention and mitigation of occupational health and safety impacts

directly linked by business relationships  Pages: 

Workers covered by an occupational health and safety

management system  Pages: 65, 96

  Pages: 65, 96

Work-related ill health  Pages: 65, 96

GRI Description GRI Section Illumina Report



Management approach: Training and Education  

Average hours of training per year per employee  Pages: 6, 63, 98

Programs for upgrading employee skills and transition

assistance programs  

Percentage of employees receiving regular performance and career

development reviews  Pages: 64, 98



Management approach: Diversity and Equal Opportunity  

Diversity of governance bodies and employees  

Ratio of basic salary and remuneration of women to men  Pages: 98



Management approach:  

Incidents of discrimination and corrective actions taken  Pages: 100



Management approach: Freedom of Association and

Collective Bargaining  

Operations and suppliers in which the right to freedom of association

and collective bargaining may be at risk  Page: 106



Management approach: Child Labor  

Operations and suppliers at significant risk for incidents of child labor  Page: 77



Management approach: Forced and Compulsory Labor  

Operations and suppliers at significant risk for incidents of forced or

compulsory labor  Pages: 77, 81, 100



Management approach: Security Practice  

Security personnel trained in human rights policies or procedures  Page: 100



Management approach: Local Communities  

Operations with local community engagement, impact assessments,

and development programs  

GRI Description GRI Section Illumina Report



Management approach: Supplier Social Assessment  

New suppliers that were screened using social criteria  Page: 101



Management approach: Public Policy  

Political contributions  Pages: 84, 102



Management approach: Marketing and Labeling  

Requirements for product and service information and labeling  Pages: 76, 106

Incidents of non-compliance concerning product and service

information and labeling  Page: 106

Incidents of non-compliance concerning marketing communications  Page: 106



Management approach: Customer Privacy  

Substantiated complaints concerning breaches of customer privacy

and losses of customer data  Page: 100

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

GRI Index continued

GRI Description GRI Section Illumina Report



Management approach: Training and Education  Pages: , 54

Average hours of training per year per employee  Pages: 6, 60, 95

Programs for upgrading employee skills and transition

assistance programs  Pages: 58, 

Percentage of employees receiving regular performance and career

development reviews  Pages: 61, 95



Management approach: Diversity and Equal Opportunity  Pages: , 54, 57

Diversity of governance bodies and employees  Pages: , 69, , 97

Ratio of basic salary and remuneration of women to men  Page: 95



Management approach:  Pages: , 54, 59

Incidents of discrimination and corrective actions taken  Page: 97



Management approach: Freedom of Association and

Collective Bargaining  Pages: , 54

Operations and suppliers in which the right to freedom of association

and collective bargaining may be at risk  Page: 103



Management approach: Child Labor  Pages: , 68, 74

Operations and suppliers at significant risk for incidents of child labor  Page: 74



Management approach: Forced and Compulsory Labor  Pages: , 68, 74, 77, 78, 97

Operations and suppliers at significant risk for incidents of forced or

compulsory labor  Pages: 74, 78, 97



Management approach: Security Practice  Pages: 

Security personnel trained in human rights policies or procedures  Page: 97



Management approach: Local Communities  Pages: , 33

Operations with local community engagement, impact assessments,

and development programs  Pages: 

GRI Description GRI Section Illumina Report



Management approach: Supplier Social Assessment  Pages: , 49, 68, 77

New suppliers that were screened using social criteria  Page: 98



Management approach: Public Policy  Pages: , 68, 81

Political contributions  Pages: 81, 99



Management approach: Marketing and Labeling  Pages: , 68, 73

Requirements for product and service information and labeling  Pages: 73, 103

Incidents of non-compliance concerning product and service

information and labeling  Page: 103

Incidents of non-compliance concerning marketing communications  Page: 103



Management approach: Customer Privacy  Pages: , 68, 72, 

Substantiated complaints concerning breaches of customer privacy

and losses of customer data  Page: 97

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview





Dimension General Issue Category Disclosure Topic Code Accounting Metric Response



Social

Capital

Access & Affordability

Affordability and Pricing  Ratio of weighted average rate of net price increases to the annual increase in the U.S. Consumer Price Index 76

Affordability and Pricing  Description of how price information for each product is disclosed to customers or to their agents 76

Product Quality & Safety

Product Safety  Number of FDA recalls issued, total units recalled 0

Product Safety  List of products listed in the FDA’s MedWatch safety alerts for human medical products database 0

Product Safety  Number of fatalities related to products as reported in FDA Manufacturer and User Facility Device Experience 0

Product Safety   0

Selling Practices &

Product Labeling

Ethical Marketing  Total amount of monetary losses as a result of legal proceedings associated with false marketing claims 0

Ethical Marketing  Description of code of ethics governing promotion of off-label use of products 76, Illumina Code of Conduct

Business

Model &

Innovation

Product Design &

Lifecycle Management

Product Design &

Lifecycle Management  Discussion of process to assess and manage environmental and human health considerations associated with chemicals

in products, and meet demand for sustainable products 43, 49

Product Design &

Lifecycle Management  

 48, 92

Supply Chain Management

Supply Chain Management  

and product quality 71, 83

Supply Chain Management  Description of efforts to maintain traceability within the distribution chain 83

Supply Chain Management  Description of the management of risks associated with the use of critical materials , 83

Leadership &

Governance Business Ethics

Business Ethics  Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption 0

Business Ethics  Description of code of ethics governing interactions with health care professionals , Interactions with HCP Policy

Other Activity Metrics Activity Metrics  Number of units sold by product category 101

Supplemental SICS Industry: Biotech & Pharma

Human

Capital

Employee Engagement,

Diversity & Inclusion

Employee Recruitment,

Development & Retention  Discussion of talent recruitment and retention efforts for scientists and R&D personnel 

Employee Recruitment,

Development & Retention   97

Supplemental SICS Industry: Software & IT Services

Human Capital Employee Engagement,

Diversity & Inclusion

Recruiting & Managing

a Global, Diverse &

Skilled Workforce

  , 

SASB Index

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview





TCFD Disclosure Element Topic Description Illumina CSR Report Section/CDP Questionnaire Response

Governance

Describe organization’s governance around climate-related

risks and opportunities.

Board oversight Describe Board’s oversight of climate-related risks and opportunities. CSR Report , 41, 69, 7

CDP C1.1, C1.1a., C1.1b

Management role Describe management’s role in assessing and managing risks and opportunities. CSR Report , 41, 71

CDP C1.2, C1.2a

Strategy

Describe the actual and potential impacts of climate-

change risks and opportunities on the organization’s

business, strategy, and financial planning where such

information is material.

Climate risk and opportunities timeline Describe the climate-related risks and opportunities the organization has identified

over the short, medium, and long term.

CSR Report 

CDP C2.1a, C2.1b, C2.2, C2.2a, C2.3, C2.3b, C2.4, C2.4b

Climate risk and opportunities impact Describe the impact of climate-related risks and opportunities on the organization’s

businesses, strategy, and financial planning.

CSR Report 11, 16, , 71

CDP 2.2, C2.2a, C2.3b, C2.4b, C3.1, C3.2, C3.2a, C3.2b, C3.3, C3.4, C3.5

Targets to manage climate risk

and opportunities

Describe the resilience of the organization’s strategy, taking into consideration

different climate-related scenarios, including a 2°C or lower scenario.

CSR Report , 69, 71, , 

CDP 2.2, C3.1, C3.2, C3.2a, C3.2b, C3.3

Risk Management

Disclose how the organization identifies, assesses, and

manages climate-related risks.

Process to identify climate risk Describe the organization’s processes for identifying and assessing climate-related risks. CSR Report , , 69, 71, 

CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3

Process to manage climate risk Describe the organization’s processes for managing climate-related risks. CSR Report , , , 69, 71, 

CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3

Process to integrate climate risk in

overall risk management

Describe how processes for identifying, assessing, and managing climate-related risks

are integrated into the organization’s overall risk management.

CSR Report , , , 69, 71, 

CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3

Metrics & Targets

Disclose the metrics and targets used to assess and

manage relevant climate-related risks and opportunities

where such information is material.

Climate-related metrics Disclose the metrics used by the organization to assess climate-related risks and

opportunities in line with its strategy and risk management process.

CSR Report , , , 68, 78, 79, 

CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a,

C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c

GHG emission data 

and the related risks.

CSR Report , , , 68, 78, 79, 

CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a,

C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c

Targets to manage climate risk and

performance to targets

Describe the targets used by the organization to manage climate-related risks and

opportunities and performance against targets.

CSR Report , , , 68, 78, 79, 

CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a,

C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c

Task Force on Climate-related Financial Disclosures (TCFD) Index

CY’22 CSR Report 

Message from the CEO CSR Strategy & Governance Access Community People Operate Responsibly Appendix

Introduction Sustainability

2022 CSR Highlights About Us Business Overview

About This Report 2030 Targets Recognition Key Performance Indicators GRI Index SASB Index TCFD Index Assurance Statements Disclosures

2022 CSR Highlights About Us Business Overview

Independent Limited Assurance Report to Illumina, Inc.

We have not performed any procedures with respect to other information included in the Illumina 2022 Corporate Responsibility Report and, therefore, no conclusion on the Report as a whole is expressed.

Background and Introduction



















Integrating Environmental Sustainability: Nurturing Our People:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reporting Criteria



Inherent Uncertainty















Illumina’s Responsibilities



 

 



 



Our Responsibilities





Work Performed

 

 

 

 



 

 

 



 

 

 



 









Restriction of Use















Conclusion













Independent Limited Assurance Report to Illumina, Inc.

Background and introduction

ISOS Group, Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited assurance

engagement in accordance with ISAE 3000 and ISAE 3410 covering select information reported within Illumina’s Corporate

Social Responsibility Report CY ’22 (“CY22 CSR Report”) for the period beginning January 1, 2022, and ending December 31,

2022 (“CY22”).

We have performed our limited assurance engagement in accordance with the International Standard on Assurance

Engagements 3000 (ISAE 3000), Assurance other than Audits or Reviews of Historical Financial Information, as well as the

International Standard on Assurance Engagements 3410 (ISAE 3410) Assurance Engagements on Greenhouse Gas Statements,

issued by the International Auditing and Assurance Standards Board. The engagement covered all entities and all facilities under

the operational control of Illumina.

Our review was limited to the data reported in the Key Performance Indicator Summary sections (pages 90 – 95) marked with

the symbol “*” (“Reported Information”), comprising of the following metrics and their respective segmentations:

We have not performed any procedures with respect to other information included in the Illumina CY22 CSR Report and,

therefore, no conclusion on the Report as a whole is expressed.

Reporting criteria

The reporting criteria are the standards identified in the CY22 CSR Report – Reporting Overview (“Reporting Criteria”).

Inherent uncertainty

The nature of non-financial information and the methods used to determine non-financial information, allow for different, but

acceptable measurement techniques which can result in materially different measurements and can impact accuracy and

comparability. Furthermore, the nature and methods used to determine such information, as well as the measurement criteria

and the precision thereof, may change over time.

The Reported Information has been measured applying the Reporting Criteria which has been adopted solely for the purpose of

providing this non-financial information. As such the Reported Information may not be suitable for another purpose. Where

significant assumptions or deductions are utilized, they are disclosed. Where direct data was unavailable, the company used

industry standards as estimates. The assurance provided therefore does not guarantee or provide certainty over the

completeness of reported data.

Illumina’s responsibilities

The Company’s management are responsible for:

• The accuracy and completeness of the information contained in the Reported Information.

• The design, implementation, and maintenance of internal controls relevant to the preparation of the report to

provide reasonable assurance that the report is free from material misstatement, whether due to fraud or error.

• Ensuring the Reported Information is fairly stated in accordance with the applicable criteria (“Reporting Criteria”) and

for the content and statements contained therein.

Integrate Sustainability:

Nurturing Our People:

Energy Consumption

Regional, Country, and Facility Emissions

Emission Intensity

Scope 1 and 2 Emissions

Scope 3 Emission

Water

Workforce Data

Gender Data

EEOC Minority Summary (US)

New Hire Data

Promotion Data

Veteran Data (US)

Employee Turnover Data

Other Identities Self-Reported (US)

Learn More: 

2022 CSR Highlights About Us Business Overview

披露

R¥Jª0˙.«0]/œ›e'1$&vp`>AFm‚-xoﬂF¤£oI’m‚&.0-V’5’˜&t¡~‡5z{

o’H5z03J?]>J¤}USS&x’ª(f-xoﬂF¤£&¥m‚}USSRc>JFBD ;  I’J>

Rj.B5m‚7§¸hg0.˚ <  I’’a1w1$Rj.nq,"m‚>PJ*/@O¤¡nPR…1$}F0VG

,< I’(dI’m‚OP,‹ºRRßHOﬁXDOEm‚J. <  I’k0’a(’4<

1$rRm‚J. <  &xI’uJ’0m‚’a1w1$Rj.P0I. <  D0n-V#1$L-P

’a1w1$Rj.R¥gJ>«&m‚KI{.«KMJ8—I0R?-V#&.{’˜/œ(Fu&rP0(C

2AL¿(,"§v¨’ <  RR[L-I‹º+,Bm‚’a1w1$Rj.?h¡Rc’a1w1$Rj.m‚Eg

1< I’s&gYD0CL-’4<nrR1$’a1wm‚J.w.«KMkK  D0

m‚mSl?vCS¯U,]5m‚x{’˜/œƒˇ?I’JﬁR'C05¨~-P’a1wnRj.1$Ck=’˜

/œK*?B5m‚J. <  9uSSI’RR}JI.Oﬁ0V {&x  &.Oﬁ0Vnq,"

m‚›e'1$IR¥{’˜/œI’I.>Jh¡nq,"m‚‹ºR/80ZOjCm‚J. <  &xI’>$I

 OPnq,"m‚~Y·›e'{’˜/œI’03J‡[’˜ZæI’OP  PnqB

E8·m‚Rı’-2  m‚,¨I¨-4’aIRm‚03JF <  I’RR[>$I?

m‚OPI’ª(fnq,"m‚\EIn/vsC‚I&—.J>CRßm‚CJ?]I’&.w.«

KMI’E2-xm‚-"1$Xx0Lm‚›e' <  I’&E⁄u&rP0’Y·’m‚J,¥{&„

GVOJª§H’a1w)k=m‚J. <  I’’¢O_C˛R…S,&E⁄’a1wn/v03m‚J. < 

I’&x,&’›,0@1$}F}II.0V(rD0P’a1wnK*?B51$0?&.m‚J. < 

Q\Ly0m‚(/†--m‚Ck=wo’H/†--«C"8R˙{]/œ8·&”)œn(.1$-< 

P x<  u(\nn/vs?1$}Q]80?’˜/œI’5L¿’\}[~‘5B-Z’\P:<0(m‚

O’&¥J>+}H9P¨m‚,&’›5z{.«KMI’RR[7,Wm‚  1$  TT{IO5

,DkO"(w,&PR1$P¤B”’5&-x0Bx&sJŒ““m‚)LGoI’\5Rc&—.&&v

JgvR?Po’H-xoﬂF8nP¨{’‘&v((.Ip`Ø-S@Bm‚nq,"‹ºR1$L¿(E2=˝Cm‚

&¥RJª0˙IR?PO’o

Illumina 中国

&s]s.,>T kO "w x ( n«w x

.’i.,>T kO "w x ( n«w x

JﬁR'OEKoc}A

)BkJ>RcR-DoJ>Rc,&’›1wfe1$0\sf5†&„,&0PHKFRcOm‚

’ao

,"\⁄I’{&0RRPP¤nOf’2’˜/œR?8·,;>o

照片来源：

Juraj Krivda

因美纳员工分销规划师

新加坡兀兰基地

0 views·106 pages

基因向善：因美纳企业社会责任报告 PDF Free Download

基因向善：因美纳企业社会责任报告 PDF free Download. Think more deeply and widely.

Uploaded by _larry_garrett_ on 4/8/2026

/106